|
|
·|û¡GCliff10135274 µoªí®É¶¡:2014/10/15 ¤W¤È 01:05:51
|
¥»ª©°w¹ï¯E¹©°ò¥»±°Q½×Àù¯gªvÀø¡B§K¬ÌÀøªk¡BÁ{§É¸ê°T¡F¯E¹©¦U¶µ²£«~¬ãµo¶i«×°lÂÜ°Q½×¡FÄvª§¹ï¤â°ÊºA»P¦U¤è¶i«×°lÂÜ¡C¦P®É¯Ç¤Jª©¡uOBI-822¡BOBI-833¥H¥~ªº²£«~¡vªº¤º®e¡C·q½Ð¦U¦ì¤j¤j´N¥H¤WijÃDªº°ò¥»±Ä~Äò´£¨Ñ´¼¼z¡C ¥un¨¥¤§¦³ª«¡A¥ß½×¦³¾Ú¡A¦hªÅ¬ÒÅwªï¡C ¥»ºô»{¬°©¹«áY¹J¨ìÃþ¦üªºª¬ªp¡A¥i¥H¥Ñ¸Ó¶}ª©¤§¥D¤H¨Ó§P©w¡A ¨Ò¦p¦¹ª©´N¥ÑCliff¤j¤j¨Ó§P©wµo¨¥¤º®e¬O§_²Å¦X¸Óª©¤º®e¡A Y¥D¤H»{©w¤£²Å¡A¦A¥Ñ¥»ºô¤©¥H§R°£¡A¦p¦ó¡HBYª©¥D
|
|
·|û¡Gµ½¤H10137888 µoªí®É¶¡:2015/10/29 ¤U¤È 03:49:16²Ä 520 ½g¦^À³
|
Cliff¤j, ¤p©_¤j, ¥Xª©¤j, «D±`«D±`·PÁ±z̪º´¼¼z©M¼ö¤ß¦X§@ªºµ²´¹! ºÃ°Ý©MÃøÃD³£³Q±z̤ƸѤF! |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2015/10/29 ¤U¤È 03:28:47²Ä 519 ½g¦^À³
|
·PÁÂCliff¤jªº¸Ñ»¡¡I ·PÁÂ¥Xª©¤jªº200¶¤¤¤åª©¡I |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/10/29 ¤U¤È 02:05:10²Ä 518 ½g¦^À³
|
¤p©_¤jªGµM¦³¤ß¡C ¥Xª©¤j´£¨Ñªº¤¤¤åª©±M§Q¤å¡Aªº½T¥O§Ú¦Õ¥Ø¤@·s¡A¤@¨Ç¦b^¤å±M§Q¤å¤W±`¨£ªº±Ôz¡Aì¨ÓĶ¬°¤¤¤å«á¬O³oӼҼˡA¤¤^¹ï·ÓµÛ¬ÝÁÙÆZ¦nª±ªº¡A·PÁÂ¥Xª©¤jªº´£¨Ñ¡C §Úı±o¨º¼Ëªº±Ôz/¥Î»y¤è¦¡¡A¥i¯à²[»\ªk«ß¥Î»yªº§Î¦¡¡A¬O±a¦³¥Íª«¬ì§Þ¤º®eªºªk«ß¥Î»y¡A±a¦³³¯z¡u¬J¤w°µ¹L/½T»{¹L¡vªº¼Æ¾Ú/±Ôz¡A¦A¥[¤W¸g¹L¡u±À´ú/±À¦ô¡v«áªº¥i¯àª¬ªpªº±Ôz¡A¥Øªº¥i¥H§â±M§Q«OÅ@ªºÅ@«°ªeªº¥±¦AÂX¤j©Î¬O²`«×¦AÀà²`¡A¹F¨ì§ó¨Îªº«OÅ@®ÄªG¡C ¹³¡uIn another embodiment¡v«ÜÃø½Ķ¡A²{¦bª¾¹D¬O¡u¦b¥t¤@Ó¹ê¬I¨Ò¤¤¡v¡C ©Ò¥H¹³¡u[019] In another embodiment, there are exactly or about 60, 61 , 62, 63, 64, 65, 66, 67, 68, 69, 70, 71 , 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 , 82, 83, 84, 85, 86, 87, 88, 89, 90, 91 , 92, 93, 94, 95, 96, 97, 98, 99, 100, 101 , 102, 103, 104, 105, 106, 107, 108, 109 or 110 lysine conjugation sites on each monomeric KLH moiety subunit available for binding to or actually bound to a Globo H moiety¡v ¤¤¤å¡G¡u[0019]¦b¥t¤@Ó¹ê¬I¨Ò¤¤¡A¦b¦UÓ³æÅ骺KLH³¡¥÷¦¸³æ¤¸¤W¦³½T¤Á¬°©Î¤j¬ù60¡B62¡B63¡B64¡B65¡B66¡B¡K..109©Î110Ó¥iµ²¦X¦Ü©Î·Ç½T¦aµ²¦X¦ÜGlobo H³¡¤ÀªºÂ÷Ói»Ä¦@³m¦ìÂI¡C¡v¸ÌÀYªº¥Îµü¬O¡uexactly or about¡v¡]¡u½T¤Á¬°©Î¤j¬ù¡v¡^¡A¤]´N¬O»¡¨Ã¤£¬O±q60¨ì110¥L̳£¤@¤@°µ¹L¡A¦ý¥LÌ¡u»{¬°¡vÁ|¤@¤Ï¤T¡A¦b¬YÓ¥i¹w´úªº·Ç«h/½d³ò¤U¡A¬O¥i¥H¦PÅé¾A¥Îªº¡A©ó¬O¦b±M§Q¤å¥ó¤¤¼Ð©ú¡A¡u¥D±i¡v³o¨Ç¤]³£À³¸Óºâ¬O¥L̪º±M§Q½d³ò¡A¦p¦¹¤@¨Ó¡AY¸g¹L±M§Q¼f®Ö³æ¦ì®Ö¥i«á¡A´N¬O¤@¶µ¨ã¦³ÂX¤j«OÅ@®ÄªGªº±M§Q¡C ªº½T¡A¡uGH³¡¤À¡v¡]GH moiety¡^»P¡uKLH³¡¤À¡v¡]KLH moiety¡^ªºÁäµ²¤ñ¨Ò¬O¾ãÓ±M§Qªºknow how¡A¤]À³¸Ó¬O¤½¥q¡u§Q¥ÎOBI ¤º³¡¬ÛÃö§Þ³N¡A½T»{¨âªÌ³Ì¨Î¤ñ¨Ò¡vªººëµØ¡Cì²z¥i¬Ý±M§Q¤åªº[0124]³¡¤À¡C©Ò¿×ªº¡uGH³¡¤À¡v©Ò«ü¬°¸g¹L¯ä®ñ³B²z¡AîǤƫ᪺GH¡]¨£[0122]¡^¡G©Ò¿×ªº¡uKLH³¡¤À¡v©Ò«ü¬°¸g¹L²¸¾J¤Æ¡]thiolation¡^³B²zªºKLH¡]¨£ [0123]¡^¡G³o¨âÓ¡uGH³¡¤À¡v»P¡uKLH³¡¤À¡v¸g¥ÑMMCCHÁäµ²¡A¥H¯S©w¤ñ¨Ò¨Ó°µµ²¦X¡A¥i¤j¤j¼W¥[§Üìµ²¦X¦ì¸m¡]epitope¡^¡A¤]¦]¦¹¤j¤j¼W±j¥D°Ê§K¬Ìªº®ÄªG¡C ¤À¨É¤@Ó·Qªk/·Pı¡A¤S¬OÁÞ§Üì»PÄâ±a³J¥Õ¶¡Áäµ²¤ñ¨Òªº°ÝÃD¡I»P833¡GGH5.1-DT/QS-21¦p¥X¤@Âá¡]ÂÇ´£°ªÁÞ§Üì±K«×¨Ó¡K.¡^¡A©Ò¥H¤~¦³¡u¥»¤½¥q¤w¦b¥t¤@¶µ²£«~OBI-822 ¤W¦¨¥\ÅçÃÒ¡vªº»¡ªk¡A¥u¬O¶¶§Ç¦³§O¡A¨Æ¹ê¤W¬O¥ý¦b822¦¨¥\¤~±À¼s¦Ü833¡A¦ý¬O§Ṳ́F¸Ñªº¶¶§Ç«o¬O¥ýµo²{833Áäµ²¤ñ¨Òªº¨Æ¡A²{¦b¤~ª¾¹Dì¨Ó822®É¤w¸g¥ý¥Î¤F¡C |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2015/10/29 ¤U¤È 01:31:13²Ä 517 ½g¦^À³
|
¦U¦ì¤j¡A ¦Y¤Oªº¬Ý¤F¤å¨¥¤å ¦³¥H¤U´XÂI·P·Q¡A¦ý¥u¬O·P·Q¡A½Ð¤Å°µ¬°§ë¸êªº¨Ì¾Ú¡A ¤£¨¬¤Î¿ù»~¤§³B¡AÁÙ½ÐCliff¤j«ü¾É¡C 1.Globo H-KLH¬O¦@³mª«¡A¤£¬O¤Æ¦Xª«¡A¦]¦¹Globo H©MKLHªº¤À¤l¼Æ¤ñ¨Ò¤£¬O¤@Ó«í©w¤£ÅܪºÂ²³æ¾ã¼Æ¤ñ¡C¤Æ¦Xª«¡A¨Ò¦pNaCl¡A²³æ¾ã¼Æ¤ñ=1¡G1¡A½Ö¨Ó°µ¡A¦b¤£¦Pªº±ø¥ó¤U¡A¥Í¦¨ªºNaCl³£¬O²³æ¾ã¼Æ¤ñ=1¡G1¡C 2.³æ¯ÂªºGlobo H»P³æ¯ÂªºKLH¦ü¥G¤£¬O¨º»ò®e©ö¦@»ù³s±µ¡A¤]¥i¯à¦@»ù³s±µªºÃ©w«×¨S¨º»ò°ª¡A©ÎªÌ»¡¦@»ù³s±µªº®Ä²v¤£¬O«Ü°ª¡A¦]¦¹³æ¯ÂªºGlobo H¥H¤Æ¾Ç¤èªk±µ¤@Ól¥Íª«¥s°µMMCCH¡AÅܦ¨Globo H-MMCCH¡F ³æ¯ÂªºKLH¤]±µ¤@Ól¥Íª«¡A±NGlobo H-MMCCH»PKLHªºl¥Íª«²V¦X¤Îº¯Âo§@¥Î´N¥i¥H§Î¦¨Globo H-KLH¦@³mª«¡C 3.Globo H-KLHªºGlobo H©MKLH¤§¶¡¤£¬O«í©w¤£ÅܪºÂ²³æ¾ã¼Æ¤ñ¡A¨Ì¨âÓl¥Íª«¤£¦Pªº¶q»P¤£¦PªºÀô¹Ò±±¨î°Ñ¼Æ¤U¡A¤@¯ë¤@ÓKLH¥i¯à±µ1~160ÓGlobo H¡A©Ò§Î¦¨ªºGlobo H-KLH¦@³mª«¥i¯à¬OnÓGlobo Hl¥Íª«°t¤WmÓKLHl¥Íª«¡A¨ä¤¤ n¥i¯à¦b1~3000¡Am¥i¯à¦b1~20¡C 4.±M§Q¤å¤¤¡A¤@Ó¹êÅç¨Ò¤l¤¤´£¨ì¡A¥»µo©úªºGlobo H-KLH¦@³mª«¤¤¡AKLH¦b»PGlobo H-MMCCH¦@³m«á§Î¦¨³æÅé©Î¤G»EÅé©Î¤T»EÅé¡A¤]´N¬O¥»µo©úªºm¬O1~3¤§¶¡¡C¥t¥~Globo H«¶q¡GKLH«¶q¥i¥H¨Ì¹êÅ窺»Ý¨D°µ½Õ°t¡A¤å¤¤¥H¤@ÓGH¡GKLH=0.17«¶q¤ñªº¨Ò¤l°µ¤j¹«ªº¹êÅç¡C 5.±q¡u¡K¨Ï¥Î·s¿oªº¤Æ¾ÇÁäµ²ªk¨ÓÁpµ²ÁÞ§Üì(Globo H) »P¸üÅé³J¥Õ( ¥Õ³ïÃþ¬r¯À¡ADT-CRM197)¡A§Q¥ÎOBI ¤º³¡¬ÛÃö§Þ³N¡A½T»{¨âªÌ³Ì¨Î¤ñ¨Ò¡A¥H¹F¨ì´£¤É¤HÅé§K¬Ì¨t²Î¹ïÁÞ§Ü쪺¿ëÃѯà¤O¡A±q¦Ó¹F¨ì¥D°Ê¦¡§K¬ÌªvÀøªº¥Øªº¡C³oÃþ«¬¤Æ¾Ç×¹¢³J¥Õ½èªº§Þ³N¡A ¥»¤½¥q¤w¦b¥t¤@¶µ²£«~OBI-822 ¤W¦¨¥\ÅçÃÒ¡A¨Ã¤w¦b¥xÆW¶i¤JÁ{§É¤T´Á¸ÕÅç¡C¡K¡v¥H¤Î¡]http://pubs.acs.org/appl/literatum/publisher/achs/journals/content/achre4/2015/achre4.2015.48.issue-3/ar5004187/20150311/images/large/ar-2014-004187_0010.jpeg ¡^¡A¤W¹Ï¤@ÓKLHl¥Íª«n±µ800~1500ÓGlobo Hl¥Íª«¡A¤U¹Ï¤@ÓDT-CRM197n±µ3~5ÓGlobo Hl¥Íª«¡A³£¤£¬O©T©w¤£Åܪº¼Æ¦r¡A¦ý±q¤å¦r´yz»PÁp±µªº¼Æ¥Ø¡ADT-CRM197¦ü¥G³£¤ñKLH®e©ö±±¨î¡A¦ý¤£ºÞ¦n¤£¦n±±¨î¡A¤]¤£ºÞ¨ì©³¹ê»Ú¤WDT-CRM197©ÎKLHÁp±µ¤F´XÓGlobo H¡A³Ì«á³£n½T»{³Ì¨Îªº«¶q¤ñ¤~¬O°µ²×¥Øªº¡A·í°µÁ{§É¤Î«áÄò·sÃĤW¥«ªº°t¤è¡C 6.Globo H-KLH¬JµM¬O¦@³mª«¡A´N¤@©w·|¦³¡uÅܲ§©Ê¡vªº°ÝÃD¡A¦ý¤£ºÞ·LÆ[ªºGlobo H©MKLH¬O¥H¦h¤Öªº¼Æ¥Ø°µ¦@»ùÁp±µ¡A³Ì²×ªºGlobo H¡GKLH«¶q¤ñ¤~¬O¼vÅT³Ì¤jªº«ÂI¡A¹êÅç«Ç¤¤©Î¥Í²£¼t©Ð¤¤´M§ä³Ì¾A°Ñ¼Æ¨Ó²£¥X©Ò»ÝnªºÃÄ«~¤~¬O¥\¤O©Ò¦b¡A822§Ö¸Ñª¼¤F¡AY¶¶§Q¸Ñª¼¡A¨Ì®Éµ{´N§Ö·Ç³Æ¤W¥«¸ò¸~½F§@¾Ô¤F¡A¦b¹êÅç«Ç¤¤»s³y¤p¶q©Î¸û¤j³W¼Òªº§å¦¸¸Õ²£³o¼Ë¤lªº½m§L°Ê§@¡AÀ³¸Ó¤w¸gºt½m«Ü¦h¦¸¤F§a¡C 7.¬Ý¤F±M§Q¤å¡A·PıGlobo Hl¥Íª«»PKLHl¥Íª«²Õ¦X¦¨©Ò»Ýnªº«¶q¤ñªºGlobo H-KLH¦@³mª«¡A¨ä¦b¤Æ¾Ç»sµ{¤W¤ñ»sÁÞÃø«×§C¤F«Ü¦h¡A¦]¦¹¥un¬ãµoªø±aµÛ³Õ¤h¥Í¥h°µ´N¦æ¤F¡AµL»Ý°|ªø¥X¤â¡C ¥H¤W¥u¬O·P·Q¡C ÁÂÁ¤p´²¤á¤jªº¸gÅç¤À¨É¡I |
|
|
·|û¡G¤p´²¤á10134411 µoªí®É¶¡:2015/10/29 ¤U¤È 12:25:59²Ä 516 ½g¦^À³
|
µo©ú±M§Q´N¬O³o¼Ë¡An»¡©úµo©úªº¤º®e¬°¦ó¡A¨Ã¥Î¹ê¬I¨ÒÁ|¨Ò»¡©ú¥i¦p¦ó¨Ï¥Î¸Ó±M§Q¡C ¦]¦¹¡A¹ê¬I¨Ò¥u¬O¤@ºØ»¡©ú±M§Qªº¤èªk¡A´N¬OÁ|¨Ò»¡©úªº·N«ä¡A¤£¥Nªí¯uªº¦³³o¼Ë°µ¹L¡C ±M§Q«nªº³¡¥÷¬O¦b±M§Qªº«OÅ@½d³ò¬°¦ó¡A´N¬Oclaim¦³¨º´X¶µ¡H¦³¤@¨Ç¬O¿W¥ß¶µ¡A¦³¤@¨Ç¬OªþÄݶµ¡C p.s. ¹J¥h¼g¹L´XÓµo©ú±M§Q¡A³o¬O§Úªº¸gÅç»{ª¾¡A¤£¤@©w§¹¥þºë½T¡C |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2015/10/29 ¤W¤È 11:02:25²Ä 515 ½g¦^À³
|
Cliff¤j¡A ½Ð±Ð±z ±M§Q¤º¤å¤¤¤£Â_ªº¦³ ¡u¦b¤@Ó¹ê¬I¨Ò¤¤¡v¡B¡u¦b¥t¤@Ó¹ê¬I¨Ò¤¤¡v ³o¼Ëªº¤å¦r¥X²{ ½Ð°Ý³o¬O¹êÅç«Ç¤¤¤w¸gµo¥Íªº¨Æ¹êªº³¯z ÁÙ¬O³o¬O±M§Q½d³òªº§t·§ ªº¥Î»y ©ÎªÌ¬O¨ä¥¦ªº·N«ä ·PÁ¡I °e³ø¤j¡A ±M§Q¤º¤å¯uªº¬O¤å¨¥¤å¡I |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2015/10/29 ¤W¤È 09:21:27²Ä 514 ½g¦^À³
|
·í¦U¦ì¦b¬°"Åܲ§©Ê"ª§½×¤£¥ðªº¦P®É¡A¤w¸g¦³¤H¤£@¦Ó¥ý¦æ¤U¨®-->¦pªG¤µ¤Ñ4174¶}°ª¨«§Cªº¸Ü ¬Û¤ÏªºµL·µL«Bªº3081²{¦bº¦¤F27¤¸§Ö7%¤F ªÑ²¼´N¬O³o¼Ë¡A¦ÒÅç§ë¸ê¤Hªº«ùªÑ«H¤ß¡A400¤¸¥H¤W¥un¤@ÂI·§j¯ó°Ê³\¦h´²¤á´N·|¤ßÅåÅå ¥ý¦æ¤J³U¬°¦w¡A¥u¯à»¡°ò¥»±£¸ª½³£¨S¦³ÅÜ¡A¦ó¥²£¸ª½°õµÛ©ó£¸Ó©Î³\®Ú¥»¤£¦s¦bªº°ÝÃD¦b§xÂZ¦Û¤v¦Ó¤w |
|
|
·|û¡G¦V«e¦æ10140498 µoªí®É¶¡:2015/10/29 ¤W¤È 08:48:00²Ä 513 ½g¦^À³
|
¦U¦ì¤j¤j¡G ¦³ÃöÅܲ§©Ê°ÝÃD¡A¦bµ²ªGÁÙ¥¼¥X¨Ó«e¡A¨C¦ì¤j¤jªºÆ[ÂI³£¥i¯à¬O¥¿½T¡AÓ¤H¤@¦V¥H¸ûÄY®æªº¼Ð·ÇÀ˵ø¯E¹©¡C ¨C¦ì¤j¤j¥Î¤ß§ä´M¸ê®Æ¡A´£¥XÆ[ÂI¤Î¬Ýªk¡A¶°²³¤H¤§¤O¶q§ä´MºÃ¼{¡A³o¬OȱoÅý¤H·q¨Ø¤§³B¡A¤£ºÞ±z´£¥Xªº¬O¥¿±©Î¬Ot±¤§¸àÄÀ¡C Y§Ú¬O¤½¥q¬£¡AªÑªF¦³´£°ÝÅܲ§©Ê°ÝÃD§Ú·|¦^µª¡A¦]¬°¸Ñ¨M¥u¬O¹Lµ{¡A¦p¦ó¸Ñ¨M¤~¬O¾÷±K¡A¹Lµ{¤w¸Ñ¨M¡A¥iÅýªÑªF¦w¤ß¡A¾÷±K·íµM¤£»¡¡C ±i¸³¦bÃĬɤw¾Ä°«¼Æ¤Q¸ü¡A822¤wªá¤F¨ä10´X¦~µØ¡A¹ï©óÅܲ§©Ê°ÝÃD±i¸³¤£¥i¯à¤£ª¾¨äÄY«©Ê¡AÁöµM´¿¸gµo¥Í229¯QÀs¨Æ¥ó¡AY¬O²{¤µ¤w¨ì¸Ñª¼¶¥¬q¦¹°ÝÃDÁÙ¦b¼vÅT822¡A©^ÄU¦U¦ì¥i¥H°h¥X¯E¹©¡A¦]¬°¸g²z¤Hªº¯à¤O¯uªº¤£¨¬¡C ÁÞ¦X¦¨§Þ³N¨Ó¦Û¯Î°|ªø¤Î¤¤¬ã°|¡AY¬O¦³¦¹°ÝÃD¦s¦b¡A¯Î°|ªø°Z¦³¤£¿n·¥³B²z¡A¥ô¨ä¦s¦b¦Ü¤µ¡H¤j®a¥i§O§Ñ°O¯Î°|ªø¡B±i¸³¤Î¤¨¦Ñ¤§Ãö«Y¡C |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/10/29 ¤W¤È 08:19:25²Ä 512 ½g¦^À³
|
¦Ñ´¤j ÁÂÁ±z,§Ú·Q±z¤w»¡±o«Ü©ú¥Õ¤F ´µ¯S¤j ¦n¤[¤£¨£ ¥t¥~ ©IÀ³°e³ø¤jªº´£°Ý¤p§Ì¤]´£¥X¥t¤@Ó²³æªº°ÝÃD 833«ç»òÁÙ¨S¶}©l? |
|
|
·|û¡G´µ¯S10135783 µoªí®É¶¡:2015/10/29 ¤W¤È 07:55:17²Ä 511 ½g¦^À³
|
½a¤H¦bÃhºÃ¤¤©Úµ´¡A´I¤H¦bÃhºÃ¤¤¤F¸Ñ |
|
|
·|û¡G¤j¤á¤H®a10140174 µoªí®É¶¡:2015/10/29 ¤W¤È 06:54:16²Ä 510 ½g¦^À³
|
kenken¤j§A¤]¤£»Ýn³o¼ËÁ«¤H,§Ú¤W¦¸¬Ý¿ù,¦Ü¤Ö·í®É§Ú¬O´£¥X§ÚÓ¤Hªº¬Ýªk,¥»¨ÓªÑ»ùªº¹w´ú´N¦³¹ï¦³¿ù,¤§«e¦³¦h¤H¤H¦b400¥H¤W¬Ý¦n¶^¨ì«á¨Ó250ªº,²{¦b¥u¬O°w¹ï¤@¨Ç°ò¥»±ªº°ÝÃD¦bÂç²M.±z«ç»ò¤£»¡§Ú¦b©³³¡ªº®ÉÔ¦³¬Ý¥XÄw½X±ªºÅܤÆ.¨º®ÉÔ´N»¡¦³¤j¤á¦A¶i³õ¤F©O? |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/10/29 ¤W¤È 12:45:15²Ä 509 ½g¦^À³
|
ÁÙ¦³¤@Ó°ÝÃD.·Q½Ð±Ð¦U¦ì¤j¦³µL¬ÛÃö¸ê®Æ©Î®ø®§.. OBI-833 ·|¤£·|¸õ¹L¤@¥N§ï¥Ñ¤G¥N¶}©l¤@´Á¸ÕÅç?? »Ýn«·s¥Ó½Ð¶Ü??? |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/10/29 ¤W¤È 12:33:33²Ä 508 ½g¦^À³
|
Hi Faith¤j.. ·í¤@¬Ý¨ì±M§Q¤º¤å.µo²{Áö¬O¤¤¤åª©«o¬O¤å¨¥¤å.©Ò¥H·Q°Ý¦³¤H¬Ý§¹¤F¶Ü...¤pªº©ñ±ó¤F. ¤]¤£ªº¤£¨ØªA Cliff¤j ¬Ý§¹.¾ã²z.¦A¥Î¥Õ¸Ü¤å¸Ñ»¡.. Cliff¤j.·P®¦þ.. ¤@ÂI¤p·Qªk.. ÁÞ¤À¤l·sÃĶi«×³Ì§Öªº¬O822 ³Ì¦¹J¨ì»sµ{°ÝÃDªº¤]¤@©w¬O¯E¹©.¯àµo²{§xÃø¨Ã¸Ñ¨Mªº·íµM¤]¬O. ¨C¤@ӸѨM°ÝÃDªº¤èªk³£·|Åܦ¨±N¨Ó§Þ³NªºªùÂe.§O®a·Q¸ó¶VªºÃø«×·|ÀHµÛ822ªº§¹¦¨¶V¨Ó¶V°ª. ¦w¤ß©êµÛ§a.......... |
|
|
·|û¡G¦Ñ´10141055 µoªí®É¶¡:2015/10/28 ¤U¤È 11:35:28²Ä 507 ½g¦^À³
|
¦U¦ì¤j¤j¡G °ÝÃD¨S¦³¨º»ò½ÆÂø¡A¤£n·Q¤Ó¦h¡IÂå¾Ç¬ì¾Ç¬ã¨s¤åÄm¼gªºlimitations¡A°£¤F¦ÛÁ¾¤§¥~¡A³Ì«nªº´N¬O¬°¤U¤@½g©Î¤U¤@¨B¬ã¨s§G§½çE¸ô¡I¨ä¹ê¦¤w¯Ý¦³¦¨¦Ë¡A¬ã¨sºtªº¬O³sÄò¼@¡A¤£µM650½g¬O«ç»ò¥Í¥X¨Óªº¡H¦p¦ó¸Ñ¨M¬O¾÷±K¡I¦³¨S¦³¸Ñ¨M§ó¤£¥Î»¡¡A¨S¦³¸Ñ¨M¤S«ç»ò·|¦³phase II, phase III¡H¨ä¹ê¦b¤j®a±À½×ªº¹Lµ{¡Aµª®×¤]¦´N¦b¨ä¤¤¤F¡C |
|
|
·|û¡Gkenken10138351 µoªí®É¶¡:2015/10/28 ¤U¤È 11:00:27²Ä 506 ½g¦^À³
|
¤j¤á¥ý¥Í§A¤]¤Ó¿E°Ê¤F.§A¤£»Ýn§i¶D§Ṳ́°»òÅܲ§©Êªº°ÝÃD,¥u»Ýn§i¶D§Ų́º¤ÑªºÁ×¹p°w«ç»òµeªº°ÝÃD¤w¸g¸Ñ¨M©Î¬O¥i¥H¸Ñ¨M.¥u¬O³o¼Ë¦Ó¤w,¥i¥H½Ð±z¦A»¡©ú¥Õ¤@¨Ç¶Ü?¤p§Ì¤£¬O«ÜÀ´? |
|
|
·|û¡G£~£~10134649 µoªí®É¶¡:2015/10/28 ¤U¤È 10:35:44²Ä 505 ½g¦^À³
|
¨ä¹ê©Ò¦³ªº°ÝÃD¥u¦³¤@Ó:¡u´N¬O§A³Q¬~¥X¥h¤F¡v¡Cn¸Ñ¨M°ÝÃD«Ü²³æ:¦A§â¥¦¶R¦^¨Ó´N¦n¤F¡C·U±µªñ¸Ñª¼,·U¤£®e©ö¦³§CÂI¥X²{,µ¥¨ì¸Ñª¼,§A´N¦A¤]¨S¦³¡u¦^ÀY¬O©¤¡vªº¾÷·|¤F¡C·V«ä!·V«ä! |
|
|
·|û¡G¤j¤á¤H®a10140174 µoªí®É¶¡:2015/10/28 ¤U¤È 10:00:21²Ä 504 ½g¦^À³
|
³Í¤l³Í¤j§A¤]¤Ó¿E°Ê¤F.¤½¥q¤£»Ýn§i¶D§Ú̦p¦ó¸Ñ¨M,¥u»Ýn§i¶D§Ú̳oÅܲ§©Êªº°ÝÃD¦o̤w¸g¸Ñ¨M©Î¬O¥i¥H¸Ñ¨M,±N¨Ó¦b¶q²£¤W¤£¬O°ÝÃD.¥u¬O³o¼Ë¦Ó¤w,³o·|¦³¤°»ò°Ó·~¾÷±Kªº°ÝÃD,¥i¥H½Ð±z¦A»¡©ú¥Õ¤@¨Ç¶Ü?¤p§Ì¤£¬O«ÜÀ´? ¥t¥~¤j¤j¦A250¤¸³£¥i¥H»{½ß¥X³õ,¥Nªí±zªº«H¤ß¤]¤£¬O¤Ó°í±j,¬Ý¨ìªÑ»ù¤£¦n¤]¬O½æ¥X¤Fªü.³o¸ò¤@¯ë¤H¤]¨S¤°»ò¤£¦P¹À. §ÚÓ¤H¬Ý¨ìcliff¤j´£¥Xªº³o¨Ç°ÝÃD,§Ú¤]¬O´£¥X§ÚªººÃ°Ý¦Ó¤w,³oÀ³¸Ó¤£¬O«Ü¹L¥÷§a. |
|
|
·|û¡G³Í¤l³Í10140178 µoªí®É¶¡:2015/10/28 ¤U¤È 09:40:30²Ä 503 ½g¦^À³
|
§Ú¤£¬O¤@¿×ªº¬Ý¦n,§ÚÁÙ¦b250¶ôÁ«¿ú³Q¬~¥X¥h ¦ý¬O°Ó·~¾÷±K´N¬O°Ó·~¾÷±K,½Ð¦Û¤v¦³¿ìªk´N¥h°Ý°ª¼hªº¤H¤h ³£¦bªO¤W»¡2 3¦¸¤F,ì¼t·íµM¬On§G¤U¤Ñù¦aºô(³s²£«~µ²´¹ªº·»¾¯³£¦³ì¼t¦b¥Ó½Ð±M§Q),¯à°÷©Ôªø²£«~ªº§Q¼í¸ò®É¶¡,ÁÙ¦³¤H³q³q«õ¥X¨Ó¤H¬Ý??? |
|
|
·|û¡G³Í¤l³Í10140178 µoªí®É¶¡:2015/10/28 ¤U¤È 09:31:47²Ä 502 ½g¦^À³
|
«ô°U...¯E¹©¬O¤j¾ÇÁÙ¬O¾Ç³N¾÷ºc??¥L¬O¤½¥qnÀò§QnÁÈ¿ú °£¤F¨ä¥L§OºØ¾÷¨îªºÀù¯gÃÄ,¤§«á¤£·|¥X²{¾Ç¦WÃļt.¤¤°êªºì®ÆÃļt¨Ó¥Ê¤À§Q¼í??? ì¼t°£¤F¥Dµ²ºc¥»¨¦³±M§Q«OÅ@¤§¥~ »sµ{§Þ³N¤]¥i¥H«OÅ@²£«~,isomer³B²z¤èªk¤]¬O¤@Ó±M§Q«OÅ@ ==================== Á¿¥Õ¸Ü¤@¨Ç,¤µ¤Ñ822¤w¸g¬O¤@Ó¦¨¥\ªºÃÄ 20XX¦~±M§Q§Ö¨ì´Á,ì®ÆÃļt,¾Ç¦WÃļt¶}©l·Ç³Æ§ë¤J µ²ªG°µ¨ì¤@¥bµo²{"Åܲ§©Ê"ªº°ÝÃD,ªá¤F«D±`¦hªº®É¶¡³B²z¤§«á ¯E¹©®³¥X»sµ{±M§Q,¤£¦n·N«ä,³o³B²z¤èªkèè¦n¬O§Ú̪º±M§Q,«OÅ@¨ì20xx+3¦~ ì®ÆÃļt«·s§ä±ø¥ó,¨Ó¦^¥i¯à´N¬O1.2¦~(³o§Q¼í¬O¦h¤Ö¿ú???) ==================== §A̲{¦b¬On¦b³oÃä´N¬L§i¤Ñ¤U,¦U¬°«áÄòªºÄvª§¹ï¤â §AÌ°µ¨ì³oÃä,·|¦³"Åܲ§©Ê"ªº®t²§ ³B²z¤è¦¡¬OYYYYY±M§Q ½Ð§O¸ò§Úªº±M§Q½Ä¨ì,½Ð¥t¥~·Q¿ìªk³B²z,¯E¹©°Q½×°Ï¬°±z´£¨Ñ³Ì¦nªº¸ê°T??? |
|
|
·|û¡G¤j¤á¤H®a10140174 µoªí®É¶¡:2015/10/28 ¤U¤È 07:22:07²Ä 501 ½g¦^À³
|
ÁÂÁÂ¥¬µÜ®¦¤jªº©ï·R,ÁÞ¬ì¾Ç¥»´N¬O¤@ªùÆZ·sªº»â°ì. «Ü¦hªF¦èÀ³¸Ó³£ÁÙ¬O¦bºN¯Á¶¥¬q,©Ò¥H¥»´N¸Ó§Ù·V®£Äß.¥i¯à¥un¥u¤@Ó¤p¤pªºÀôµ²¨S§Ë¦n,³Ì«á´N¾ÉP¾ãÓ¥¢±Ñ.³o¦¸ªºÅܲ§©Ê°ÝÃD,¤§«e¦b°ê¥~ªº½×¤å¤¤´N¦³´£¨ì,¥i¨£³o¬O¤@Ó¹L¥h´¿¸gµo¥Í¹Lªº°ÝÃD,²{¦b¤]¤£½T©wÁÙ¬O¤£¬O¤@Ó°ÝÃD.§Ú¤]¤£½T©w³o¬O¤£¬OÄÝ©ó°Ó·~¾÷±K,¦]¬°¯à°÷¸Ñ¨M®Úª¾¹D¸Ñ¨M±o¤èªk¬O¤£¦Pªº.©Î³\¦b¶q²£ªº¤èªk¤W¤½¥q¤]ÁÙ¦bºN¯Á. |
|
|
·|û¡G¥¬µÜ®¦10140670 µoªí®É¶¡:2015/10/28 ¤U¤È 04:22:59²Ä 500 ½g¦^À³
|
¡yOBI ¯S®í»sÁÞ§Þ³N¥i¥H¦³®Ä²v¦a±o¥X³Ì²×©Ò»Ýn²£ª«¡I¡z ¡yOBI ¯S®í»sÁÞ§Þ³N¥i¥H¦³®Ä²v¦a±o¥X³Ì²×©Ò»Ýn²£ª«¡I¡z ¡yOBI ¯S®í»sÁÞ§Þ³N¥i¥H¦³®Ä²v¦a±o¥X³Ì²×©Ò»Ýn²£ª«¡I¡z «Ü«n¡A©Ò¥Hn»¡¤T¹M¡I¡I¡I ÁÂ¥x¿}¤j¡I ¤j¤á¤j¡A ¨ä¹ê§ÚÓ¤H«Ü°ª¿³¨C¤Ñ¨£§A¦b¯E¹©¦¹½×¾Â¶K¤å¡A ¦]¬°³z¹L§Aªº¶K¤å»P«áÄò¦U¯E¤Íªº½×ÃÒ¹Lµ{¤¤¡A §Ú³o¥Í§Þ¡BÃҨ骺¦×¸}´N¥i¥H¦h¾Ç«Ü¦h¡I ¦AªÌ¡A¤@¨¥°óªº¦a¤è³Ì²×ªÖ©w·|¥X¤j¶Ã¤lªº¡A ¹L¦hªººq¥\¹|¼w¡BÀA¤W²Kªá¹L«×·¸¬üªº¶K¤å¡A ¤]»Ýn¤j¤á¤j§AªºÄµ¥@¤å³¹¨Ó¥¿Å¤@¤U¡A¦P®ÉÁÙ¥i¥H¤Ï«ä»P¾Ç²ß¡I ÁÂÁ¤j¤á¤j¡A¤]´Á«Ý¨C¤é§A³£¦³·sªº¶K¤å¡A¤À¨É¯E¤Í¡I ¥H¤WÓ¤H·P·Q¡A¥i¯à¦³«Ü¦h¤H¤£·|»{¦P§a~~~ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/10/28 ¤U¤È 02:49:51²Ä 499 ½g¦^À³
|
¤j¤á¤j §A¬O¤£¬O¬Ý¿ù¤F,°Ó·~¤Æ¥Í²£¤£¦A¬O»»¤£¥i¤Îªº¹Ú·Q »P»»¤£¥i¤Îªº¹Ú·Q ®t«Ü¤jC »¡©ú®Ñ¤º®e¬O:OBI ¯S®í»sÁÞ§Þ³N¥i¥H¦³®Ä²v¦a±o¥X³Ì²×©Ò»Ýn²£ª«¡A¥Ñ©ó³o¶µ§Þ³Nªº¶}µo¡A ¨Ï±oÁÞ¤À¤lªº°Ó·~¤Æ¥Í²£¤£¦A¬O»»¤£¥i¤Îªº¹Ú·Q (¤WÂd¤½¶}»¡©ú®Ñ¤£¯à¶Ã¼g,¦]¨ã¦³¬ÛÃöªk«ßªk³W¬ù§ô¤O) OBI ¯S®í»sÁÞ§Þ³N¥i¥H¦³®Ä²v¦a±o¥X³Ì²×©Ò»Ýn²£ª« ¥i¥H´N¬O¤w¸g¦³¯à¤O°õ¦æªº·N«ä, ¬O¤w¸g§¹¦¨ªºª¬ºA ¥H¤W¬O§Úªº¸ÑŪ ¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡G¤j¤á¤H®a10140174 µoªí®É¶¡:2015/10/28 ¤U¤È 01:14:53²Ä 498 ½g¦^À³
|
¥xÁÞ¤jªº²Ä¤TÂI...»»¤£¥i¤Îªº¹Ú·Q,³o¥y¸Ü¤½¥qªº·N«äÀ³¸ÓÁÙ¦³¤@¨ÇªF¦èn§JªA,¯àÅý¹Ú·Q¦¨¯u§a. |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/10/28 ¤U¤È 12:38:09²Ä 497 ½g¦^À³
|
±q2014¦~12¤ë¤½¶}»¡©ú®Ñ´£¨ìªº¸ê°T¦A±À²z¤@µf ¶È¨Ñ°Ñ¦Ò 1³o¶µ¤Æ¾Ç¦X¦¨§Þ³N¡A¤D¥xÆW¯E¹©¹Î¶¤¡Aµ²¦X¤WzªºÁÞÅé§K¬ÌÀøªk¬ì §Þ¡A¥H¤Î¦yºÝªºÁÞ¦X¦¨§Þ³N¡A¦@¦P§V¤O¡B³v¨B½Õ¾ãÀu¤Æ¤Uªº¦¨ªG (³oªí¥Ü¥xÆW¯E¹©¹Î¶¤¤w¸Ñ¨MÃöÁä°ÝÃD,¨S¦³¸Ñ¨M¦ó¨Ó³v¨B½Õ¾ãÀu¤Æ¤Uªº¦¨ªG? ) 2 ¯à½T«O¥ÎÃįf¤Hªº¦w¥þ¤Î¦³®Ä©Ê¡Aªø´Á¨ÑÀ³©Ò»Ýnªº¯f±w¨Ï¥Î (³o¬O§_ªí¥Ü¦X®æ¦¨«~¦b«O¦s¹Lµ{¤¤¥i¦b®e³\½d³ò¤ºÅܲ§ §_«h¦p¦óªø´Á¨ÑÀ³©Ò»Ýnªº¯f±w¨Ï¥Î?) 3OBI ¯S®í»sÁÞ§Þ³N¥i¥H¦³®Ä²v¦a±o¥X³Ì²×©Ò»Ýn²£ª«¡A¥Ñ©ó³o¶µ§Þ³Nªº¶}µo¡A¨Ï±oÁÞ¤À¤lªº°Ó·~¤Æ¥Í²£ ¤£¦A¬O»»¤£¥i¤Îªº¹Ú·Q (¦³®Ä²vªº¦a±o¥X³Ì²×©Ò»Ýn²£ª«³oªí¥Ü¥xÆW¯E¹©¹Î¶¤¤w¸Ñ¨MÃöÁä°ÝÃD,Åý²£«~éw,²£«~¤£Ã©w¦p¦ó¹Ú·Q¦¨¯u?) 4 Faith ¤j §A´£¨Ñªº¸ê°T«ÜÄ_¶Q ¥i¸Ñ¨M¦U¦ì§ë¸ê¤HªººÃ¼{(Åܲ§©Ê¬O¦³®e³\½d³òªº) |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/10/28 ¤W¤È 11:40:06²Ä 496 ½g¦^À³
|
ÁÂÁÂ¥xÁÞ¤j.¹x¥Û¤jªº»¡©ú ¡iÃÄ°Ê¢AÃĮġj¥ÍÅé¬Ûµ¥©Ê¸ÕÅç,°w¹ï°ªÅܲ§©ÊÃÄ«~¡A¦b¤°»ò¼Ëªº°ò¦¤U¤~¯à©ñ¼e90%«H¿à°Ï¶¡¡A¨ä°e¼fµ{§Ç¬O§_¤£¦P¡C ¥Zµn¤é´Á¡G2014-08-26 | ¸ê®Æ¨Ó·½http://www.cde.org.tw/faq/faq_more?id=216 ®Ú¾Ú§Ú°ê¥ÍÅé¬Ûµ¥©Ê¸ÕÅç·Ç«h²Ä¤Q¤K±ø¡A「¸g¨Æ¥ý¥Ó½Ð®Ö©w¡A¥B©ó»{¥i¦w¥þ©Ê¤Î¦³®Ä©Ê¤U¨Ã²Å¦X°ê»Ú³W©w®É¡A³Ì°ª¦å¤¤¿@«×(Cmax)±o©ñ¼e¦Ü0.75~1.33」¡A¥Ø«e¨Ã¥¼¹ïAUC0-t¡BAUC0-¡Û¶i¦æ©ñ¼e¡A¦¹¥~¶·¦³ÃÒ¾ÚÅã¥Ü¸ÓÃÄ«~¨Ã«D¬°Àø®Ä½d³ò¯U¯¶¡BÄÝ©ó°ªÅܲ§ÃÄ«~¡BCmaxªºÅܲ§¨Ã¤£¯A¤ÎÀø®Ä©Î¦w¥þ©Ê¨Ã¸g¨Æ¥ý¥Ó½Ðªº«e´£¤U¤~¯à¶i¦æCmaxªº©ñ¼e¡A§_«h¤´À³¥H0.8~1.25¼Ð·Ç¬°¥D¡C °ªÅܲ§©ÊÃÄ«~(highly variable drug, HVD)«üªº¬O「ÃÄ«~¦b§l¦¬³t²v(Cmax)»P/©Î§l¦¬¶q(AUC)¨ã¦³°ªªºÓÅ餺Åܲ§(intra-subject variability)」¡C¤@¯ë·íintra-subject CV%¶W¹L30% §Y»{¬°ÄÝ°ªÅܲ§©ÊÃÄ«~¡A¥Ñ©ó°ªÅܲ§©ÊÃÄ«~¥H¶Ç²Îtwo-way crossover design¡A±ý¹F¨ì¥ÍÅé¬Ûµ¥©Ê»Ýnªº¼Ë¥»¼Æ·|«Ü¤j¡A¦]¦¹¥Ø«eU.S. FDA»PEMA¹ï©óHVDªº¥ÍÅé¬Ûµ¥©Ê¬ã¨s¬Ò«Øij¥i±Äreference-scaled average bioequivalence (RSABE)¤èªk¤ÀªR¡A¸ÕÅç³]p±Ä3-way©Î4-way replicated crossover design¡A·í¸ÕÅçÅã¥Ü¹ï·Ó«~ªºÓÅ餺Åܲ§¥¼¹FHVD¼Ð·Ç®É(§Yintra CV%<30%©ÎSWR<0.294)¡A¤´À³¦^Âk¨ìunscaled ABE¤ÀªR¡A¨Ã¥H80~125%§@¬°BE criteria¡C¦Ó¹ï·Ó«~ªºÓÅ餺Åܲ§(within-subject standard deviation of the reference product, SWR)ªº¸Ô²Ó¦ôºâ¤èªk½Ð°Ñ¦ÒU.S. FDAªºBioequivalence Recommendations for Progesterone Capsule (2011, Draft)¡C µM¦Ó§Ú°êªk³W¥Ø«e¨ÃµL°w¹ï°ªÅܲ§ÃÄ«~¥HRSABE¤è¦¡ªºÃþ¦ü«Øij¡A¦Ü©óCmax¤§BE criteriaªº©ñ¼eÀ³¦^Âk¥ÍÅé¬Ûµ¥©Ê¸ÕÅç·Ç«h²Ä¤Q¤K±ø¤§³W©w¡A¥ç§Y¡A·í¥Hreference-replicate cross over design°õ¦æ©Ò´ú±oªº¹ï·Ó«~intra-subject CV%¶W¹L30%®É¡ACmax©ñ¼e¦Ü75~133%¬O¥i¥H±µ¨üªº¡A¦ý·íintra-subject CV%¨Ã¥¼¶W¹L30%¡A¨äCmax¤§BE criteria¤´À³¥H80~125%¬°¥D¡A¤Wz²Îp¤è¦¡À³¦b¸ÕÅç«e¸Ô²Ó¸ü©ú©ópµe®Ñ¡C¦Ó¨Æ¥ý¥Ó½Ð®Ö©wªº®É¾÷¡A¬°BE¸ÕÅç¶}©l°õ¦æ¤§«e¡C ¨ä¤è¦¡¦³¤G¡A¤@¬°´£¨Ñ¬ÛÃö¼Æ¾Ú¸ê®Æ¨ç¸ß½Ã¥ÍºÖ§Q³¡¹«~ÃĪ«ºÞ²z¸p¡A»¡©ú¹ï·ÓÃÄ«~Y¦b¦P£¸¸ÕÅç¤U³QÃҹꬰ°ªÅܲ§©ÊÃÄ«~¡A¬O§_¯à±NCmax¤§90% CI©ñ¼e¦Ü75~133%¡C¨ä¤G¬°ÀË°e§¹¾ã¤§BE¸ÕÅçpµe®Ñ¡Apµe®Ñ¤¤©ú½T©w¸q¸ÕÅç³]p¤Î²Îp¤ÀªR¤èªkµ¥¡A¥H¶i¦æpµe®Ñ¼f¬d¡C |
|
|
·|û¡G¹x¥Û10140865 µoªí®É¶¡:2015/10/28 ¤W¤È 11:15:54²Ä 495 ½g¦^À³
|
Åܲ§©Ê¬OÃöÁä°ÝÃD¡A¤£¹L¥¦ªº¼vÅTn¬Ý¹M²§©Êµo¥Íªº¸`ÂI¡C ¦pªG¬O»sµ{¤¤ªºÅܲ§©Ê¡A¦Ó¦b»s³y§¹¦¨¤§«á¥i¥HÂǥѥͤÆÀË´ú¤©¥H¿z¿ï¡A¤£¦X®æªº¤©¥H¯Â¤Æ©Î¥á±ó¡A¨º»ò¥¦©Ò¼vÅTªº´N¥u¬O»s³y¦¨¥»ªº°ª§C¡C¦Ó¥B³o¤]ªí¥Ü±qMSKCC¨ì¥Ø«e¤G´Á¡B¤T´Á©Ò¥ÎªºÃľ¯¡A§Y¨Ï»sµ{¦³©Ò§ó°Ê¡AÃľ¯ªº³W®æÁÙ¥i¥H¬O¬Û¦Pªº¡C (¤p§Ì¹ïFDAªº³W©w¤£²M·¡¡A¬O§_¤¹³\¦bÁ{§É¹Lµ{¤¤©Î¬OÃĪ«¤W¥«¤§«á¤¹³\±Ä¥Î¤£¦P¥Í²£»sµ{©Ò²£¥Xªº»s¾¯¡Hª½Ä±§PÂ_¡A¤p¤À¤lÃÄÀ³¸Ó¥i¥H¡A¦Ó¥Íª«»s¾¯À³¸Ó¤£¦æ¡C822¬O¥Íª«»s¾¯»PÁÞªºµ²¦XÅé¡A¦pªG¥u¬OÁÞ°ò¤WªºÅܲ§©Ê¡AÀ³¸ÓÁÙ¥i¥H§a¡H) ¥t¤@ºØÅܲ§¬O¦bÃľ¯»s¦¨¤§«á¡A¥¦ªºÅܲ§©ÊµLªk¥Î¥Í¤ÆÀËÅ礩¥H¿zÀË¡A©Î¬O¦X®æ¦¨«~¦b«O¦s¹Lµ{¤¤·|²£¥ÍÅܲ§¡A¨º³oºØÅܲ§©Ê´N¬O®Ú¥»ªº°ÝÃD¡A¨S¦³¸Ñ¨M¤§«eÀ³¸Ó¬O®³¤£¨ìÃÄÃÒªº¡C ¤p§Ì¤£¾ÇµL³N¡A·Q¨ìþ»¡¨ìþ¡CYª©¥D»{¬°¨S¥²n¯dµÛ¶Ã¤H¦Õ¥Ø¡Aª½±µ¬å±¼«K¬O¡C ¤U¦¸ªk»¡·|¡Aþ¦ì«Ñ¤l¸Ìªº¤j¤jÀ°¤j®a°Ý°Ý¡H |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/10/28 ¤W¤È 10:47:53²Ä 494 ½g¦^À³
|
¦U¦ì¤j¤j ¥H¤U¬O2014¦~12¤ë26¤é¤WÂd¤½¶}»¡©ú®Ñ´£¨ìªºOBI ¯S®í»sÁÞ§Þ³N ¥H¤U¬O§Úªº¸ÑŪ ¶È¨Ñ°Ñ¦Ò §Ú»{¬°¯E¹©¤w¸Ñ¨M¤FCliff¤j»P¤j®a¾á¤ßªº°ÝÃD 1Cliff¤j»¡ªº¨S¿ù³oºØ°ÝÃD¬O°Ý¤£¥Xµª®×ªº(ÄÝ°Ó·~¾÷±K) 2°ÝÃD¸Ñ¨M«á¤~·|¦³2104¦~4¤ë¯E¹©»P¤¤¬ã°|ñ¸pÁÞ¤À¤l¦X¦¨§Þ³N±MÄݱÂÅv«´¬ù,¬°¥¼¨Ó¤j¶q»s³y°µ·Ç³Æ 3´Á¦b¥¼¨Ó¤W¥««á¡A¯à¥H³Ì¨Î¤Æªº±ø¥ó¡A¦b¨}¦n«~ºÞªºÀô¹Ò¤U¡A²£¥X¨ã¦³¤@P©Ê«~½èªºÃÄ«~¡A½T«O¥ÎÃÄ ¯f¤Hªº¦w¥þ¤Î¦³®Ä©Ê¡Aªø´Á¨ÑÀ³©Ò»Ýnªº¯f±w¨Ï¥Î (³Ì«n¤@¬q) 4¥Í²£ÃöÁä¨BÆJ¤Î±±¨î°Ñ¼Æªº¬ÛÃö§Þ³N¡A§¹¥þ´x´¤©ó¥xÆW¯E¹©¤â¤¤(³o¤@¤p¬q¤]ȱoª±¨ý) 5 OBI822 ¦]¬OªvÀø©Ê¬Ì] ¤£¬O¹w¨¾©Ê¬Ì] ªø´Á°O¾ÐIgG ¤ñIgM ¤Ö¤@¨Ç°ÝÃD¤£¤j(¦]·|¶¡¹j¬I¥´«O¦³§ÜÅé¶q) 6 ¨ÅÀùOBI822Àø®Ä¤]·|»¡©ú°ÝÃD¦³¨S¦³¸Ñ¨M ,¦p·|¼vÅTÀø®Ä¦´N³Q¢¸Ñª¼¤F P92 OBI ¯S®í»sÁÞ§Þ³N¡B¤j³W¼Ò»Ã¯ÀÁÞ¦X¦¨ªk ±N Globo H »P KLH(¦åÂųJ¥Õ)¸g¤Æ¾Ç³sµ²«á¡A§Y¥i±o¨ìÀù¯g¬Ì] OBI-822 ªºì®ÆÃÄ¡C³o¶µ¤Æ¾Ç¦X¦¨§Þ³N¡A¤D¥xÆW¯E¹©¹Î¶¤¡Aµ²¦X¤WzªºÁÞÅé§K¬ÌÀøªk¬ì §Þ¡A¥H¤Î¦yºÝªºÁÞ¦X¦¨§Þ³N¡A¦@¦P§V¤O¡B³v¨B½Õ¾ãÀu¤Æ¤Uªº¦¨ªG¡A¥Í²£ÃöÁä¨B ÆJ¤Î±±¨î°Ñ¼Æªº¬ÛÃö§Þ³N¡A§¹¥þ´x´¤©ó¥xÆW¯E¹©¤â¤¤¡A´Á¦b¥¼¨Ó¤W¥««á¡A¯à¥H ³Ì¨Î¤Æªº±ø¥ó¡A¦b¨}¦n«~ºÞªºÀô¹Ò¤U¡A²£¥X¨ã¦³¤@P©Ê«~½èªºÃÄ«~¡A½T«O¥ÎÃÄ ¯f¤Hªº¦w¥þ¤Î¦³®Ä©Ê¡Aªø´Á¨ÑÀ³©Ò»Ýnªº¯f±w¨Ï¥Î P92 OBI ¯S®í»sÁÞ§Þ³N¡B¤j³W¼Ò»Ã¯ÀÁÞ¦X¦¨ªk ¥xÆW¯E¹©¦Û¬ü°ê Optimer Pharmaceuticals Inc.¤Î¥xÆW¤¤¥¡¬ã¨s°|¡A§ÞÂà¦hÁÞÅé ªº¥Í²£§Þ³N¡A¬ð¯}¹L¥h¼Æ¤Q年¡A¬ì¾Ç®aÁöµMµo²{ÁÞÃþ¦bÀù¯g§êºt·¥«nªº¨¤¦â¡A «oµLªk¤j¶q»s³Æªº§x¹Ò¡C¦p¤µ¡A¥xÆW¯E¹©¾Ö¦³³Ì¦yºÝªºÁޥͲ£§Þ³N¡A¥i¬ð¯}¥Ø«e ÁÞÃþµLªk¼sªx¥Î©ó·sÃĬãµo¤Î¶q²£ªº²~ÀV¡A¤j´T°§C¦X¦¨¨BÆJ¤Î¥Í²£¦¨¥»¡AÅýÁÞ ÃþÃĪ«¥i¥H¶q²£¶i¤JÂåÀø¥«³õ¡COBI ¯S®í»sÁÞ§Þ³N¥i¥H¦³®Ä²v¦a±o¥X³Ì²×©Ò»Ýn²£ª«¡A³o¼Ëªº¤Æ¾Ç¦X¦¨¤è ªk¡C¥Ñ©ó³o¶µ§Þ³Nªº¶}µo¡A¨Ï±oÁÞ¤À¤lªº°Ó·~¤Æ¥Í²£¤£¦A¬O»»¤£¥i¤Îªº¹Ú·Q¡A ³þ©wÀù¯g§K¬ÌÀøªkªº°ò¢¡C¤j³W¼Ò»Ã¯ÀÁÞ¦X¦¨ªk(Chemo-Enzymatic Process)¡A§ó¶i¤@¨B±NÁÞÃþ³z¹L»Ã ¯À¡A¦b 4 ¨B¤ÏÀ³¤¤§¹¦¨¤»ÁÞªº»s³Æ¡A¦¹¬° OBI ¯S®í»sÁÞ§Þ³N«á¬°§ó·sªº¬ð¯} P100 -101 ²£«~¥Í²£¶}µo§Þ³N¤§½T«O(±M§QÅv¤Î©Ò¨üªk«ß«OÅ@ª¬ªp)»P´£¤É Globo H Àù¯g§K¬ÌÀøªk§Þ³N²¾Âà¦Û¬ü°ê Memorial Sloan Kettering Cancer Center «á¡A¥»¤½¥q¤w¸g¿n·¥¶i行±M§Q§G§½¡A¥Ø«e¦b OBI-822, OBI-833, OBI-868 »P OBI-888 §¡¤w¾Ö¦³¡uª«½è²Õ¦¨¡]composition of matter¡^¡v ªº±M§Q¡A¤@¯ë¨Ó»¡¡A¤½¥q¾Ö¦³ª«½è²Õ¦¨±M§Q¡A¬°±M§Q«OÅ@ªº³Ì¤j¤Æ¡A¤]¬O³Ì¦³ »ùȪº±M§Q¡A¦]¦¹¡A¥»¤½¥q¤w¸g½T«O©Ò¦³²£«~§¡¾Ö¦³´XÓª«½è²Õ¦¨±M§Q¡A¤½¥q ¥h年±M§Q¥Ó½Ð¼Æ¶q¹F¨ì·s°ª¡A¥»¤½¥q¥h年Àòã¤F 16 ¶µ±M§Q¡A¨Ã¦³ 8 ¶µ±M§Q¤w ¥Ó½Ð¨Ã¶i¤J¼f¬dµ{§Ç¡C¾ãÅé¦Ó¨¥¡A¥»¤½¥q¥Ø«e¾Ö¦³ 23 ¶µ±M§Q¥þ²y®Öã¡A¦P®É ¦³ 16 ¶µ±M§Q¥¿¦b¦U°ê±M§Q§½¼f¬d¤¤¡A¥»¤½¥q¥ç¿n·¥§G§½¤£¦Pªº±M§Q¥Í©R©P ´Á¡A¥H«O»Ù¤½¥q²£«~´¼¼z°]²£ªº³Ì¤j年¡C |
|
|
·|û¡Gjm042310140224 µoªí®É¶¡:2015/10/28 ¤W¤È 09:27:35²Ä 493 ½g¦^À³
|
Cliff¤j ¯E¹©ª©¦³±z¯u¦n ±z°l®Ú¨s©³ªººë¯«¡B¯à@µL¤H¯à¥X¨ä¥k ±z´£¥Xªº°ÝÃD¡A¤p§Ì³£·Q¦^À³ µL©`©|ÄÝ¥®¸X¶é¯Z¡C ´Á¬ß±z¤£®É´£ÂI²³ª©¤Í |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2015/10/28 ¤W¤È 08:19:24²Ä 492 ½g¦^À³
|
Cliff¤j¡A ¯E¹©ª©¦³±z¯u¦n¡I ¹ïªÑ»ù¤w¦³¬J©w·Qªk ©È£¸¦À¬K¤ô¼vÅTªÑ»ùªº¤H ¥i¥H¸õ¶}¦¹°Q½×ª© ¥u±Mª`¦b5112¤¸¨º¤@ª©´N¦æ¤F |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/10/28 ¤W¤È 07:48:58²Ä 491 ½g¦^À³
|
Cliff¤j ÁÂÁ±z ¬Ýª©¬Ý¤[¤F,³£ª¾¹DCliff¤j¤@¶µ¹ê¨Æ¨D¬O,ª`«¬ì¾Çªººë¯«,¦³´X¤ÀÃÒ¾Ú»¡´X¤À¸Ü,¦Ó¥BÀ´±o¤º®e³£¬Û·í±M·~,§Ú̱æ¹Ð²ö¤Î Cliff¤j¤]¤£¤Ó¦b¥GªÑ»ù,¦ý·|¦bªÑ»ù§C°g®É,§i¶D§ÚÌ"°ò¥»±¨SÅܧr",Á`¬Oµ¹¯E¤Í̳\¦h¹ªÀy ª©¤W´N»Ýn¹³Cliff¤j³o¼Ëªº¸êÀu¥Í,¤~¯à¤Þ»â§ÚÌ»{Ãѳ\¦h¬ì¾Ç¶ø¯µ,¤]¤~¯à¦b¼Ó¬n®É¤@¦A±N¤j®a±a»â¦^"ì¥ýªº¿O¶ð" ¸Ü»¡~ª©¤W¤]¨S¦³¤H¯àÂZ¶Ã´X¦À¬K¤ô,¬ì¾Ç´N¬O¬ì¾Ç,°Z¬O¤j®a¦b³oÃä³Û³Û´N·|§ïÅܪº? ¥t¥~,¥»ª©ªº¥i¶Q´N¬O¦b©ó¤½¥q¤£·|»¡ªº¨Æ,¥Ñ¯E¤Í̬ۤ¬¤Á½R,´£¥X°Q½×,¸òª©¤[ªº¤H³£ª¾¹D,¯E¤ÍÌ¥i¼F®`ªºù,«¢«¢«¢~~ ¦A¦¸ÁÂÁÂCliff¤j ¨º¤p§Ì½Ð±Ð¤@¤U,§Ú°O±o¶À¨q¬üÁ`¸g²z´¿´£¹L,¥xÆW¬O¤G¤T´Á¦P®É¶i¦æ,¦ý¬O«e±¦¬®×ªº45¤H¬O¤G´Á ¦³¨S¦³¥i¯à,Á{§É¤G¨ä¹ê¤w¸gµo²{,¦b¤T´Á®É¤w×¥¿¤F©O?¶Ã²q¤@³q, ¯E¤ÍÌ,»°§ÖÀ°¤p§Ì×¥¿§Úªº²q´ú,«¢«¢«¢,ÁÂÁÂÅo °e³ø¤j ÁÂÁÂÅo 200¶¤p§Ì²¤¬Ý¹L¤F,¤j³¡¤À´N¬O´£¨ì±M§Qªº¤º®e,¤p§Ì¤]¬Ý¤£¤Ó¥X©Ò¥HµM(¤p§Ì¸ê½è¤£¦n) ³o´Nn¦³³Ò³Ì·|¾ã²z¸ê®Æªº¥xÁÞ¤jÅo,«¢«¢«¢~~ |
|
|
·|û¡Gµ½¤H10137888 µoªí®É¶¡:2015/10/28 ¤W¤È 02:15:07²Ä 490 ½g¦^À³
|
Cliff¤j, «D±`·PÁ±zªºÄÀºÃ. Ó¤H¤£¦¨¼ôªº·Qªk, ¦pªG³s±µ·|¦³¤£Ã©w©M¤£¤@P©Êªº°ÝÃD, ±i¸³©M´å¬ãµoªøÀ³¸Óª¾¹D¨äÄY«©Ê, ¦b¨S¦³¸Ñ¨M°ÝÃD«e, «ç»ò´±ªá¤j¿ú©M¤»¦~ªº®É¶¡¶i¦æ¤G/¤T´Á¤HÅéÁ{§É¸ÕÅç? ¸U¤@¥X°ÝÃD, «ç»ò¹ï±o°_¯Î°|ªø©M¤ä«ùªº¤jªÑªFÌ? ±i¸³©M´å¬ãµoªø¤£·|¹³§Ú³o»ò²Â§a! ¥t¥~, ¦pªG³s±µ¦³°ÝÃD, ¤¨¦ÑÁó·|³Q´e¦b¹ª¸Ì¶Ü? ¤¨¦ÑÁ󴱤j¶R¯S¶R, À³¸Ó¬O±o¨ì¨S°ÝÃDªº°T®§. ¦pªG¥X°ÝÃD, «ç»ò¦VªÑªF¥æ¥N? ÁöµM§ë¸ê¦³¦¨±Ñ, ¤£P©ó±Ñ±o³o»ò·M§a? ¦V¤¨¦ÑÁó¶Ç»¼°T®§ªº¤H, ¥H«á«ç»ò¨£±¥æ©¹? |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/10/28 ¤W¤È 12:48:50²Ä 489 ½g¦^À³
|
¬°¤FÁקKµL¿×ª§Ä³¡A§Ú¥ýÁn©ú¡A§Ú¨Ã¤£¬OÃhºÃ¤½¥q©Î¤£¬Ý¦n¤½¥q¡A¤£n»~·|¡C §Ú¥u¬O¦n©_Åܲ§©Êªº°ÝÃD¦b822ªº¨¤WÁÙ¦s¦b¶Ü¡HÁÙ¬O¤w¸g³Q¤½¥qª½±µ¸Ñ¨M¡H©Î¬O»¡±À¥X833´N¬O¸Ñ¨M¤èªk¡H°ò¥»¤W§Ú¨Ã¨S¦³µª®×¡A©Ò¥H»¡¹ê¦b¦a¤]µL©Ò¿×¬Ý¦n©Î¬ÝÃaªº°ÝÃD¡A¤½¥q³£¦Ñ¯«¦b¦b¤F¡A§Ú¬O¤£©È¡A¥u¬O·Qª¾¹D¬O«ç»ò¸Ñ¨Mªº¡]¡K¦pªG¥i¥Hª¾¹Dªº¸Ü¡K¡^¡C §Ú·íµMª¾¹D³oºØ°ÝÃD¬O°Ý¤£¥Xµª®×ªº¡A¤½¥qùت¾¹Dªº¤H¡A¤T½p¨ä¤f³£¨Ó¤£¤Î¤F¡F¸Ü»¡¦^¨Ó¡A´N¬O°Ý¤£¨ìªº¨Æ¡A¤~·|¨Ó³oª©¤WªF±À±À¦èºVºV¡A½Ð¤£n·í§@§ë¸ê¦Ò¼{¡F»¡§Ú§j¿¨¤@¦À¬K¤ô¡A¦Ñ¹ê»¡¡A§ÚÁÙ¯u§Æ±æ¦Û¤v¾Ö¦³³o¼Ëªº¡u¶W¯à¤O¡v¡I·QÅ¥§Ú§j½K²Ä¤G¦À¶Ü¡Hºâ¤F¡I ¦^¨ì³Ìªì¡A´N¬OIriswu¤j´£¨ìÃĪ«¦³Åܲ§©Êªº»¡ªk¡A°_ªì§Ú¤]¤£ª¾¹D¡A«á¨ÓŪ¨ìªº¤@¨Ç¸ê®Æ¡AÁÙ¯uªº¬O¦³¦¹¤@¨Æ¡]¨£«e¤åªº2011¦~ª©ªº¡uToward Automated Oligosaccharides synthesis¡v¨º¤@¬q¡^¡Aª©¤W½Ñ¦ì¥ý¶iÀ³¸Ó°O±o¡A¬O¥h¦~§a¡H§Ú¦bª©¤W´¿°Ý¹L¤j®a¡A822ªº¯ÊÂI¬O¬Æ»ò¡Hµ²ªG¤]¨S¤H´£°_³oÓµ²ºc¤W«D±`°ò¥»ªº°ÝÃD¡A²{¦bµo²{¤F´N®³¥X¨Ó±´°Q¤@µf¡A´N³o»ò³æ¯Â¡A¯u¥¿ªºµª®×¡A§Ú¤]ı±o°Ý¤£¥X¨Ó°Õ¡I³»¦h¥u¬O±o¨ì¼Ð·Çªº¨î¦¡¦^µª¡C¦ý¬O¦Ñ¸Ü¨â¥y¡A³o¨Æ¤@«hµLÃö§ÚÓ¤H¹ï¤½¥q/²£«~ªº«H¤ß¡A¤G«h¤£n®³¨Ó·í§@§ë¸ê°Ñ¦Ò¡C§ÚÓ¤H¶K¤å¤@¦V¤£¬°«P¾P/ÄU¶i¡A¦b¦¹¦A¦¸Án©ú¡C¤½¥q¥i¥H°µ¦h»¡¤Ö¡A¤£ª¾¹Dªº¥Ã»·¬O§ÚÌ¡A§Ú¬Û«H¤½¥q¤ßùجO©ú¥Õªº¡A¥¿¨Æ/Ãø¨Æ´NÅý¤½¥q·Ð´o¥h¡A§Ú¥u¬O¤ñ¸û¦n©_¦Ó¤w¡Aª¾¨äµM¤§¥~¡AÁÙ·Qª¾¨ä©Ò¥HµM¡C©Ò¥H§Ú·|±`¥h°Ý¤½¥q¤@¨Ç¤@¯ë§ë¸ê¤Hı±o«ÜµL²áªº°ÝÃD¡A°ò¥»¤W§Ú¬O§â¥¦·í§@¤@ªù¾Ç°Ý¨Ó°µ¬ã¨s¡CNot only for investment¡Abut also for increase of koowledge¡C §ÚªººÃ°ÝªºÅÞ¿è«Ü²³æ¡A¡u¡K¨Ï¥Î·s¿oªº¤Æ¾ÇÁäµ²ªk¨ÓÁpµ²ÁÞ§Üì(Globo H) »P¸üÅé³J¥Õ( ¥Õ³ïÃþ¬r¯À¡ADT-CRM197)¡A§Q¥ÎOBI ¤º³¡¬ÛÃö§Þ³N¡A½T»{¨âªÌ³Ì¨Î¤ñ¨Ò¡A¥H¹F¨ì´£¤É¤HÅé§K¬Ì¨t²Î¹ïÁÞ§Ü쪺¿ëÃѯà¤O¡A±q¦Ó¹F¨ì¥D°Ê¦¡§K¬ÌªvÀøªº¥Øªº¡C³oÃþ«¬¤Æ¾Ç×¹¢³J¥Õ½èªº§Þ³N¡A ¥»¤½¥q¤w¦b¥t¤@¶µ²£«~OBI-822¤W¦¨¥\ÅçÃÒ¡A¨Ã¤w¦b¥xÆW¶i¤JÁ{§É¤T´Á¸ÕÅç¡C¡K¡v³o¤@¬q¤å¦rŪ°_¨Ó´N¤@ª½Ä±±o©Ç©Çªº¡A·Q·Q¬Ý¡A822ªºPhase I¬OMSKCC°µªº¡A¤]´N¬O»¡ÃĪ«°t¤è/²Õ¦¨¬OMSKCC¨M©wªº¡F¦ý¬Ophase II/III¬O¤½¥q°µªº¡A¨º°t¤è©O¡H¡u§Q¥ÎOBI ¤º³¡¬ÛÃö§Þ³N¡K³oÃþ«¬¤Æ¾Ç×¹¢³J¥Õ½èªº§Þ³N¡A ¥»¤½¥q¤w¦b¥t¤@¶µ²£«~OBI-822 ¤W¦¨¥\ÅçÃÒ¡A¨Ã¤w¦b¥xÆW¶i¤JÁ{§É¤T´Á¸ÕÅç¡C¡v³o¼ËŪ¤U¨Ó¡A¤£¬O¥Ù¬Þ¤F¡HÃø¹D¡u¦b¥xÆW¶i¤JÁ{§É¤T´Á¸ÕÅç¡vªº822¬O¸g¹LOBI×¹¢¹Lªº¡A¸òMSKCC°µªºPhase Iªº822°t¤è/²Õ¦¨¬O¤£¦Pªº¡H³o¡K³o¡K¡A±À½¤F¤@¯ë¤Hªº»{ª¾¡CÄ~Äò¦M¨¥ÁqÅ¥¤@¤U¡A½Ð¬Ý¤W¤@½g¶K¤åªºµù1¡A¥|¥¨ÀY½×¤åªºFig.10¡A¤W¥b³¡ªº¹Ïµù©úµÛ¡uGlobo H-KLH vaccine in phase III Clinical Trial¡v¡A¬°¦ó¯S§O¼Ðµù¬O²Ä¤T´Á¡A»á@¤H´M¨ý¡C´¿´N¦¹½Ð±Ð¹L¤½¥q±M·~¡A¥u±o¨ì¤@¨Ç¤è¦V¤Wªº«ü¤Þ¡A¨ä¾lªº´N¾a¦Û¤v§V¤O¡A¤~·|·Q±q¤½¥qÀò±oªº±M§Q¥h§ä´M¥¦»Pì©lªºMSKCCªºª©¥»¦³¦ó®t²§¡Aµ²ªG´N¬O¦p¶K¤å©Ò¨¥¡A§Ú¤´¨S·dÀ´ºÃ°Ý¤´¦b¡C¡]¦pªG»P¤@´Áªº°t¤è¬O§¹¥þ¬Û¦P¡A«ç½ü±o¨ì¥Ñ¤½¥q¥h¥Ó½Ð±M§Q©O¡H¡^ Iriswu¤jYÄ@´£¨Ñ·í®ÉÅ¥¨ì¡uÅܲ§©Ê¡vªºI´º/²Ó¸`/¨Ó·½¡A·íµM¦A¦n¤£¹L¡C µ½¤H¤j¡A§Úı±o±M§Q¥Ó½Ð¦¨¥\»P§_¸ò°Ó«~¦n¤£¦n¤£¤@©w¬ÛÃö¡A¥unµo©ú¬O«e©Ò¥¼¦³¡A§Y¨Ï¬O¤£¦n¥Î/¤£@¥Î/¤£¦n¦Y¡AÁÙ¬O¥i¥H¨ú±o±M§Q¡A¦Ü©ó¦n¤£¦n½æ´N¬Ý¥«³õ¨M©w¡C¤w±o¨ì±M§Q«OÅ@ªº°Ó«~¡A¨Ã¤£¨£±o¦³²¼©Ð«OÃÒ¡AÓ¤H¨£¸Ñ»P±z¤Á½R¡A·PÁ¡C ¥Xª©¤j¡A±z¯u¬O¼F®`¡A§â¤¤¤åª©ªº³£«õ¥X¨Ó¤F¡A¨ØªA¨ØªA¡C |
|
|
·|û¡G¥¤ß¦Ó½×10139639 µoªí®É¶¡:2015/10/27 ¤U¤È 11:02:14²Ä 488 ½g¦^À³
|
¥¤ß¦Ó½×¡A¤j¤á¤j¦n¹³«Ü¤£¬Ý¦n¯E¯E¡A¯E¹©¬O¤£¬O¨SÁȨì¿ú´N»Ä¯E¤Í¡A¸²µå§An¦Y¤F¤~·|ª¾¹D»Ä©Î²¢¡A¤£n¥ú¬Ý¤£¶R¤]¤£¦Y¡A¥u¯à¬y¤f¤ô¬Ý§O¤H¦Yªº«Ü²n Åܲ§©Ê¤£«n¡A¦]¬°¹êÅçµ²ªGÁÙ¬O¦bPFS,p value,¦³®Ä´N¦n¡A¨ä¾l³£¬O¤p¨Æ¡AÀù¥½¯f±w¯àÄò©Rºû«ù¥Í¬¡«~½è¬°ºn¡A¥t¥~¤£n®³ÂûÀn¡A«OÄÖ²y¡A´¼¸V¤ñ¡A¤£¦PÀɦ¸ªº¡ALPÂû»LJ¶Ã¤ñ¡A¯º¸Ü¦Ó¤w |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/10/27 ¤U¤È 08:33:13²Ä 487 ½g¦^À³
|
°e³ø¤j ÁÂÁ´£¨Ñ 200¶,¤p§Ì¤£¬O¸êÀu¥Í¨S¨º»ò§Ö°Õ.nµ¹§Ú¦hÂI®É¶¡ µ¥Cliff¤j¤ñ¸û§Ö,«¢«¢«¢ ÁÂÁÂÅo |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2015/10/27 ¤U¤È 07:57:29²Ä 486 ½g¦^À³
|
ÃÙ¦¨¥xÁÞ¤j Y¤Ö¤F³o¸s¥Í§Þ¤j®v»P«e½ú·RÅ@¥xÆW §ë¸ê¥xÆW ¥xÆW´NÅܦ¨§b¤Y ¤×¨ä¬O¯Î±Ò´f°|ªø§ÞÂà©Ò±o ®½µ¹¤¤¬ã°|±Nªñ¤»»õ ¥O¤H¨ØªA ¶}±Ò¥xÆWÁÞ¤À¤l²£·~ ¦¨¬°¥@¬É²Ä¤@²£·~ ÃÙ¦¨¤j¤á¤jÆ[ÂI ¼f¬dCMC(¤Æ¾Ç»s³yºÞ¨î)ªº¥Øªº¦b½T«OÃÄ«~ªº«~½è¡A¥H«O»Ù¤H¥Á¥ÎÃĦw¥þ¡CCDE¤À§O°w¹ïì®ÆÃÄ»P¦¨«~ªº¸ê®Æ¶i¦æ¼f¬d¡Cì®ÆÃĪº³¡¤À¡A°w¹ïì®ÆÃĪºÀËÅ綵¥Ø¡B¤ÀªR¨BÆJ»P±µ¨ü°ò·Çªº¦X²z©Ê¡A¨Ï¨ä¹ï«~½è¦³¾A¤Á¤§«O»Ù¡Q¹ï©ó·s¦¨¤À¤§ì®ÆÃÄÂǥѦX¦¨¤èªk»Pµ²ºcŲ©w¸ê®Æ¥i½T»{¦¹ì®ÆÃÄ»P©Ò«ÅºÙ¤§¤Æ¦Xª«¬Û²Å¡C¦¨«~ªº³¡¤À¡A¼f¬dªº«ÂI¦b½T»{½á«¬¾¯ªº«~½è¡B§t¶q»P¥\¯à¡A¨Ã¸g»s³y¬yµ{¡B»sµ{ºÞ¨î»P§å¦¸¬ö¿ý¼f¬dÃÄ«~ªº¥Í²£¬O§_¹F¨ì§å¦¸¶¡¤@P©Ê»P¦A²{©Ê¡AÂÇÀËÅ綵¥Ø¡B¤ÀªR¨BÆJ»P±µ¨ü°ò·Ç¹ï©ó¦¨«~¬O§_«~½è¦³¦X²z¤§ºÞ¨î¡A®Ö©w¦³®Ä´Á¥H½T«OÃÄ«~©ó¬[Àx´Á¨ã¦w©w©Ê»P¦³®Ä©Ê¡C (¤Þ¥Î¦Û http://cde.org.tw/FAQ/NDA/Pages/%E5%8C%96%E5%AD%B8%E8%A3%BD%E9%80%A0%E7%AE%A1%E5%88%B6(CMC).aspx) ©Ò¥H¯u¤ß§Æ±æ¯E¹©§âÃÄ°µ¦n¨Ó½æ ¦]¬°¥H«á§Ú¥i¯à»Ýn¥´´X°w |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/10/27 ¤U¤È 07:47:15²Ä 485 ½g¦^À³
|
¶À©üªº¬G¶m Áö¬O¨¦b²§¶mªº¹C¤lªíµª¹ï¬G¶m¥À¿Ëªº«ä©À,³o¤@¸s¤Ñ¤ý¯Åªº¥xÆW¥Í§Þ¤H¤~ »{¦P¥xÆW¬O¥L(¦o)̥ͩRªºì¶m Âk¤ß¦ü½b ¨ã¦³°ê»Ú¤Ñ¤ý¯Å±ø¥ó¥xÆW¥Í§Þ¤H¤~¤£¤Ö¡A³o¨Ç¥xÆWªº¥Í§Þ±M®a¦h¼Æ«Ý¦b¬ü°ê¡A ¦~ÄÖ¤w¤j,¥»¥i§t¹~§Ë®]¡A¬°¤F¥xÆW¥Í§Þ²£·~¥L(¦o)ÌÄ@·N¸¨¸Âk®Ú,³o¨Ç¤H¤~ ³£¸g¹L§¹¾ãªº²£·~¾ú½m¡A±aµÛ²z©À »ùÈ Ä@´º»P«H¥õ¯É¯É¦^°ê³Ð·~¥[¤W¥xÆW¶Ò¸ê ®e©ö,ªÑªFªº±¡¸q¬Û®¼,¥xÆW¥Í§Þ²£·~¯à¦³¤µ¤Ñ,³o¨Ç¸¨¸Âk®Úªº®ü¥~¥Í§Þ¤H¤~¥\¤£¥i¨S ¨C¦¸Å¥¨ì¦nÅ¥ªº ¶À©üªº¬G¶m ¿ûµ^¿W«µ ¹ï¦^°ê³Ð·~°^Äm¤ß¤Oªº®ü¥~¥Í§Þ¤H¤~·|¦³¤@ºØ»¡¤£¥Xªº·PÁ |
|
|
·|û¡G¤j¤á¤H®a10140174 µoªí®É¶¡:2015/10/27 ¤U¤È 07:40:00²Ä 484 ½g¦^À³
|
¼ç¤ô¤j,´¼ÀºÄ_ÄÖ¤£¬O³£¤w¸gªíºt¹L¨â¦¸µ¹±z¬Ý¤F.Ä_ÄֲĤ@¦¸¤j®a»¡¨S¬Ý¹L´Nºâ¤F,¦n¤F²{¦b´¼Àº¤]³o¼Ë,¤S»¡´¼Àº«ç»ò¸òÄ_ÄÖ¤£¦P.·íµM¤£¦P£«,¥i¬OªÑ»ù³£¬O§Q¦h¥XºÉ,²{¦b¤S¦A»¡¤¤¸Î«ç»òÓ¤£¤@¼Ë¤F¡C §Ú«Ü©_©Ç¤j®a«ç»ò³£¤@©wn¨M±o¦Û¤v§ë¸êªº¤½¥q³£¬O³Ì´Îªº.¨ä¥L¥¢±Ñªº¨Ò¤l¬O¦]¬°²£«~¤£°÷¦n,©Î¬O³æ¤@ªº²£«~.¦pªG¤¤¸Î¦¿¨Ó¤]¬O¨ÓÓ§Q¦h¥XºÉ©O?¤¤¸Î·|¶RªºÀ³¸Ó³£¬O¶R¦b40´X,´N¬O¦bµ¥²{¦bªº§Q¦h¤£¬O¶Ü?±N¨Ó§A´Á«Ý½Ö¨ÓÀ°§A¦b©ïÃâ©O?¥~¸ê¶Ü?ÁÙ¬O´²¤á? ¦A¨Ó»¡²{¦b¯E¹©Åܲ§©Êªº°ÝÃD?¦pªG¬O¥X¦b822, 833¬O¸Ñ¨M¼w¤è®×.n³oºØªF¦è¤£¬O¹³¨ä¥Lªº²£«~¦³§é°Jªº,822¹L¤£¤FCMC,´N¬O¦³¨Ä¨Äªºµ¥833.¨º¬O¦Ü¤Ö¦A¦h¤¦~ªºµ¥«Ý.ÃÄ«~¥Í²£¤WªºÅܲ§©Ê¦pªG¬O¤£¥i±±¨î,ÃĮĮګ~½è¤Wªº¸¨®t,½Ð°Ýn«ç»ò¤W¥«? |
|
|
·|û¡G¼ç¤ô«È10134451 µoªí®É¶¡:2015/10/27 ¤U¤È 07:28:09²Ä 483 ½g¦^À³
|
¨ä¹ê±q¤j¤á¥X²{¨ì²{¦bªºµo¨¥¡A¥iª¾¥L¨Ã¤£«Dªì¤J¥«³õªº·s¤â 4147,4174¨ì©³¦n¤£¦n§Ú¬Û«H¥L«Ü²M·¡¡A ¦ý¥LÁ`¨è·Nªº´£°Ý¥L¤ß¸Ì쥻¤wª¾ªºµª®×¡A ¦p¤¤¸Î Ä_ÄÖ ´¼Àº ±¡ªp®Ú¥»¤£¦P ¥L¤ß¸Ì¤]ª¾«o¨è·N´£°Ý §Ú·Q¬O¥L¤@ª½·Q§C±µ«oµ¥¤£¨ì ©Ò¥H«æ¤F ¤£µM¥L¤§«eªºµo¨¥¨ä¹ê³£Áٻᦳ²`«× ¤£¦üªñ´Á°Ê¤£°Ê´N®³NBI¡BÁ×¹p°w¨ÓÀ~¤H¡A §Ú«ù¦³¤¤¸Î¤]¤w¤T¦~¦h¤F ¬Û«Hª©¤W³\¦h¤H¤]¬O ¤j®a³£¬O©êµÛ@¤ß ÁÙ¦³«Ü¦hªº®É¶¡¦¨¥»¨Óµ¥µÛ¤¤¸Î¦¨ªø ¤j¤á¦p·Q¶X¦¹®Én¶}ªáµ²ªG¤§»Ú ·Q·f¶¶·¨®¤]µL¤£¥i ¦ý¦p§A¯uªº¦³¤j®a¤£ª¾ªºt±®ø®§ ¤£½×§Þ³N±©Î®ø®§±³£¦n ³£½Ð´£¥X ¦ýY¬O¦ü¯u«D¯uªºÁqÅ¥¦M¨¥ ´N§O¦A»¡¤F¦n¶Ü? ¦]¬°§A¨C¤ÑÁ`¶µÛ4147 4174ª©±Âà ¦p§A¯uªºÄ±±o³o¨â¤½¥q³o»ò®t ¦ý¤¤¸Î¤S¤£¯àªÅ ¥H§A¸gÅçÀ³¥i§ä¨ä¥L¼Ðªº§a §O¦A®ö¶O®É¶¡¤F ©Î¬Oµ¥¤¤¸Î¤WÂd§A¦A¨ÓªÅ¥L¹À ¬Û¸û¤§¤U¡A¤p·¨¤j˯uªº²vª½¦h¤F |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/10/27 ¤U¤È 07:01:04²Ä 482 ½g¦^À³
|
¦³¨S¦³¤j¤j§â¤¤¤åª©200¶³£¬Ý§¹ªº.. |
|
|
·|û¡G³Í¤l³Í10140178 µoªí®É¶¡:2015/10/27 ¤U¤È 06:22:41²Ä 481 ½g¦^À³
|
¤j¤á¤j±z¯u¬OÅý¤p§Ì¶Ì²´.............(§AÁÙ¦Û¤v¸ÑŪ:¤Æ¾Çµ²ºc¥Í²£ªº¤è¦¡³£¥X²{¦b³o»ò¤jªººÃ¼{) C¤j¦³»¡²{¦bªº822¦³°ÝÃD?? C¤jªºì¤å: §Ú·Q¤F¸ÑMMCCH¦³¨S¦³¸Ñ¨M¡uÅܲ§©Ê¡vªº°ÝÃD C¤jªºì¤å:±q¤â¤W§ä¨ìªº´X¥÷¸ê®Æ¤ñ¹ïªºµ²ªG¡AÁÙ¬O·d¤£²M·¡³o¶µ°ÝÃD¯E¹©¸Ñ¨M¤F¨S¡H C¤j·Qª¾¹Dªº¬O¥L¤âÀY¤WÃö©ó822¥i¯àªº¯ÊÂI,¯E¹©¬O¤£¬O¤w¸g¸Ñ¨M¤F ©ÎªÌ¬O833¬O¤£¬O´N¬O¸Ñ¨M³o¨Ç°ÝÃDªº²£«~ ¦ý¬O§Ú¤w¸g¦^µª: ³o¨Ç¬O¤½¥q¾÷±K,½Ö·|¦b³o¸Ì¸ò§A»¡,§Ú̥Τ°»ò¤èªk,±o¨ì¤°»òµ²ªG,³o¨Ç°ÝÃD§ÚÌ«ç»ò³B²z(©ú¤Ñ´N³Q¤½¥qª£¤F©Î§i¤Wªk°|) C¤j¤j,±z¯u¬OµLºÝÂZ¶Ã¤@¦À¤ô |
|
|
·|û¡G¤j¤á¤H®a10140174 µoªí®É¶¡:2015/10/27 ¤U¤È 05:46:01²Ä 480 ½g¦^À³
|
³o«ç»ò¬O¦M¨¥ÁqÅ¥,¦pªG³oºØÅܲ§©Ê¦b²{¦bªº³W¼Ò³£¦³¥X²{,¨º½Ð°Ý±N¨Ó¬On«ç»ò¶q²£.FDA±N¨Ó¦bCMC¼f¬d®Én«ç»ò§JªA. |
|
|
·|û¡G¶Wô10139528 µoªí®É¶¡:2015/10/27 ¤U¤È 05:20:54²Ä 479 ½g¦^À³
|
¥Á¶iÄÒÁ`²Î°Ñ¿ï¤H½²^¤å27¤éµoªí¡u¨È¤Ó¥Í§ÞÂåÃĬãµo²£·~¤¤¤ß¡v¬Fµ¦¡C ½²^¤å¦bÁy®Ñpo¤å«ü¥X¡A¥Íª«¬ì§Þ¡A¬O¤HÃþ¬ì§Þ·í¤¤¡Aµo®i±o³Ì¨³³t¡BÀ³¥Î¤]³Ì¦hªº»â°ì¡C¥xÆW¦b³oÓ»â°ì¡A¦³µÛÀu¨qªº¤H¤~¡BÂרKªº¬ãµo¯à¶q¡B¥@¬É¯ÅªºÂåÀøÅé¨t¡A§Ú«D±`²M·¡¡C¦]¬°§Ú¦Û¤v´N´¿ºÉ¹L§V¤O¡A¬°°ê®a§ß«ù¥Í§Þ¡C ¬Fªvªº°«ª§¡A¤£·|ÅýªÀ·|¶i¨B¡A¥u¦³°ê®a¹Îµ²¡A¤~¯à¤ä¼µ¥xÆWªº²£·~¡C§Æ±æ¥¼¨Ó¡A§Ú̦b±¹ï«¤j¬Fµ¦ªº®ÉÔ¡A¯à°÷µL¨p¡B±M·~¡A³o¤~¬O»OÆW¦A³Ð¸gÀÙ©_Âݪº¥²n±ø¥ó¡C ¤µ¤Ñ¤½¥¬¡u¤¤j³Ð·s¬ãµop¹º¤§¤T¡G¨È¤Ó¥Í§ÞÂåÃĬãµo²£·~¤¤¤ß¡v¬Fµ¦¡A§ÚÌnµ²¦X²£©x¾Ç¬ãªº¤O¶q¡AÄ~Äò±j¤Æ¤H¤~¡B¸êª÷¡B´¼°]¡Bªk³W¡BÀô¹Ò¡B¿ïÃDªº¥¬§½¡A¥H¡u³sµ²¥¼¨Ó¡B³sµ²°ê»Ú¡B³sµ²¦b¦a¡v³o¤T¤j³sµ²¬°¥D¶b¡A¥þ¤O¥´³y¥xÆW¦¨¬°¡u¨È¤Ó¥Í§ÞÂåÃĬãµo²£·~¤¤¤ß¡v¡C ¤@¡B ³sµ²¥¼¨Ó¡G¾ã¦X®Ö¤ß³]¬I»P¸ê·½¤¤¤ß¡B¤ä´©²£·~ªº³Ð·s¬ãµo¡B«Øºc¥xÆW°·±d¥¨¶q¸ê®Æ®w¡A¼W¶iÁ{§É«e¸ÕÅ窺®Ä²v©M®Ä¯à¡C¿n·¥°ö¨|³Ð·s¬ãµo¤H¤~¡B²£·~¸gÀç°ª¶¥»â¾É¤H¤~¡A¹ªÀy¾Ç¬ã¤H¤~°Ñ»P·s³Ð¤½¥q¡C ¤G¡B ³sµ²°ê»Ú¡G±µy¥]¬A¬ü°ê¤T¤j¥Í§ÞÂåÃĬãµo«Âí--ªi¤h¹y¡B¥[¦{ÆW°Ï¡B¸t¦a¤úô¡A¥H¤Î¼Ú¬w·sÃĬãµo°ê®a--·ç¤h¡B¤ñ§Q®É¡B·ç¨å¡B²üÄõµ¥¥ý¶i°ê®a¡C±Ò°Ê¸ó°ê¬ãµo¦X§@¤ÎÁ{§É¸ÕÅçpµe¡B«Ø¥ß¤H¤~¥æ¬y¤Î©µÅó¾÷¨î¡A±À°Ê¥ø·~¬Û¤¬§ë¸ê¡B¥H¤Î³Ð§ë¤Î¨p¶Ò°òª÷¦X§@¡C±À°Ê°ê»Úªk³W¼Ð·Çªº¨ó¦X¡A¸¨¹ê¨â©¤ÂåÃĽåͦX§@¨óij¡C ¤T¡B ³sµ²¦b¦a¡G¥xÆW¦³¥R¤À±ø¥ó¡A¥i¥H°µ¬°¥ý´Á¥«³õ©M¸ÕÅç°ò¦a¡A¥ý¦]À³¦b¦a»Ý¨D¡A¶i¤@¨B±À¼s¨ì°ê»Ú¥«³õ¡C´x´¤¬J¦³ªº²£·~Àu¶Õ¤Î¸ê·½¡A¦êÁp¤À´²ªº»E¸¨¡A¾ã¦X¥Í²£»P»Ý¨D¨âºÝ¡A¦¨¬°§¹¾ã¤£Â_Ã쪺²£·~»E¸¨¡C |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/10/27 ¤U¤È 05:12:05²Ä 478 ½g¦^À³
|
¤¤¤åª© http://worldwide.espacenet.com/publicationDetails/originalDocument?FT=D&date=20150616&DB=EPODOC&locale=en_EP&CC=TW&NR=201521766A&KC=A&ND=4 |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/10/27 ¤U¤È 04:43:13²Ä 477 ½g¦^À³
|
ÁÂÁÂCliff¤j ¤å¤¤´£¤Î "¨Ì·Ó2014/8/25¤½¶}»¡©ú®Ñ©Ò¸ü¡A¤½¥q¦b2013/9¤ë¥Ó½Ð¤F¤@¶µ¥þ²yªºª«½è²Õ¦¨±M§Q¤§¥~¡A2014¦~ÁٷdzƥӽФT¶µ±M§Q¡A¨ä¤¤¥]§t¤F¤èªk±M§Q¤Î¾¯«¬±M§Q¡C©Ò¥H¥¼¨Ó¼Æ¦~¤¤¡A§ÚÌÀ³¸ÓÁÙ·|³°Äò¬Ý¨ì³o´X¶µ±M§Q³Q®Öã" ¤j®a¥i¥H±Àºâ¨C¤@¶µ±M§Qªº¥Ó½Ð®É¶¡ ¤½¥q¦b«Ü¦¤§«e¤]´¿´£¤Î,§Ṳ́£«æµÛ¥Ó½Ð±M§Q,·|«ö·Ó¤@©w®Éµ{¶i¦æ ¨º»ò2014¦~·Ç³Æ¥Ó½Ðªº¤T¶µ±M§Q,°²³]®Éµ{¬O2¦~¥ª¥k,¤]´N¬O¤j¬ù¦b2016¦~·|¦A®³¨ì3¶µ±M§Q |
|
|
·|û¡G³Í¤l³Í10140178 µoªí®É¶¡:2015/10/27 ¤U¤È 03:58:56²Ä 476 ½g¦^À³
|
c¤jªº·N«ä¬O¦b°Ý: 822¦b·í®É¹êÅç¬O¤°»òÅܲ§?¦³¨S¦³¸Ñ¨M? ¥H¤Î¬O¤£¬O833´N¬O¸Ñ¨M³o¨ÇÅܲ§ªº²£«~? ¤j¤á¤j¡A½Ð§O¦M¨¥ÁqÅ¥ C¤jªº°ÝÃD¡A¤@¾ãÓ·Pı´N¬O¤½¥q¾÷±K¡A½Ö·|¦b³o¸ÌÁ¿ |
|
|
·|û¡Gµ½¤H10137888 µoªí®É¶¡:2015/10/27 ¤U¤È 03:49:08²Ä 475 ½g¦^À³
|
Cliff¤j, «D±`·PÁ±z¼ö¤ßªº¤À¨É! «_¬Nªº½Ð±Ð±z, ¦pªG¯E¹©ÁÙ¨S¸Ñ¨MGlobo H©MKLHªºÃì±µ°ÝÃD? Globo H-KLH/QS21¯à¥Ó½Ð¨ÃÀò±o¨º»ò¦h±M§Q¶Ü? ±M§QÅv¤w³q¹L¼f¬d¨Ã®Öã, ¬O§_ªí¥ÜGlobo H©MKLHªºÃì±µ¨S¦³°ÝÃD? ¦pªGÃì±µÁÙ¦³°ÝÃD, ¨º¨Ç±M§Q¦³¬Æ»ò¥Î? «ô°UCliff¤jÄÀºÃ. «D±`·PÁÂ! |
|
|
·|û¡G¤j¤á¤H®a10140174 µoªí®É¶¡:2015/10/27 ¤U¤È 02:00:58²Ä 474 ½g¦^À³
|
«ù¤[ªº¯E«È¤j,±z·|¤£·|¤Ó¼ÖÆ[¤F©O,cliff¤j¤w¸g«Ü²M·¡ªºÂI¥X¤F²{¦bªº«Ü¤jªº°ÝÃD. ½Ð°Ý±z¦³¬ÝÀ´°ÝÃD¥X¦bþ¸Ì¶Ü? ¤@¬Nªº¬Ý¦n,³oӤƾǵ²ºc¥Í²£ªº¤è¦¡³£¥X²{¦b³o»ò¤jªººÃ¼{.½Ð°Ý±N¨Ó¬On«ç»ò¤W¥«. |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2015/10/27 ¤U¤È 01:31:23²Ä 473 ½g¦^À³
|
Cliff¤j ·PÁ±z²`¤Jªº»¡©ú §ÚÁÙ¬OÄ~Äò¬Ý¦n822 §ó¬Ý¦n833 §Úµ¹822 ¨âÁû¬P |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/10/27 ¤U¤È 12:10:14²Ä 472 ½g¦^À³
|
5¤Ñ«eªº®ø®§¡C 2015/10/22¯E¹©¨ú±oOBI-822ªº¥t¤@¶µ±M§Q¡A³o¬O³oӤ몺²Ä¤G¶µ±M§Q¡A²Ä¤@¶µ¬O¥Xª©¤j´X¤Ñ«e´£¨Ñªº¡]±À´ú¬OOBI-888ªº²Õ¦¨¦¨¤À±M§Q¡^¡C¨Ì·Ó2014/8/25¤½¶}»¡©ú®Ñ©Ò¸ü¡A¤½¥q¦b2013/9¤ë¥Ó½Ð¤F¤@¶µ¥þ²yªºª«½è²Õ¦¨±M§Q¤§¥~¡A2014¦~ÁٷdzƥӽФT¶µ±M§Q¡A¨ä¤¤¥]§t¤F¤èªk±M§Q¤Î¾¯«¬±M§Q¡C©Ò¥H¥¼¨Ó¼Æ¦~¤¤¡A§ÚÌÀ³¸ÓÁÙ·|³°Äò¬Ý¨ì³o´X¶µ±M§Q³Q®Öã¡C ±M§Q¤å¥ó¡GWO2015159118¡G¡uCOMPOSITIONS OF A CARBOHYDRATE VACCINE FOR INDUCING IMMUNE RESPONSES AND USES THEREOF IN CANCER TREATMENT¡v¡]¸ô®|®¤²¤¡A¶K¤£¤W¨Ó¡^ ¸Ì±±Ôz¤FGlobo H»PKLH¤§¶¡ªºÁäµ²¡GMMCCH¡]µù1¡^¡F§Ú·Q¤F¸ÑMMCCH¦³¨S¦³¸Ñ¨M¡uÅܲ§©Ê¡vªº°ÝÃD¡C 103¦~12¤ë¼W¸ê¤½¶}»¡©ú®ÑùØ´£¨ìªº±Ôz¡A¦³Ãö¡u¡K¨Ï¥Î·s¿oªº¤Æ¾ÇÁäµ²ªk¨ÓÁpµ²ÁÞ§Üì(Globo H) »P¸üÅé³J¥Õ( ¥Õ³ïÃþ¬r¯À¡ADT-CRM197)¡A§Q¥ÎOBI ¤º³¡¬ÛÃö§Þ³N¡A½T»{¨âªÌ³Ì¨Î¤ñ¨Ò¡A¥H¹F¨ì´£¤É¤HÅé§K¬Ì¨t²Î¹ïÁÞ§Ü쪺¿ëÃѯà¤O¡A±q¦Ó¹F¨ì¥D°Ê¦¡§K¬ÌªvÀøªº¥Øªº¡C³oÃþ«¬¤Æ¾Ç×¹¢³J¥Õ½èªº§Þ³N¡A ¥»¤½¥q¤w¦b¥t¤@¶µ²£«~OBI-822 ¤W¦¨¥\ÅçÃÒ¡A¨Ã¤w¦b¥xÆW¶i¤JÁ{§É¤T´Á¸ÕÅç¡C¡K¡v¬O¤£¬OMMCCH¥i¥H ¸Ñ¨M¡uÅܲ§©Ê¡vªº¯ÊÂI¡Cµ²ªGºÃÂI¤´¦b¡G 1. MMCCHÁäµ²¦b822Phase I¡]1997¡H©Î1998¡H¡^®Éªº¸ÕÅç¥ÎÃÄ´N¤w¨Ï¥Î¤F¡A¦ý¦b2011¦~¤@¥÷°|ªø¼gªº¡uToward Automated Oligosaccharides synthesis¡vªº¤åÄm¤¤¡]http://onlinelibrary.wiley.com/doi/10.1002/anie.201100125/full ¡^¡A¡u7.3.1.1. Globo H¡v¸`¤´´£¨ì¡G ¡uAlthough there are several successful examples, some limitations of semisynthetic conjugate vaccines remain. First,the carbohydrate density achieved on protein glycoconjugates is highly variable. Thus,the resulting batch to batch variations may influence the clinical evaluation and vaccine efficacy. Moreover, the production of irrelevant antibodies against the carrier protein or linker may lead to carrier-induced epitopic suppression.¡v¡C¦ü¥GMMCCH¨Ã¥¼¸Ñ¨MGH»PKLH¤§¶¡³s±µªº¤£Ã©wªº°ÝÃD¡]¼Æ¶q¤£Ã©w¡HÁÙ¬Oµ²¦X«×¤£Ã©w¡H¡^¡C ¤W±´£¨ì¨â¶µ822¥i¯àªº¯ÊÂI¡G I.¡uthe carbohydrate density achieved on protein glycoconjugates is highly variable.¡v¡C ³o¤@ÂI´N¬O¤§«eIriswu¤j´£¨ìªºÅܲ§©Êªº°ÝÃD¡A±q¤â¤W§ä¨ìªº´X¥÷¸ê®Æ¤ñ¹ïªºµ²ªG¡AÁÙ¬O·d¤£²M·¡³o¶µ°ÝÃD¯E¹©¸Ñ¨M¤F¨S¡H¡A II.¡uthe production of irrelevant antibodies against the carrier protein or linker may lead to carrier-induced epitopic suppression.¡v¡C822¦b¤p¹«¸ÕÅ礤ªº½T¬O²£¥Í³\¦hÂøÂøªº§ÜÅé¡]¯»¶ê½×¤å¡^¡Aì¨Ó¨ä¤¤ÁÙºUÂøµÛ¹ï§ÜKLH¤ÎMMCCHªº§ÜÅé¡A1998¦~3¤ë¤@½g¬ã¨sµo²{¦b¦´ÁÁÞ§Üì»PKLH³s±µªº§Î¦¡«Ü²³æ¡]MSKCCªº±M§Q¤å¥ó¡^¡A¦]¬°³sµ²Áu¹Lµu·|³y¦¨ªÅ¶¡ªýê¡AµLªk®e³\¸û°ªªºÁÞ§Üì-KLHµ²¦X¶q¡A±À´ú¥i¯à´N¦¹¦b822§ï¥ÎMMCCH¨Ó§ïµ½¡]µù2¡^¡C¦ý³o¨Ç¹ï§ÜÄâ±a³J¥Õªº§ÜÅé¦b¦X¦¨ªºÁÞ§Üì²Õ¦X¤¤¡A¤´·|³y¦¨ÁÞ§Üì»PÄâ±a³J¥Õ¤§¶¡ªº¥iÁäµ²§Üì¹ï¦ì¼Æ¥Ø¡]epitope¡^°§C¡]µù3¡^¡Aªø»·¤§p´N¬O´«±¼KLH¡A©Ò¥H¥i¯à°ò©ó³o¼Ëªº¦Ò¶q¡A¦b833´N§ï¥ÎDT-CRM197¬°Äâ±a³J¥Õ¡C µù¡G 1.ɥΥ|¥¨ÀY½×¤å¡uThe development of Globo H vaccine¡vªº¹Ï¡FFig.10¥k¤W¤è¹Ï´N¬OGH³sµ²MMCCH«áªº¼Ë¤l¡C linker¡G4-(4-N-maleimidomethyl) cyclohexane-1-carboxyl hydrazide (MMCCH) ¡]http://pubs.acs.org/appl/literatum/publisher/achs/journals/content/achre4/2015/achre4.2015.48.issue-3/ar5004187/20150311/images/large/ar-2014-004187_0010.jpeg ¡^ 2.¡uA novel and efficient method for synthetic carbohydrate conjugate vaccine preparation: synthesis of sialyl Tn-KLH conjugate using a 4-(4-N-maleimidomethyl) cyclohexane-1-carboxyl hydrazide (MMCCH) linker arm.¡v¡]http://www.ncbi.nlm.nih.gov/pubmed/?term=A+novel+and+efficient+method+for+synthetic+carbohydrate+conjugate+vaccine+preparation ¡^ 3.¡uCarrier-induced epitopic suppression, a major issue for future synthetic vaccines.¡v¡]http://www.ncbi.nlm.nih.gov/pubmed/2411793 ¡^ |
|
|
·|û¡G¥¬µÜ®¦10140670 µoªí®É¶¡:2015/10/27 ¤W¤È 01:36:44²Ä 471 ½g¦^À³
|
ÁÂÁÂ¥xÁÞ¥S¡I |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/10/26 ¤U¤È 08:52:03²Ä 470 ½g¦^À³
|
¥¬µÜ®¦¥S ¦³ÃöAbraxane ¥iGoogle ¬d: ¨È§B§üª`®g¾¯ (¤º®e¦³§Anªºµª®× ¼gªº¬Û·í²M·¡) Àø®Ä¤£¬O«Ü²z·Q ¬r©Ê¤j ©ñ¤ß ¤£·|«Â¯ÙOBI822 |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2015/10/26 ¤U¤È 07:07:10²Ä 469 ½g¦^À³
|
ÁÂÁÂÅó±ø±ø¤jªº¸Ñ»¡ ì¨Ó¬Q¤Ñ¹Ú¤¤¥P¤H«ü¸ô ´N¬OÁÞ¤À¤l²£·~n¨ú¥N¥b¾ÉÅé²£·~ |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2015/10/26 ¤U¤È 02:09:35²Ä 468 ½g¦^À³
|
ªþ¤W2Óºô§} http://money.udn.com/money/story/5612/1136700-%E9%86%A3%E5%9F%BA-%E8%A6%81%E7%95%B6%E7%94%9F%E6%8A%80%E6%A5%AD%E7%9A%84Apple http://www.businesstoday.com.tw/article-content-80731-101920 |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2015/10/26 ¤U¤È 02:05:45²Ä 467 ½g¦^À³
|
¤£¬O¯E¹©¤]¤£¬OÁÞÁp¡A¬O"ÁÞ°ò" ¦¨¥ß©ó2013¦~ªºÁÞ°ò¡A¦p¤µ³Æ¨ü¥þ²y¥Í§Þ·~¬É´Á«Ý¡A¥D¦]·íµM¬O¤¤¬ã°|°|ªø¯Î±Ò´f¡C2004¦~ªì¡A¥@¬É³»¦y¬ì¾ÇÂø»x¡mScience¡n¥H¤j½g´T¤¶²Ð¯Î±Ò´f©MµÛ¦WªºThe Scripps Research Institute¡]´µ§J¨½´¶´µ¬ã¨s©Ò¡^±Ð±ÂµÎ¯÷¦@¦P¦X§@¡A¦¨¥\¨Ï¤j¸z±ìµß²£¥Í¬ðÅÜ¡A¨Ã¯àª½±µ¤j¶q¥Í²£ÁÞ³J¥Õ¡A³o¶µ³Ð·s¬°°ò¦]ÃĪ«§Þ³N¬ã¨s¥´¶}¥t¤@¤ù·s¤Ñ¦a¡A¤]Åý¯Î±Ò´f¦¨¬°¿Õ¨©º¸¼ú©IÁn³Ì°ªªºÔ¿ï¤H¡C ¤¤¬ã°|³Ì¤j§ÞÂà ³y´NÁÞ°ò±j°·Åé½è ¨S·Q¨ì¡A±M§Q»PµÛ§@µ¥¨ªº¯Î±Ò´f¡A«o±N¦Û¤vªº17¶µ±M§Q¡A¨ä¤¤¥]¬AÁÞ³J¥Õ¡BÁÞ´¹¤ù¡BÁÞ±´°w¡B¤À¤l¬Ì]µ¥¨t¦C±M§Q¡A¥þ³¡µLÀv®½µ¹¤¤¬ã°|¡A¤]¶}±Ò¤FÁÞ°ò¤é«á¦¨¥ßªº°ò¦¡C¨Ý¤¤¤Ñ¶°¹Î³Ð¿ì¤H»PÁÞ°ò¸³¨Æªøªº¸ô¤Õ©ú¡A»¡¤F¤@¬q¤p¬G¨Æ¡C¡u¥þ¥@¬Éªº·sÃĦ³¤T¦¨¨Ó¦Û¤jÃļt¡A¤C¦¨¨Ó¦Û¾Ç¬ã³æ¦ì¡A¦ý§Y¨Ï¦p¦¹¡A³\¦hÁôÂæb¾Ç®Õ»P¬ã¨s¾÷ºc¦³»ùȪº±M§Q¡A«Ü¥i¯à²×¨ä¤@¥Í³£¤£·|³Q¬Ý¨£¡C¡v ÁÞ°òÃöÁä§Þ³N¤§¤@ªºÁÞ«²Õ¡A´N¬O¯Î±Ò´fªº«¤j³Ð·s¡A¦ý¤@ª½¨S¦³¤HÄ@·N¸Õ¡A¦³¤@¦¸¸ô¤Õ©ú«K¦V¤¤¬ã°|´£Ä³¡A¡u¤£¦p¤¤¤Ñ¥ý®³¥X¤@µ§¿ú¨Ó¸Õ¸Õ¬Ý¡AÃÒ©ú¥i¤£¥i¦æ¡C¡vµ²ªG¬ã¨s°µ¤F¤@¾ã¦~¡A¦¨ªG¨Ã¤£¦n¡A³Ì«á³Ñ¤U´X¦Ê¸U¤¸¡A¤¤¬ã°|¨Ì¦X¬ùnÁÙµ¹¤¤¤Ñ¡A¦ý¸ô¤Õ©ú»¡¡A¬JµM³£°µ¨ì³o¸Ì¤F¡A³Ñ¤Uªº¿ú¯dµÛÄ~Äò¦A°µ¹êÅç¡C¨S·Q¨ì¦b«á±´XӤ뤤¡A³º°µ¥X¤ñì¨Ó¦n¦Ê¿¥H¤Wªº®ÄªG¡AÅý°Ñ»Pªº¬ì¾Ç®a³£«D±`¿³¾Ä¡C ÁÞ°ò¦b¦¹±¡ªp¤U¦¨¥ß¡A¯Î±Ò´f¤]¦P·N¤¤¬ã°|±N³o§å±M§Q²¾Â൹ÁÞ°ò¡A¨Ã³Ð¤U¤¤¬ã°|¾ú¨Ó³Ì¤jªº§ÞÂàª÷ÃB¡CÁÞ°ò³Ì¦¶Ò¶°12»õ¤¸¸ê¥»¡A¤¤¬ã°|¥e¥b¼ÆªÑ¥÷¡A¥h¦~¤C¤ë¤S§¹¦¨²Ä¤G¦¸¼W¸ê¡A¥H¤@ªÑ·¸»ù40¤¸µo¦æ¡AªÑ¥»¼W¥[¤»»õ¤¸¡AÁ`p¤S¶Ò¶°¤F24»õ¤¸¡C ¤£¹L¡A³o¦¸¼W¸êI«á¤]¦³¤@¬q¤p´¡¦±¡C¼W¸ê¹Lµ{¤¤¡A¯Î±Ò´fı±o¤~µuµu¤@¦~¦h´Nn¦A¦VªÑªF¶Ò¸ê¡An¨DÁÞ°ò¤@©wnÀÀ©w²M·¡ªº·~°Èµo®ipµe¡]BP¡^¡A¸Ôz¿ún«ç»ò¥Î¡A¡u§_«h¾Ì¤°»ò¤@ªÑ¦VªÑªFn40¤¸¡H¡v ·í®É¡A쥻pµe¼W¸ê¥|»õ¤¸¡A¨CªÑ¥H40¤¸¼W¸ê¡A¦@¶Ò¶°16»õ¤¸¡A¦ý¦b¸³¨Æ·|´N¦³¤@¦ì¸³¨Æ»¡¡A¡uÁÞ°ò³o»ò¦nªº®×¤l¡A¤@©w»Ýn§ó¦h¿ú¡A°®¯Ü¼W¸ê32»õ¤¸¦n¤F¡I¡v¨S·Q¨ìÀò±o¦b³õªÑªF¤@P¹ª´x¡C ¡u·í®É³oÓ·|ij¡A§Ú¹ê¦b¬O¥D«ù¤£¤U¥h¡A¡v¸ô¤Õ©ú»¡¡A¤j·§«Ü¤Ö¦³¤½¥q·|¤£§Æ±æ¦VªÑªF¦hn¤@ÂI¿ú¡A¦ý³o¦¸«o¬OªÑªFnµ¹¿ú¡A¦Ó¤½¥q«o¤£¯àn¡A¡u¦]¬°§Ṳ́£¯à¥¢«H©ó¯Î°|ªø¡A³Ì«á¥u¦n»PªÑªF̨ó½Õ§é°J¡A¦b16»õ»P32»õ¤¸¶¡¨ú¤¤¶¡È¡A¶Ò¸ê24»õ¤¸¡C¡v ºë^¹Î¶¤»â¥ý¬ãµo ¥iµo®i¦h¤¸¤Æ²£«~½u Y²Îp«e«á¨â¦¸¼W¸ê¡AÁ`pªÑªF§ë¤JÁÞ°ò¹F30»õ¤¸²{ª÷¡A¤]¬O¨´¤µ¥xÆW·s³Ð¥Í§Þ¤½¥qÀò±oªº³Ì¤j¤@µ§§ë¸êÃB¡C¥Ø«eÁÞ°ò©µÅó¤F20¦ì°ê¤º¥~³Õ¤h¡A¥¼¨Ó¹wpn¼W¥[¨ì50¦ì¡A¥Ø«e¦h¶µ¬ã¨spµe³£¤w®i¶}¡A¹wp©ú¦~´Nn¦b¬ü°ê¥Ó½ÐÁ{§É¸ÕÅç¼f¬d¡]IND¡^¡C ¹ï©óÁÞ°òªº°ªºÝÁÞÃþ·sÃĬãµo¡A°£¤F¦³°í±jªº¬ãµo¹Î¶¤¥~¡AÁÙ¦¨¥ß¬ì¾Ç¿Ô¸ß©eû·|¡A©eû§t¬A¤FÁÞ¬ì¾Ç¡B§ÜÅé¡B¤Æ¾Ç¡BÀù¯g¡BÁ{§É¡Bªk³Wµ¥±M·~ªº°ê»Ú¯Åºë^¬ì¾Ç®a¡A¥L̦b¨C¥b¦~¤@¦¸ªº³ø§i»P°Q½×·|¡A³£·|´£¥X«Ø¨¥¡AÅýÁÞ°ò¥i¥H½T¹ê±NÁÞÃþ§Þ³N¥¥x¡AÀ³¥Î©ó·sÃĶ}µo¤ÎÁÞÃþ¬ÛÃö¯e¯fªºªvÀø»PÀË´ú¡C ¥Ø«e¡AÁÞ°ò¥H¦Û¤¤¬ã°|²¾Â઺17¶µ±M§Q¬°°ò¦¡A¸g¹L¨â¦~¤Sl¥Í¥X§ó¦h±M§Q¡A¥Ø«e±M§Q¼Æ¥Ø¤w¹F¨ì30¶µ¡A¦P®É¤]µo®i¥X¤»Ó§Þ³N¥¥x¡A¥]¬A§¡¬Û¤Æ§ÜÅéÃĪ«¡BÁÞ¤À¤l¦X¦¨Å²©w¤Î¶}µoÀ³¥Î¡BÁÞÃþ¬Ì]»PÃĪ«¡BÀù¯g»P§K¬Ì¬ÛÃö¤§³æ®è§ÜÅé¡BÁÞ´¹¤ù¤ÎÁÞ±´°wµ¥¡A¨CÓ¥¥x³£¯à¦Aµo®i¥X§ó¦hªº²£«~½u¡C §ë¤J·sÃĶ}µo¤w¤Q¦h¦~¡A¤]¬O¥xÆW°ß¤@¤w¦¨¥\¶}µo¨â¶µ·sÃĪº¸ô¤Õ©ú»¡¡AÁÞ°ò¯¸¦b¥¨¤HªºªÓ»H¡A°µªº¬O³Ì³Ð·sªº·sÃÄ¡A¨ä¤¤«Ü¦h§Þ³N³£¬O¥@¬É¤W³Ì³»¦yªº¥ýºÝ¬ã¨s¡A¦³¦p¦b¶³ºÝ¤W±¡A¥²¶·«D±`§V¤O±N³o¨Ç§Þ³N³v¤@¸¨¹ê¶}µo¦¨¥\¡A¥¼¨Óªº¬D¾Ô±N¶V¨Ó¶V¤j¡C ÁÞ°ò¿n·¥¬D¾Ô¥þ²y·sÃĶ}µoªº¥ø¹Ï¤ß¡A§V¤O¥´³y¥xÆW¦¨¬°¥þ²yÁÞ¶}µoªº«Âí¡A¨Ã·¥¦³§Æ±æ¦¨¬°¥þ²y¥Í§Þ·~ªºApple¡A¦p¤µ¦b²³¦h°ê¤º¥~±M®a¾ÇªÌªº¥[«ù»P§V¤O¤U¡A¬Ý¨ÓÁÞ°ò¤w¦V³oӥؼСA§óÁÚ¶i¤@¨B¤F¡C |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2015/10/26 ¤U¤È 01:04:42²Ä 466 ½g¦^À³
|
¤¤¬ã°|°ò¦]Åé¬ã¨s¤¤¤ß ·s»D½Z ºô§} http://www.genomics.sinica.edu.tw/index.php/tw/news/lastest-news/402-2013-11-06-03-18-14 ¨ä¤¤¤@¬q ¬ãµoÄáÅ@¸¢Àù¬Ì] 2013WU-1²ø§»´ªº³Õ¤h¬ã¨sªº¼Ðªºª«¡A´N¬O¤@Ó»PÄáÅ@¸¢Àù¦³±K¤ÁÃö«YªºRM2§ÜìÁÞ¤À¤l¡C¦¦b2005¦~¡A´N¦³¤é¥»¾ÇªÌHakomori±Ð±Âµoªí¬ã¨s¡A«ü¥X¤HÅé²£¥ÍªºRM2§ÜìÁÞ¤À¤l©MÄáÅ@¸¢ªº´c¤Æ±¡§Î¦³Ãö¡A·íÄáÅ@¸¢Àù´c¤Æ®É¡ARM2§Üì¤]·|¸òµÛÅܦh¡C¦]¦¹¡ARM2·í¤U¦¨¬°¬ã¨sÄáÅ@¸¢Àùªº¥Íª«¼Ð°O(biomarker)¡A¬ì¾Ç¬É§Æ±æ§Q¥Î¦¹¤À¤l·í¦¨§Üì¡A¥Î¥Hµo®i¥XÄáÅ@¸¢Àù¬Ì]ªº¬ã¨s¯É¯É®i¶}¡C ·í¬ã¨s¹Î¶¤¿ï©wÃD¥Ø«á¡A²ø§»´¨Ì¾Ú¹Î¶¤ªº¬ã¨s¼Ò¦¡¡At³d¦X¦¨RM2§Ü쪺¥ô°È¡A¦b¹Î¶¤ªº«á¬Þ¤ä´©¤U¡A»â¥ý¥@¬É¦U°ê¡A²Ä¤@¦¸¦¨¥\ªº¥Î¤H¤u¦X¦¨ªº¤è¦¡¡A±N¦¹½ÆÂøµ²ºcªº¤»ÁÞ¤À¤lRM2§Üì¦X¦¨¥X¨Ó¡C µM¦Ó¡A³oÓ¦¨´N¶È¬O¹Î¶¤¥Ø¼Ðªº²Ä¤@¨B¡A¦b¦³¤F¤H¤u¦X¦¨»s³yRM2§Ü쪺¯à¤O«á¡A¥LÌnµÛ¤â»s³y¬Ì]¡CY¶È¥u¬OÁÞ¤À¤l¡A¨ä¹ê¤£®e©ö²£¥Í¦nªº§K¬Ì¤ÏÀ³¡A©Ò¥H¡A¦b»s³y¬Ì]®É¡A´Nn¿ï¤@Ó®e©ö»¤µo§K¬Ì¤ÏÀ³ªºÄâ±a³J¥Õ©MÁÞ¤À¤lµ²¦X¦b¤@°_¡C¹Î¶¤³Ì«á¦bRM2§Üì¤W±µ¤FÄâ±a³J¥Õ-CRM197¡A¦¨¬°¤@ÓÄáÅ@¸¢Àùªº¬Ì]Âú«¬¡C ¤§«á¡A±N¦¹¬Ì]°t¦X¥ý«e¬ã¨s¹Î¶¤¬ãµo¥XªºÁޯ׽èC34·í¦¨¦õ¾¯¡A§Q¥Î¦Ñ¹«·í¦¨¬Ì]ªº°Êª«¼Ò¦¡¡C´ú¸Õµ²ªGÅã¥Ü¡A³oÓ¬Ì]¥i¥H»¤¾É¥X¨ã®ø·ÀÄáÅ@¸¢Àù²ÓMªº¦³®Ä§ÜÅé¡C¦¹¥~¡A¦b°ö¾i¥×¤ºªº¹êÅç¡A¥H¤Î§Q¥ÎÁÞ´¹¤ùªº´ú¸Õ¡A³£ÃÒ©ú³o¨Ç§ÜÅ餣¦ý¨ã¦³§í¨îÄáÅ@¸¢Àù²ÓMªº®ÄªG¡Aݨã«Ü°ªªº±M¤@©Ê©M¥Íª«±j«×¡C ³oÓ¬ã¨sµ²ªG¥Z¸ü©ó2013¦~7¤ë¥Xª©¤§135´Á¡m¬ü°ê¤Æ¾Ç·|´Á¥Z¡n (Journal of the American Chemical Society) ¡CÄáÅ@¸¢Àù¬Ì]¤]¤w©ó¤é«e§ÞÂ൹·~¬É°µ¶i¤@¨Bªº¶}µo¡C ~~~~~~~~~~~~~~~~ ½Ð±Ð¤j®a ¬O§ÞÂ൹þ¤@®a? ¯E¹© ÁÙ¬OÁÞÁp?©Î¨ä¥L? ÁÂÁ |
|
|
·|û¡G¥¬µÜ®¦10140670 µoªí®É¶¡:2015/10/26 ¤W¤È 11:43:38²Ä 465 ½g¦^À³
|
¶g¤é½¾\¬ì¾Ç¤HÂø»x2015¤»¤ë¸¹¡y¤ñ¼Ð¹vÃĪ«§óºë·Ç¡zhttp://sa.ylib.com/MagCont.aspx?Unit=featurearticles&id=2729 ¤@¤å¡A¨£µÛAbraxane ¦¹ÃĦW¡Agoogle«á¥H¤U¬°©Ò±o¡C Abraxone¤]¬O°w¹ïÂಾ©Ê¨ÅÀù»P³¡¤ÀªÍ¸¢ÀùªvÀø©Ò¥Î¡A¥B¬ü°êFDA¤]³q¹LÃÄÃÒ¡A¤£ª¾¨äÀø®Ä¦p¦ó¡H¬Û¸ûOBI-822ªº®t²§¦ó¦b¡H ¥i¦³±M·~ªº¯E¤Í¹ïAbraxone¦³¸û²`¤Jªº»{ÃÑ©O¡HÁÂÁÂÄÀºÃ¡I ¥H¤UÂà¸ü¦Û©M«HªvÀù¤¤¤ßÂå°|ºô¯¸ http://www.kfsyscc.org/about/interview-topics/Abraxane-yu-tai-ping-xiang-zi-sha-chun-zhi-yi-tong Abraxane»P¤Ó¥¬vµµ§ü¾J¤§²§¦P ¤å / ¾G¶®ªåÃÄ®v (Ãľ¯¬ì) ¡@¡@¦b2013¦~®É¡A¬ü°êÃÄ«~¹ª«ºÞ²z§½¡]FDA¡^³q¹L¤F¤@Ó·sÃÄAbraxane¡]Protein-bound Paclitaxel¡^¡Ð±N¥»¨Ó´N¦³¦b¥«±¤W¨Ï¥Î¨âÓÃÄ«~¡A¤Ó¥¬vµµ§ü¾J¡]Paclitaxel¡^©M¤HÅ骺¥Õ³J¥Õ¡]Albumin¡^µ²¦X©Ò§Î¦¨·sªºÃÄ«~¡C¤HÅ骺¥Õ³J¥ÕÀ°§U¤Ó¥¬vµµ§ü¾J¸û®e©ö¶i¨ì¸~½F¸Ì¡A¨Ï¸~½F¸Ìªº¤Ó¥¬vµµ§ü¾J¿@«×¤j´T´£°ª¡A¦]¦¹»Ýn¥´ªº¾¯¶q¸û§C¡C¦b³o¸Ìn¯S§O»¡©ú¡AAbraxane¸ò¤Ó¥¬vµµ§ü¾J¬O¨âÓ§¹¥þ¤£¤@¼ËªºÃÄ«~¡A©Ò¥H¬O¤£¯à¤¬¬Û¨ú¥N¨Ï¥Îªº¡C ¡@¡@Abraxane¸ò¤Ó¥¬vµµ§ü¾J¦³¬Æ»ò¦@¦PÂI¸ò¤£¦PÂI©O¡H¦bªvÀø¤è±¡AAbraxane¸ò¤Ó¥¬vµµ§ü¾J³£¥i¥Î©óÂಾ©Êªº¨ÅÀù©M§½³¡©ÎÂಾ©Ê«D¤p²ÓMªÍ¸¢Àù¡AAbraxane¥t¥~ÁÙ¥i¥H¥Î©óÂಾ©Ê¯ØŦÀù¡C¦Ó¤Ó¥¬vµµ§ü¾J«h¥t¥i¥H¥Î©ó§Z±_Àù¡C¦b¬I¥´®É¶¡¤è±¡AAbraxane»Ýn30¦Ü40¤ÀÄÁ¥ª¥k¡A¤Ó¥¬vµµ§ü¾J«h¬O¨Ì·Ó·f°tªºªvÀø²Õ¦X±q1¤p®É¦Ü¼Æ¤p®É¤£µ¥¡C¦b°Æ§@¥Î¤è±¡AAbraxane¸ò¤Ó¥¬vµµ§ü¾J±`µo¥Í±¼¾v¡Bäú¤ß¹Ã¦R¡B¸¡Âm¡B¦Ù¦×©ÎÃö¸`¯kµh¡B¥½±é¯«¸g¬r©Ê¡]¨Ò¦p¡G¤â«ü³Â¨ë¡^¡B¬õ¦å²y´î¤Ö¡B¥Õ¦å²y´î¤Ö¸ò¦å¤pªO´î¤Ö¡CAbraxaneµo¥Í¯h·P¡B¨x¥\¯à«ü¼Æ¤W¤É¸òµo¿N¾÷²v¤ñ¤Ó¥¬vµµ§ü¾J°ª¡A¤Ó¥¬vµµ§ü¾J«h¬O¥´°w®É¸û©öµo¥ÍÃþ¦ü¹L±Óªº¤ÏÀ³¡C ¡@¡@¦bÃĪ«¥æ¤¬§@¥Î¤è±¡AAbraxane¸ò¤Ó¥¬vµµ§ü¾J³£¬O¥ÑCYP3A4¡BCYP2C8¡]¨xŦ¤¤ªº±`¨£¥NÁȕÀªºÂ²ºÙ¡^¥NÁ¡A©Ò¥H¬I¥´ªº´Á¶¡¬O¤£¯à³Ü¸²µå¬c¥Ä¡A§_«hÃÄ«~¦b¨Å餺ªº¿@«×·|¤W¤É¡A¾¯¶q¹L°ª·|¾ÉP¤£±`¨£ªº°Æ§@¥Î©Î¬r©Êªºµo¥Í¡C ¡@¡@Abraxane¸ò¤Ó¥¬vµµ§ü¾Jªº¥Î¶q·|¬Ò¨Ì¾Ú¯f¤Hªº¨°ªÅé«¡B¦å²G¤¤¦å²yªº¼Æȸò¨x¥\¯à«ü¼Æ§@¾¯¶qªº½Õ¾ã¡A©Ò¥H¨CÓ¤H¥´ªº¾¯¶q·|¦³¨Ç³\ªº¤£¦P¡CÃÄ«~¬I¥´ªºÀW²v¡A¨Ì·ÓªvÀøªº¯e¯f¦Ó¤£¦P¡C¦bÂಾ©Êªº¨ÅÀù¤è±¡AAbraxane¬O¨C¤T¶g¥´¤@¦¸¡A¤Ó¥¬vµµ§ü¾J¥i¥H¬O¨C¤T¶g¥´¤@¦¸©Î¬O¥Î¸û§Cªº¾¯¶q¨C¶g¥´¤@¦¸¡C¦b§½³¡©ÎÂಾ©Ê«D¤p²ÓMªÍ¸¢Àù¡AAbraxane¬O¨C¶g¥´¤@¦¸¡A¤Ó¥¬vµµ§ü¾J«h¬O¨C¤T¶g¥´¤@¦¸¡C¦bÂಾ©Ê¯ØŦÀù¡AAbraxane¬O¨C¶g¥´¤@¦¸¡A³sÄò¥´¤T¶g«á¥ð®§¤@¶g¡C¦b§Z±_Àù¡A¤Ó¥¬vµµ§ü¾J¥i¥H¬O¨C¤T¶g¥´¤@¦¸©Î¬O¥Î¸û§Cªº¾¯¶q¨C¶g¥´¤@¦¸¡C ¡@¡@¥Ø«eAbraxane¥xÆW¨Ã¨S¦³¤W¥«¡A©Ò¥H¬O»Ýn±M®×¶i¤f¤~¯à¨Ï¥ÎªºÃÄ«~¡C±M®×¶i¤f¬O«ü¤@ÓÃÄ«~¥Ø«e¦b¥xÆW¨S¦³¤W¥«ªº³\¥iÃÒ¡A¦ý¦]¬°¯f¤H»Ýn©Ò¥H¥Î¯S®í®×¨Ò¡A¯S§O¤¹³\ÃÄ«~¶i¤f¡C°ò¥»ªº¬yµ{¬O»Ýn¥ÑÂå®v¦VÂå°|ªºÃÄ©e·|´£¥X¦¹ÃĪº¥²n©Ê¡A¤§«á³sµ¸¥i¥H¶iÃĪº¥N²z°Ó¡C½T©w¦³¥N²z°Ó¥i¥HÀ°¦£¶i¤fÃÄ«~«á¡A¦A¦V½Ã¥Í§½´£¥X¥Ó½Ð¶i¤f³\¥iÃÒ¡A³o®ÉÔ¬O»ÝnÀ˪þ¯f¾úºKn¡B¯f¤H¦P·N®Ñ¡B¥Ó½Ð®Ñ¡Cµ¥Àò±o¤F¶i¤f³\¥iÃÒ«á¡AÃÄ«~¤~¯à³q¹L®üÃöªºÀˬd¡A¶i¤f¨ì¥xÆWµ¹¤©¯f¤H¨Ï¥Î¡C±M®×¶i¤fªº¬yµ{°ò¥»¤W¦Ü¤Ön¨âÓ¤ë¡A¦Ó¥B¦]¬°¥xÆWÁÙ¨S¤W¥«¡A©Ò¥H°·«O¨S¦³µ¹¥I¡A¦]¦¹¯f¤H¬O»Ýn¦Û¥IÃĶOªº¡C ¡@¡@Abraxane¦b¬ü°ê¤]¤~è¤W¥«¨S¦h¤[¡A©Ò¥HÃÄ«~¦w¥þ©Ê¸ò¯u¥¿ªº®Ä¯q¥Ø«e¤]¤£¬Oµ´¹ï²M·¡¡A¦ý¦Ü¤ÖÅý¯ØŦÀù¦h¤F¤@ºØ¿ï¾Ü¡A¦Ü©ó¬O§_¯uªº»Ýn¨Ï¥ÎAbraxane¡A¤]½Ð¸ò±zªºÂå®v°Q½×¡AÃÄ«~¥¼ª¾ªº·ÀI¡B®Ä¯q¸òª÷¿úªºªá¶O¤§¶¡¦p¦ó¨ú±o¥¿ÅÂI¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/10/26 ¤W¤È 10:40:49²Ä 464 ½g¦^À³
|
¯E§J¤j ·PÁ¶Qª©³\¦h¤j¤j´£¥X¤À¨É ¨ü¯q¨}¦h ·PÁ·P®¦ 1TFDA¼fÃijt«×¦ü¥G¦³¶V¨Ó¶V§ÖªºÁͶÕ, °²¦p©ú¦~¸Ñª¼¼Æ¾Ú°÷excellent¤£ª¾¹D·|¤£·| ¥xÆW»P¬ü°ê¦b¼f¬d¨ÅÀùOBI822ÃÄÃҮɵo¥Í·mÀY»ªº²{¶H 2¨Ì¾Ú²Îp¤ÀªR»Ýn®É¶¡»P¨ä¥¦¦Ò¶q¦]¯À,Ó¤H²q´ú°²¦p©ú¦~¸Ñª¼¼Æ¾Ú°÷excellent ·|¦bAmerican Society of Clinical Oncology(¬ü°êÁ{§É¸~½F¨ó·|)¶}·|«e´£¥X ¥x¬üÃÄÃÒ¥Ó½Ð,¨ì®ÉÔ¥x¬ü¨â°ê·|¨Ì¾Úªk³W»PÁ{§É¼Æ¾Ú¨Ó¶i¦æÃÄÃҥӽмf®Ö,¤]°ß¦³¦p¦¹¤~¯à ²Å¦X²Ä¤Q¤©¡¬ü¬wµØ¤H¥Íª«¬ì¾Ç¾Ç·|°ê»Ú¾Ç³N¬ã°Q·|¤¤ªº´Á¬ß (½Ð°Ñ¦Ò OBI Pharma Observer: 2015/6/27 ¯Î±Ò´f¨ÅÀù¬Ì]§Y±N¤W¥«) 3¯E¹©¸Ñª¼¬O¥xÆW¥Í§Þ¬Éªº¤j¨Æ,¤]·|¤Þ°_¥þ²yÃö¤Á,¦]¬°¨ÅÀùOBI822¬O¥þ²y²Ä¤@ÁûÀù¯g§K¬ÌÀøªk ¥Î©ó¨ÅÀùªºÃÄ,§óÃø±oªº¬O³oÁûÃĬOÄÝ©ó¥D°Ê§K¬ÌÀøªk (§C°Æ§@¥Î §C¬r©Ê °ª¦w¥þ©Ê) 4¸Ñª¼¥Dn¬O¤ñ¸û¨â²Õ¶¡¬O§_¦³ÅãµÛ®t²§,(¥HP value ¬°¥D ¨ä¥L°Ñ°u) ³Ì¤Ön¦³¤@Áû¬P(¤Ö±N)¤~¦X¥G¹w´Á( Significant ) ¤@¬P¤Ö±N»P¨â¬P¤¤±N ¬ù²¤µ¥©óYK¸Ñª¼¥|ºØ±¡ªpªº ²Ä¤GºØ ¤T¬P¤W±N»P¥|¬P¤W±NÀ³¸Ó¬Oµ¥©óYK¸Ñª¼¥|ºØ±¡ªpªº ²Ä¤@ºØ http://www.graphpad.com/guides/prism/6/statistics/index.htm?extremely_significant_results.htm ¥H¤W¬OÓ¤H·Qªk,¶È¨Ñ°Ñ¦Ò, ¦p¦³¿ù»~½Ð«ü¥¿,¨Ã½Ð¿W¥ß«ä¦Ò§PÂ_,¤Á¹ê¹ê¬I·ÀIºÞ²z |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2015/10/26 ¤W¤È 09:28:54²Ä 463 ½g¦^À³
|
ÃÙ¦¨¥xÁÞ¤j Y¯E¹©¥ý¸Ñª¼¥xÆW¤T´Á»P¬ü°ê¤G´Á¬ã¨s °Ñ¥[ASCO«á ¤Þ°_¾Ç¬É¸òÂå¬ÉÅF°Ê ¬ü°êFDA·|ÀA¤W²Kªá |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/10/26 ¤W¤È 12:37:41²Ä 462 ½g¦^À³
|
±q§A»ú§Ú»ú½Í¬ü°ê¤G´ÁÁ{§É ©ú¦~¸Ñª¼¼Æ¾Ú¤½§i¡A¬Ý¦ü¥xÆW¦b¸Ñª¼¡A ¨ä¹ê³o¬O¤@Ó¤@½bÂùó窺µ¦²¤¡A¥xÆW¸Ñª¼ ¬ü°ê¤G´Á¤]¦P¨B¸Ñª¼¡A¬ü°ê»P¥xÆW¬Ý¦ü¤£¦P Á{§É´Á§O¡A¨ä¹ê¬O§Aªd¤¤¦³§Ú¡A§Úªd¤¤¦³§A ¨â°ê¥Ó½ÐÃÄÃÒ¦U¦Û¿W¥ß¡A¥xÆW°²³]¼Æ¾ÚÀu²§¡A ¬ü°ê¤G´Á·|®t¶Ü?¥xÆWÀu²§ªº¼Æ¾Ú¹³¶Ê¤Æ¾¯¤@¼Ë Åý¬ü°ê¤G´ÁÁ{§ÉÀò±o¬ü°êFDA¯S®íªº³qÃö§¹J¡A ªº¾÷²v¤j¼W¡A¬ü°ê¬F©²¦b¤H¹D¦Ò¼{¤U¡A¤°»ò±ø¥ó ³£¥i¥H½Í¡A¥un¸Ñª¼¼Æ¾Ú°÷¦n¡A¯à¬@±ÏµL¼Æ¬ü°ê °ü¤kÄ_¶Qªº¥Í©R |
|
|
·|û¡Gµ½¤H10137888 µoªí®É¶¡:2015/10/25 ¤U¤È 10:50:07²Ä 461 ½g¦^À³
|
¦Ñ´¤j, ¦Ñ®Õ¤Í, «D±`·PÁ±z̪º§V¤O©M°^Äm, ¤£¥u¬°«n¤@¤¤ª§¥úºa, ¤]±N¬°¥xÆWªºÀù¯g·sÃĬãµo¦b¥@¬É»R¥xª§«a. «ô°U±z¦³ªÅ¶¢, ¯à®É±`¤W¨Ó¤Þ»â¯E¤Í, ½Í½Í±zªº¤ß±o©M¯E¹©ªº»·´º, Åý¯E¤Í̧󦳫H¤ß©M@¤ß. ¦b¦¹ ¥ý·PÁ±z¤F! ¦³±z³o¦ì¦Ñ®Õ¤Í, ¥ç¬O¦Ñ¯E¤Í, ¿·P·ÅÄÉ! |
|
|
·|û¡G°ß±©10140520 µoªí®É¶¡:2015/10/25 ¤U¤È 06:28:42²Ä 460 ½g¦^À³
|
ÁÂÁ¦ѷ¨¤jªº¸Ñ»¡»PFaith¤jªº¬ã¨s! |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/10/25 ¤U¤È 02:41:02²Ä 459 ½g¦^À³
|
¦Ñ´¤j ÆgÆgÆg¡I¦³¤F±zªº«ü¤Þ¡A¤p§ÌÀ´¤F¡AÁÂÁ±z «n£¸¤¤¦´Áªº¾Ç¤l¯uªº«Ü±j¡A¦³«Ü¦h©_¸´¡A¤]¬°°ê®aªÀ·|°^Äm¨}¦h ¡uµ¥¡v¹ï¤p§Ì¦Ó¨¥¬O§Ú³Ì®³¤âªº°Õ¡A«¢«¢«¢ ¦A¦¸ÁÂÁ¦Ѵ¤j ¤U¦¸¦³ºÃ°Ý¦A¸ò¤j®a¤Á½R°Q±Ð¡AÁÂÁ±z¡I |
|
|
·|û¡G¦Ñ´10141055 µoªí®É¶¡:2015/10/25 ¤U¤È 01:36:52²Ä 458 ½g¦^À³
|
Faith¤j¡G "±©¦Ò¶q¡u³]¦b105¶g¡v©M¡u¤w´c¤Æ¡v¥H¥~ªº¯f¤H¡A±N¥H³Ì«á¤@¦¸MRI·í§@¨ä´c¤Æªº®É¶¡ÂI¡A®£´î·lPFS¡A¬ã¨sû¦ôp¹êÅç²Õ¹ê»ÚªºPFSÀ³¤¶©ó16.5~18Ӥ뤧¶¡¡C"----è¬Ý§¹³o¦ì±i¸g²zªº¾ã½g³ø§i¾ã²zªº¯u¦n¡I¶È¤Ö¼Æ¤é´Á¦~»~´Ó©M¿ù§O¦rµL¶Ë¤j¶®¡C RCTªºparallel design¡Astudy ending pointn¤Á»ô¡A¥¼´c¤Æªºn¥l¦^ÃÒ©ú¥¼´c¤Æ¡A¤~¯àÃÒ©ú¬OPFS¡A¤£µM´N¥u¬OOS¤F¡C²Ä3ÃD¥ç¦P¡C ²Ä1ÃD¡A¹L¦¸Ñª¼¤½¥qÀ³¸Ó¦³«H¤ß¤~·|³o»ò°µ¡C§Ú̯వªº´N¬O.......µ¥§a¡I Anyway¡A³¯¹a¬z°Æ©ÒªøªºRCT study design¡A´Ncancerªº¬ã¨s³]p¤W¨Ó»¡¡A¨S¤°»ò¦n¬D窺¡A¤£ºÞ¬Oselection bias, attrition bias (drop out), detection bias(double blind), reporting bias(pending)³£¤w¸g«Ü¤£®e©ö¤F¡Cinclusive and exclusive criteria§ó¬O«D±`ªºÄYÂÔ¡C§Ú̦n´X¦¸¦bmeetingªºcoffee break¤W½Í¤Î¡A³£Ä±±o«Ü´Î¡I ¯Î°|ªø¡A§ÚÌ«n¤@¤¤ªºÅº¶Æ¡Aµoªí¶q¶W¹L650½g¡A§ÚÌ20´XÓ¤H¥[°_¨ÓÁÙ¤£¨ì300½g¡A¯u¤£ª¾¹D¥Lªº¸£³U¸Ëªº¬O¤°»ò¡C¬Û«H¦b¥Lªº±a»â¤U¡A¨S¤°»ò¦n¾á¤ßªº¡C §Æ±æ¨S¦³µª«D©Ò°Ý¡I jm¤j¡Gdon¡¦t be concerned!¼ÊºÙ§Ú¤]¬OÀH«K¶Ã¥´ªº¡C |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/10/23 ¤U¤È 05:00:12²Ä 457 ½g¦^À³
|
Ãö©ó¤p§Ìªº²Ä¤TÓ´£°Ý¡A¤ÏÂЫä¯Á¡A¦A§â±i¸g²zªº«e«á¤åŪ´X¹M«á µo²{¡A¦pªG¤Ï¤è¦V«ä¦Ò©O¡H¦n¹³´N¦³µª®×¤F ¦ý¤p§Ì¹ê¦b¨S§â´¤§ÚªºÅÞ¿è¬O§_¥¿½T ©Ò¥H¤~·Qťť¤j®aªº¬Ýªk |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/10/23 ¤W¤È 08:57:41²Ä 456 ½g¦^À³
|
¯E¤ÍÌ,¤p§Ì¬Ý¤F²Î¤@±i¸g²zªº³ø§i«á,¨ØªAªº¤£±o¤F,¦ý¤p§Ì¦³¨ÇºÃ´b,·Q½Ð±Ð¤j®a 1.²Ä¤T¶,¦ôp2015¦~8¤ëCR PD¤´¥¼¹F180¤H ¥H¤Î ²Ä¥|¶,Globo H³±©Êªº¤j¦h³£¤w´c¤Æ,Globo H¶§©Ê®É¶¡©Ôªø¯à§í¨î¸~½Fªº®ÄªG,¬ã¨sû¹w¦ô¨C¤ë·s¼Wªº´c¤Æ¯f¤H¥¿¦b»¼´î¤¤,¦]¦¹ ¥Lªº±À¦ô 2015¦~5¤ëCR PD ±À½×160¤H 2015¦~8¤ë 28¤é±M®a·|ij CR PD ±À½×175¤H ½Ð°Ý,§ÚÌ°²³]±i¸g²zªº±À½×¬°¯u,¥B2015¦~8¤ë´c¤Æ¤H¼Æ¤´¥¼¹F180¤HµM¨Ó¬Ý,¤p§Ì«ç»òºâ³£Ä±±o³o¼Ëªº¤H¼Æ¤Ó¤Ö!!¸Ñª¼¬O§_·|¦³·ÀI? 2.²Ä23¶ªº²Ä¤G¤j¬q ¬ã¨sû¥ý°²³]¡K±©¦Ò¶q¡u³]¦b105¶g¡v©M¡u¤w´c¤Æ¡v¥H¥~ªº¯f¤H¡A±N¥H³Ì«á¤@¦¸MRI·í§@¨ä´c¤Æªº®É¶¡ÂI¡A®£´î·lPFS,¬ã¨sû¡K. ¤p§Ì¤£¤~,½Ð°Ý³o¥y¸Ü¬O¤°»ò·N«ä? 3.²Ä¤T¶¤W¤è 822¦b2015¦~8¤ë28¤é±M®a·|ij«á,«K¶}©l±N¡u105¶g¤º¤´¥¼´c¤Æªº¯f¤H¥l¦^¶i¦æMRI¡K¡v 105¶g¬O¨â¦~¡A½Ð°Ý¬°¤°»ò¥l¦^ªº¬O¤´¥¼´c¤Æªº¯f¤H?¬°¤°»òn¥l¦^?©Ò¥Hªü¬Â¤jªº¨â¬°¨Ò¤l¤]³£n³Q¥l¦^¶Ü? ¥H¤W¥ý½Ð±Ð¯E¤ÍÌ,«áÄò¤p§Ì¦AÄ~Äò¸ÔŪ,Y¦³¤£À´¤§³B¦A´£¥X¨Ó½Ð±Ð,ÁÂÁ¤j®a |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/10/20 ¤W¤È 12:17:19²Ä 455 ½g¦^À³
|
Hi Cliff¤j.. ·PÁ¸ԲӸѻ¡.³o½g¨S±z¾ÉŪ.ÁÙ¯u¬O¤Ñ®Ñ.. ¬Ý°_¨Ó888ªºÁ{§É«e¬ã¨s.±M§Q¥Ó½ÐÀ³¸Ó§¹¦¨¤F.§Ö´£¥X¥Ó½Ð¤F§a.. |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/10/19 ¤U¤È 01:20:03²Ä 454 ½g¦^À³
|
¥Xª©¤j¡A³o¬O½Í¤@ºØ§ÜGHªº¤H·½¤Æ³æ®è§ÜÅé¦b°Êª«¹êÅ窺µ²ªG¡AÂǦ¹±M§Q¨Ó«O¥þ¨ä¡u¦¨¤À»P¨Ï¥Î¡v¡C¦ý¬O¨S§ä¨ì±MÄݪº¦W¦r©Î«¬¸¹¡A§Ú¤]¤£ª¾¹Dn«ç»òºÙ©I¡C²q´ú¥i¯à¬O888¡C ¤Ó±ßµo²{¤F¡A¤£µM¤W¶g¤¦b®v¤j´N¥i¥H°Ý°Ý¿à³Õ¤h¡C ¦³¿³½ìªº¤H¥i¥H¬Ý±M§Qªº¥þ¤å¡G¡uhttps://patentscope.wipo.int/search/docservicepdf_pct/id00000030999644/PDOC/WO2015157629.pdf¡v 2015/4/10«ØÀÉ¡A2015/10/15®Öã¡A±M§Q¦r¸¹WO2015/157629¡C ÃD¥Ø¡GANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF¡]§ÜÅé¡AÃĪ«¦¨¤À¤Î¨ä¨Ï¥Î¡^ ºKn¡G The present invention provides antibodies or the antigen-binding portion thereof, that bind to one or more carbohydrate antigens. Also disclosed herein are pharmaceutical pharmaceutical compositions and methods for the inhibition of cancer cells in a subject in need thereof. The pharmaceutical compositions comprise an antibody or an antigen- binding portion thereof and at least one pharmaceutically acceptable carrier. Page25/93¡G¡e0028¡f ³oÓµo©ú¬O´£¨Ñ¦³®Ä¿@«×ªº§ÜGH§ÜÅé¦Ü¨ã¦³ªí²{GHªº¸~½FªºÓÅé¡A¨Ó¹F¨ì§í¨î¸~½Fªº®ÄªG¡C Page27/93¡G¡e0038¡f ³oÓ³æ®è§ÜÅé¨Ó¦Û©ó¿Ä¦X½F2C2ªº¡A¬°Globo H-2C2 mAb¡F ³æ®è§ÜÅé¨Ó¦Û©ó¿Ä¦X½F3D7ªº¡A¬°Globo H-3D7 mAb¡F ³æ®è§ÜÅé¨Ó¦Û©ó¿Ä¦X½F7A11ªº¡A¬°Globo H-7A11 mAb¡F ³æ®è§ÜÅé¨Ó¦Û©ó¿Ä¦X½F2F8ªº¡A¬°Globo H-2F8 mAb¡F ³æ®è§ÜÅé¨Ó¦Û©ó¿Ä¦X½F1E1ªº¡A¬°Globo H-1E1 mAb¡F Page26/93¡G¡e0030¡f Fig.1¡]Page 11/93¡^ªº¹Ï§ÎÅã¥Ü¹ÆQ¤ô¡BGlobo H-VK9 mAb¡BGlobo H-2C2 mAb¤ÎGlobo H-3D7 mAb¦p¦ó¦b¤p¹«¤¤¼vÅT¯ØŦÀùªºÅé¿n¡C Fig.2¡]Page 12/93¡^ªº¹Ï§ÎÅã¥Ü¹ÆQ¤ô»P¤£¦P¾¯¶qªºGlobo H-2C2 mAb¦p¦ó¦b¤p¹«¤¤¼vÅT¨ÅÀù²ÓM®èMCF7ªºÅé¿n¡C Fig.3A-3F¡]Page 13-15/93¡^ªº¹Ï§ÎÅã¥Ü¤Wz¤£¦Pªº³æ®è§ÜÅé»P¤£¦PªºÁÞ§Ü줧¶¡µ²¦X«×¡]affinity¡^ Fig.3A¡GGlobo H-2C2 mAb Fig.3B¡GGlobo H-7A11 mAb Fig.3C¡GGlobo H-3D7 mAb Fig.3D¡GGlobo H-2F8 mAb Fig.3E¡GGlobo H-1E1 mAb Fig.3F¡GGlobo H-VK9 mAb ¨C¤@ºØ³æ®è§ÜÅé³£¥H¤TºØ¿@«×¡]1/16000»P1/64000»P1/256000¡^»P¦Ü¤Ö¤G¤Q´XºØÁÞ§Üì°µµ²¦X«×¤ÀªR¡A³o¤G¤Q´XºØÁÞ§Üì¥]¬A¤FTn¡]S15¡^¡BPSA¡]S18¡^¡BSTn¡]S20¡^¡BGD2¡]S28¡^¡BGM2¡]S29¡^¡BSSEA-4¡]S30¡^¡BGD3¡]S31¡^¡BFucosyl-GM1¡]S32¡^µ¥¡CÁÞ§Üì¹ïÀ³ªí¸Ô¨£Page 71/93¡e00143¡f¡C µ²ªGGlobo H-VK9 mAb»P¨ä¥L¦hºØÁÞ§Ü쪺¥æ¤e¤ÏÀ³³Ì¤p¡C¡]¥Î±¡¸û±M¤@¡A¸ò¨ä¥L®è§ÜÅé¤ñ¸û°_¨Ó¡AGlobo H-VK9 mAb·RGH¤ñ¸û²`¡^ Page32/93¡e0059¡f& Table 1. Page 32-44 §i¶D§Ṳ́Wz¤»ºØ§ÜGHªº³æ®è§ÜÅé¬O¦p¦ó³Q»s³y¥X¨Óªº¡A¥¦Ìªº«/»´Áå¥iÅܰϪºÓi°ò»Ä§Ç¦C³Q°µ¤Fþ¨ÇªºÅÜ´«¡C ¤å¥½Á|¤F´X¨Ò°µ»¡©ú¡A¥Xª©¤j±z½ÐÄ~Äò§V¤O¡A¤p§ÌºÉ¤O©ó¦¹¡C ˬO¦bPage70/93¡e00138¡f¡GExample 6¡AAnti-GH Abªº¥æ¤e¤ÏÀ³©Ê¤ÀªR¤¤¡A¬Ý¨ì¤F¡uGlycoDx¡v¡A²´¦yªº±zÀ³¸Ó·|ı±o¦ü´¿¬ÛÃÑ¡A¨S°O¿ùªº¸Ü¡A¥¦¬O¯E¹©¦b¤¤µØ¥Á°ê¤wµù¥Uªº²£«~°Ó¼Ð¦WºÙ¤§¤@¡AÓ¤H±À´úÀ³¸Ó´N¬OÁÞ´¹¤ù¤W¥««áªºÃÀ¦W¡C |
|
|
·|û¡G¦³FUªº¤H10136189 µoªí®É¶¡:2015/10/18 ¤U¤È 11:05:53²Ä 453 ½g¦^À³
|
¦¹ÃĪ«Ibrance 2015/04 FDA ®Ö¥iªºÃĪ«,¦p¤µ¨ì¤F2015/08/14 ²Îp¸ê®Æ¾P°âÃB¤wöt¤W7.1»õ¬ü¤¸,¥u¹L¤F¥|Ó¤ë7.1»õ¬ü¤¸¦Ó¥þ¦~¤W¬Ý21.3»õ¬ü¤¸(¥u¬O¬ü°ê¦a°Ï),Yn¬O¦p¤º®e©Ò¥Ü¹j¦~2016/9¤ë¨ú±o¼Ú¬w¦a°ÏªºÃÄÃÒ,¦³¾÷·|¦b2017/9¤ë¹F¨ìPfizer ¦Û¦æ¹w¦ôªº40~50»õ¬üª÷ªº¾P°âÃB(¦Ó¥B¬O3¦~¤º´N¹F¦¨¦p¦¹¨ÎÁZ).¬Ý¨Ó°£¤Fn¦nªºÃĮĤ]n¦³¶W±jªº¾P°â³q¸ô.§Æ±æ¯E¹©»P¨ä¾P°â°Ó¨ì®ÉÔ¤]·|¦³¦p¦¹±jªº¾P°â¯à¤O.²¦³º¤éXX¦ô¯E¹©ªºOBI¹ï¤WPfizer ªºIbrance½×ÃİƧ@¥Î»P»ù®æÀ³¸Ó¦n¤W«Ü¦h |
|
|
·|û¡G¦³FUªº¤H10136189 µoªí®É¶¡:2015/10/18 ¤U¤È 10:47:19²Ä 452 ½g¦^À³
|
¤p§Ì§Ú¸ò¦U¦ì«e½ú¤À¨É¤@Ó¦³Ãö©ó¯E¹©¹ï¤âPfizer(Ibrance)ªº¬ÛÃö¾P°âµû¦ô,ºô§}¦p¤U(À³¸Ó¬O¤j³°ªººô§}):https://translate.google.com.tw/translate?hl=zh-TW&sl=zh-CN&u=http://www.cphi.cn/news/show-124876.html&prev=search |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/10/18 ¤U¤È 10:02:25²Ä 451 ½g¦^À³
|
Hi ¥i¾aªºCliff¤j.. ¤pªº¤Sn§ä±z³Â·Ð¤F.. §ä¨ì¤@ÓOBI¬ÛÃö WOGENE is current through October 16, 2015 Most recent patent publication: WO2015157629 Assignee(s):OBI Pharma Inc.; Yu, Cheng-Der Tony Published:2015-10-15 (http://www.sequencebase.com/) Yu, Cheng-Der À³¸Ó¬O ¬ãµoªø ´å ¥à ¼w ¤@ª½¤£±o¨äªù¦Ó¤J.§ä¤£¨ì¤º¤å.·Q³Â·ÐCliff¤j©Î¦U¦ì¤j¦³¬ÛÃö°T®§¥iµ¹¤pªº¸Ñµª.. ·PÁÂ.. |
|
|
·|û¡G99910140657 µoªí®É¶¡:2015/10/15 ¤U¤È 11:13:42²Ä 450 ½g¦^À³
|
¥xÁÞ¤j«e½ú ·PÁ±z¦p¦¹²M´·ªº´£¥Ü»P¸Ô¸Ñ¡A¦p¦¹§Ú§ó²M·¡§ó©ú¥Õ¤F¡I ¯E¹©¥Í§Þ¯uªº¬O¤@Ó¤£¥i¦h±oªº¥xÆWªÑ²¼¥«³õ¤Ö¨£ªº§ë¸ê¾÷·|¡I ¸g¦b¦¹ºô¯¸½Ñ¦h«e½ṳ́@¦A«ü¾É¡A¶V»{ÃѯE¹©¥Í§Þ«á¡K¤£ªø§ë¯uªº¦³¥i¯à³y¦¨¥ô¦ó§ë¸êªÌªº¤@¥Í¿ò¾Ñ¡K 2016§Y±N¨ÓÁ{¡K¯E¹©¥Í§Þ¾Ö¦³½Ñ¦h¦³¯à¦³¼wªº«e½ú§ë¸ê¡A²`«HºÖ³ø¨Ó¦Û¼w¡I ·PÁ«ܦh«e½úªºÃö¤ß¡A¤]¦A¦¸ÁÂÁÂ¥xÁÞ¤j«e½ú±z½Ñ¦hªº@¤ß²Ó¤ß«ü¾É¡KÁÂÁ±z¡I |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/10/14 ¤U¤È 10:29:55²Ä 449 ½g¦^À³
|
999¤j 1·sÂå療¾¹§÷¤HÅéÁ{§É¸ÕÅç¥i°Ñ¦Ò¹Ãĸpºô¯¸(¤HÅé¸ÕÅç¥Ó½Ð¦Û§Ú¬dÀ˪í) http://www.fda.gov.tw/TC/siteList.aspx?sid=1803 ¥i¬Ý¥Xn¨D¶µ¥Ø,¦Ü©ó¦p¦óÁ{§É,¦]¥»ª©«Ü¤Ö°Q½×, §Ú¤]¤£¬O«Ü²M·¡,¦³¤Hª¾¹D¥i¤À¨É 2 À³¦pÅó±ø±ø©Ò¨¥»PÃĪ«Á{§É¸ÕÅ礣¦P(§Úª¾¹D·|¬d»s³yÁÞ´¹¤ùªº¤u¼t¬O§_²Å¦XPIC/S »P GMP) 3 103¦~«×¦~³ø²Ä84¶§â§¹¦¨ÁÞ´¹¤ùÀù¯gÀËÅç¸Õ¾¯OBI-868©ó¦hºØÀù¯gªºÁ{§É´ú¸Õ»P¤ÀªR ¦C¤Jµu´Á¥Ø¼Ð (Ó¤H²q´ú§¹¦¨®É¶¡¦³¥i¯à·|»P¨ÅÀùOBI822 ¦P¨B¤W¥«¥H§Q°lÂÜÀø®Ä) 4 ÁÞ´¹¤ù¦]Äݳзs«¬Àù¯gÀËÅç¸Õ¾¯,°²¦pÁ{§É¸ÕÅ禨¥\,¦³°ªªº±Ó·P©ÊSensitivity»P¯S²§©ÊSpecificity ¨Ì¾Ú103¦~«×¦~³ø¦~77¶: 2013 年 TriMark ¥«³õ½Õ¬d³ø§i«ü¥X¡AÀù¯g¶EÂ_ªº»Ý¨D±NÀHµÛªñ年¨ÓÀù¯g¤H¤f ¿E¼W¦Ó³v年Ãk¤É¡A¹w¦ô 2012¡ã2019 年¥þ²yÀù¯gÀËÅç¸Õ¾¯年½Æ¦X¦¨ªø²v(CAGR) ¹F 8.6%¡A¹w¦ô 2019 年 ¥«³õ±N¦³ 57 »õ¬ü¤¸¡A¬OÂåÀøÀËÅç¸Õ¾¯¤¤¦¨ªø³Ì¤jªº°Ï¶ô¡C (³o¤@¶ôªÎ¦×¯E¹©¤@©w·|¥h·m) 5 ÁÞ´¹¤ùÀù¯gÀËÅç¸Õ¾¯OBI-868«Y¥Ñ¤¤¥¡¬ã¨s°|¯Î±Ò´f°|ªø¹êÅç«Ç§ÞÂà¦Ü¥xÆW¯E¹©¡A¥H¦hÁÞµ²ºc·í§@¶EÂ_Àù²ÓM ©ÎÀù¯gªvÀøªº¼Ð¹v¡A§Q¥Î¯S©wÁÞÃþ¤À¤l·í§@±´°w¡A¨Ó±´´M¤HÅé²ÓM¥i¯à¦s¦bªºÀù¯fÅÜ¡A¨ä²³æ¡B«D«I¤J©Ê¡B§ó¦ ´ÁÀË´úÀù¯gªº¯S©Ê¡A¥¿²Å¦XÀù¯g¶EÂ_ªº´Á«Ý»P¥D¬y 6 ¤j®a·Q¤@·Q¥þ¥@¬É¤@¤ÑÅç¦h¤Ö¤H¦¸ªº CEA CA19-9 CA-125 CA15-3 PSA CYFRA21-1 SCC AFP(±Ó·P©Ê»P¯S²§©Ê¨}²û¤£»ô),¦pªG¦³¤@ºØ±Ó·P©ÊSensitivity»P¯S²§©ÊSpecificity «Ü°ªªºÁÞ´¹¤ùÀù¯gÀËÅç¸Õ¾¯,¤@¦¸¥iÅç¦hºØÀù¯g,¤j®a·Q¤@·Q³o¶µ²£«~Ävª§¤O·|¦p¦ó? 7 OBI-868±N¦bÁ{§É¸ÕÅ秹¦¨«á¡A¿n·¥¬¢½Í±ÂÅv¡AÀÀ»P°ê»ÚÂåÀø¶EÂ_¤j¼t¦X§@¡A§Q¥Î¨ä¶EÂ_¸Õ¾¯¶}µo±Mªø ¤Î¬J¦³³q¸ô¡A±À¼s²£«~¡C (103¦~«×¦~³ø¦~78¶),Ó¤H¬ã§PÁÞ´¹¤ùÀù¯gÀËÅç¸Õ¾¯OBI-868À³·|¬O¥þ²y±ÂÅv ¥H¬O¤À¨É¶È¨Ñ°Ñ¦Ò¦p¦³¿ù½Ð§ó¥¿ |
|
|
·|û¡G99910140657 µoªí®É¶¡:2015/10/14 ¤U¤È 06:24:29²Ä 448 ½g¦^À³
|
Åó±ø±ø«e½ú ÁÂÁ¡KÁÂÁ¡AÁÂÁ±z¡I ¦³ÂI²z¸Ñ¤F¡K ·sÃÄ»PÂå§÷ªº®t²§©Ê¡C §ë¸ê¯E¹©¥Í§Þ¦³±z̳o¸s¼w°ª±æ«¤S¼s¬I±Ð¾É´£¥Ü¥½¶iªº«e½úÌ¡K ¯uªº±`¤ß¦s·P¿E±zÌ¡IÁÂÁ±z¡C |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2015/10/14 ¤W¤È 11:57:09²Ä 447 ½g¦^À³
|
999¤j, ³oÓ¸ò·sÃĤ£¦P¼Ú Åé¥~¶EÂ_ÂåÀø¾¹§÷(In Vitro Diagnostic Devices, IVD)¦³§O©ó¤@¯ëªx«üªºÂåÀø¾¹§÷(medical devices)¡A¥Dn¬O«ü¤£ª½±µ±µÄ²¤HÅé¡A§Q¥Î¨ú¦Û¤HÅ骺¦å²G¡B§¿²G¡B¨ä¥LÅé²G©Î²Õ´¤Á¤ùµ¥¡A¶i¦æ¤HÅé¥~¸ÕÅç©Î¤ÀªRªºÂåÀø¾¹§÷¡CÀHµÛ¤H¤fµ²ºc¦Ñ¤Æ¡B¥Í¬¡«~½è§ïµ½¡B°·±d·NÃÑ°ªº¦¡BÂåÀø«~½è´£ª@»P§Þ³N¶i¨Bµ¥ºØºØ¦]¯À¡Aªñ¦~¨ÓÅé¥~¶EÂ_ÂåÀø¾¹§÷²£·~§e²{À¸¼@¤Æªºµo®i¡A¤£¶ÈÀËÅ窺½d³ò¤é¯qÂX¤j¡A©Ò¹B¥Îªº¤ÀªR§Þ³N¥ç·U¨£¦h¼Ë¤Æ¡C¥»¤å¥Dn¬O°Ñ¦ÒEDMA¤§¤ÀÃþªk¡A¥t¥~¦A°t¦Xªñ¦~¨Ó²£«~µo®i¤§ÁͶաA±NÅé¥~¶EÂ_¾¹§÷°Ï¤À¦¨¡GÀËÅç»ö¾¹³]³Æ¡BÀËÅç¸Õ¾¯/¸Õ¯È¡A¥H¤ÎÅé¥~¶EÂ_¨ä¥L»ö¾¹³]³Æµ¥¤T¤jÃþ¡C |
|
|
·|û¡G99910140657 µoªí®É¶¡:2015/10/14 ¤W¤È 11:27:36²Ä 446 ½g¦^À³
|
¥xÁÞ¤j«e½ú ½Ð±Ð±z¡mOBI-868¡nÁÞ´¹¤ù¦pªG¯uªº¬O¦p¤½¥q³W¹ºªº©ó2016¦~¶i¤JÁ{§É¸ÕÅç¡K¡K ¤]¬O¥²»Ý±q¢°¡Ð¢²´Áªºµ{§Ç¡A¦A¥Î¬ù¢¶¡Ð¢°¢¯¦~ªºÁ{§É®É¶¡¤~¯à¥Ó½Ð³c½æ±À¼s¶Ü¡H ·q½Ð«ü¾É¡K¡K·PÁ±z¡I |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/10/12 ¤W¤È 09:10:53²Ä 445 ½g¦^À³
|
¥xÆW¯E¹©¥t¤@¶µ¦³Ävª§¤Oªº²£«~:OBI-868 ÁÞ´¹¤ùÀù¯gÀËÅç¸Õ¾¯ 1®Ú¾Ú 2013 年 TriMark ¥«³õ½Õ¬d³ø§i«ü¥X¡AÀù¯g¶EÂ_ªº»Ý¨D±NÀHµÛªñ年¨ÓÀù¯g¤H¤f¿E¼W¦Ó³v年Ãk¤É¡A ¹w¦ô 2012¡ã2019 年¥þ²yÀù¯gÀËÅç¸Õ¾¯年½Æ¦X¦¨ªø²v(CAGR) ¹F 8.6%¡A¹w¦ô 2019 年¥«³õ±N¦³ 57 »õ¬ü¤¸¡A ¬OÂåÀøÀËÅç¸Õ¾¯¤¤¦¨ªø³Ì¤jªº°Ï¶ô¡C 2¬ü°êÀù¯gÀË´ú²£«~¥i¤À¬°®Ö»Ä¤ÀªR¡B§K¬Ì¤ÀªR»P²Õ´¬V¦âµ¥¤T¤jÃþ¡F²Õ´¬V¦âªk¦¤w¶i¤J²£«~ ¦¨¼ô´Á¡AºI¦Ü 2012 年¡A¥«³õ¤WÀËÅç²£«~§K¬Ì¤ÀªR¦û 51.9%¡A®Ö»Ä¤ÀªR¦û 27.3%¡F ¦Ó¥¼¨ÓªºÀË´ú²£«~§ó±N¥H§K¬Ì¤ÀªR¤èªk¬°¤j©v¡C¦ÓÁÞÃþ´¹¤ù¬°¥«³õ¤W²Ä¤@Ãþ(first-in-class) ·s¿oªºÀù¯gÀËÅç¸Õ¾¯¡A¹wp¥«³õ³W¼Òn¸û¶Ç²Î§K¬Ì¤ÀªRªk¨Ó±o§ó¤j¡C 3¥xÆW¯E¹©¶}µoªºÁÞ´¹¤ù OBI-868¡A¥H¦hÁÞµ²ºc·í§@¶EÂ_Àù²ÓM©ÎÀù¯gªvÀø¼Ð¹v¡A§Q¥Î¯S©wÁÞÃþ¤À¤l ·í§@±´°w¡A±NÁÞÃþ©ñ¸m´¹¤ù¤W¡A¥i¥Î¥H¼ÒÀÀ²ÓMªí±¡A¦Óµo®i¥XªºÀù¯gÀË´ú¸Õ¾¯¡C¦¹²£«~¥i¥Î©ó±´´M ¤HÅé¦å²G¤º¥i¯à¦]Àù¯fÅܦӲ£¥Íªº§Ü¯S©wÁÞ¤À¤lªº§ÜÅé¡A¥B¥iÀ³¥Î©ó¦hºØÀù¯gÀË´ú¡C 4¥xÆW¯E¹©¥Ø¼Ð¦bµo®i¥X¸û²{¦³¸~½F¦å²G¿zÀ˸վ¯§ó¨ã±M¤@©Ê¡B±Ó·P©Êªº²£«~¡A¥HÀu¶Vªº©Ê¯à»P¦P®É¶EÂ_ ¦hºØÀù¯gªº¯S®í©Ê¡A¬Û¸û©ó²{¦³²£«~§ó¨ãÀu¶Õ¡C (¥Ø«e±`¨£ªº¸~½F¥Í¤Æ¼Ð»x¡A²©ö¡B§Ö³t¡A¦ýµLªk¦³®Ä¤À¿ëÀù¯g¡A·Ç½T©Ê±`³Æ¨ü½èºÃ) 5 OBI-868 ÁÞ´¹¤ùÀù¯gÀËÅç¸Õ¾¯ ¥Ø¼Ð©w¦ì¬°¶E·Ç½T¶EÂ_¦hºØÀù¯gªº·s¤@¥NÀù¯gÀËÅç¸Õ¾¯ 6ì®Æ¬°¥xÆW¯E¹©¦Û行¦X¦¨ÁÞÃþ¡A¶È·¥¤p³¡¥÷¦V°ê¥~ÁʶR¡A¹B¥Î¬§ÃÀ¬ì§Þ(ªÑ)¤½¥q¤§³]³ÆÉx¥x»s¦¨ÁÞ´¹¤ù¡A ¥Ø«e¦b¦¨¤jªþ³]Âå°|¡B¥x¤jÂå°|¤Îªø©°Âå°|¶i行 Proof of Concept Á{§É¼Æ¾Ú¦¬¶°(2015²Ä¤T©u§¹¦¨) 2015¦~²Ä¥|©u¶i¤JÁ{§É«e¸m§@·~ ,2016¦~¶i¤JÁ{§É¸ÕÅç 7OBI-868 ±N¦bÁ{§É¸ÕÅ秹¦¨«á¡A¿n·¥¬¢½Í±ÂÅv¡AÀÀ»P°ê»ÚÂåÀø¶EÂ_¤j¼t¦X§@¡A§Q¥Î¨ä¶EÂ_¸Õ¾¯¶}µo±Mªø ¤Î¬J¦³³q¸ô¡A±À¼s²£«~¡C ¥H¤W«ÂI¨Ì¾Ú104¦~4¤ë30¤é¦~³ø ´£¨Ñ°Ñ¦Ò |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/10/5 ¤U¤È 04:54:40²Ä 444 ½g¦^À³
|
¯E¹©Á`¸g²z¤ä«ùTPP 2015-10-05 11:36:25 ¸gÀÙ¤é³ø °OªÌ¶À²Q´f¢¬§Y®É³ø¾É ¯E¹©¥Í§Þ¡]4174¡^Á`¸g²z¶À¨q¬ü¤µ¤Ñ¤W¤È«ü¥X¡A¯E¹©¤ä«ù¸ó¤Ó¥¬v¹Ù¦ñ¨ó©w¡]TPP¡^¡A³o¹ï©ó°ê¤ºªº¸gÀÙµ´¹ï¬O¥[¤Àªº®ÄªG¡A´N°ê¤ºªº¤H¤fµ²ºc¸ò³Ò°Ê¤O¤H¤f¡A°ê¤ºªº²£·~¥²¶·n¤£Â_±À°Ê°ª½è¤Æ¡A¦~»´¤H¤~¯à¦³§ó¦hªºµo®i¾÷·|¡A¦Ó¥Í§Þ²£·~ªºµo®i¬O¥¼¨ÓªºÁͶաA°ê¤º¬Fµ¦À³¸Ón¤ä«ùTPP¡AÅý°ê¤ºªº¥Í§Þ²£·~µo®i³t«×§ó§Ö¡C ¶À¨q¬ü¤ÀªR¡A·sÃĬãµo¬O¤@Ó°ª·ÀI¡B®É¶¡ªøªºªº¬ãµo¡A¦ý¬Oªø´Á¹ï©ó¤HÃþªº°·±d«h¬O¦³«Ü¤j¥[¤À®ÄªG¡A¥i¥H´î¤Ö¤HÃþ«Ü¦hªº¯fµh¡A¬ü°ê¤@ª½¬O³Ì¤ä«ù¥Í§Þ²£·~¡A¤]¹ªÀy¬ãµo¡A¥Ø«e°ê¤º³\¦h·sÃĬãµoªº±M§Qªº«OÅ@¤£¨¬¡A°ê¤ºªº¬Fµ¦À³¸Ó¤]n¤ä«ùTPP¨óij¡Aªø´Á¤~¦³±À°Ê°ê¤º¥Í§Þ²£·~¬ãµo¨«¦V°ê»Ú¡C ¤À¨Éµ¹¦n¤Í¥[¤Judn |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/10/5 ¤W¤È 07:42:38²Ä 443 ½g¦^À³
|
°e³ø¤j ¤p§Ì¸ò±zªº²q´ú¤@¼Ë,«¢«¢«¢ ¶Â´ËªL¤¤ªº¥ú¦ü¥G¤@ÂI¤@ÂIªº³zÅS¤F ¦Ü©ó¹ïªÑ»ù·|¤£·|¦³¼vÅT ¤p§ÌË»{¬°¤¤©Ê.«O¦u¬Ý«Ý,¤£»Ý¹L«×¸ÑŪ |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/10/4 ¤U¤È 11:45:42²Ä 442 ½g¦^À³
|
Hi ¦U¦ì¤j.. ³o¦¸±ÂÅv¥H¤pªº»{ª¾À³¸Óºâ¬O."Merck <= Cubist <= OPTIMER" §â¤§«e¯E¹©©Ò"¯d¤U"ªºDIFICID¥xÆW¾P°âÅv"¶R¦^¥h".. ¬ü¥[¦a°Ï.."Merck <= Cubist <= OPTIMER" ¦Û¦æ¾P°â ¨ä¥L¦a°Ï(¼Ú.¤é.¿D...)¤]¤w±ÂÅv¥X¥h..©Ò¥H¨ä¥L¦a°Ïªº¾P°â©M¯E¹©µLÃö(±i¸³.Y.KÀ³¸ÓÁÙ¦³±o¤À¨Ç.).. ¥u¬O¥HÀq¨FªF³o¼Ëªº¤j©@¦³¥²nªá300¸U¬üª÷(¥H¥xÆW¥«³õÀ³¸Óºâ¤£¿ùªº»ù¿ú)§â³o¶ô·L¤pªº«÷¹Ï¶R¦^¥h.. ©Î³\©MÀq¨FªF¦X§@ªº¶}©l§óȱoª`·N.. ¥H¤W¯Â²q´ú.. |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2015/10/4 ¤U¤È 10:37:30²Ä 441 ½g¦^À³
|
FAITH¤j 822°Ê¤O¤õ½b ¤ñ¸û¦n¥Î°Õ ¹©¸¡ªY¥u¬O»²§U¤õ½b ¤£¥Î§ó¦n ªí¥Ü822°Ê¤O¤õ½b ¤ñ¤½¥q¥H«e·Qªº§ó¦n¥Î |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/10/4 ¤U¤È 10:11:18²Ä 440 ½g¦^À³
|
¹ï¤£°_§r¡A5112¨º½g¹ê¦b¤Óªø¤F¡A¤p§Ì¤H¦b¥~±n·Æ«Ü¤[¡A¥u¦n¥ý¶K¦b³o ª`·N¶ÀÁ`»¡ªº¸Ü(¤p§Ìªº¸ÑŪ¬O¡A³ÆL¥i¥H©ñ¤U¤F¡A±M¤ß©ó§ó«nªº¡A¯E¤ÍÌÀ³¸Ó«Ü²M·¡¤F§a¡I¡^ ¯E¹©»PÀq¨FªFñ¸p¥xÆW¿W®a±ÂÅv¦X¬ù 2015/10/04 19:37 ¤¤¥¡ªÀ ¡]¤¤¥¡ªÀ°OªÌù¨q¤å¥x¥_2015¦~10¤ë4¤é¹q¡^¥xÆW¯E¹© (4174) ¤µ¤Ñ«Å§G¡A»P¬ü°ÓÀq¨FªFÃļt(MSD)ñq²£«~±ÂÅv¦X¬ù¡A¯E¹©±NºX¤U·s«¬§Ü¥Í¯À¡u¹©¸¡ªY¡vDIFICID(°Ó«~¦WFidaxomicin)¦b¥x²£«~¶}µo¤Î¾P°âÅv§Q¡A¿W®a±ÂÅvµ¹Àq¨FªF¡C ¨Ì·ÓÂù¤è¨óij¡AÀq¨FªF±N¤ä¥I300¸U¬ü¤¸¡]¬ù·s¥x¹ô9700¸U¤¸¡^ñ¬ùª÷¡A¥¼¨Ó¯E¹©ÁÙ¥i¦¬¨ú¾P°âÅv§Qª÷¤Î¨½µ{ª÷¡A²Öp¾P°â²bÃB¤Î·s¾AÀ³¯gªº¨½µ{ª÷¡A³Ì¦h¥i¹F525¸U¬ü¤¸¡CÀq¨FªF«ht³d¥¼¨Ó¡u¹©¸¡ªY¡v¦b¥x©Ò¦³¸g¾P¡B¬ãµo¡B¥Í²£¸g¶Oµ¥¨Æ©y¡C ¯E¹©Á`¸g²z¶À¨q¬üªí¥Ü¡A³o¬OÂùĹªºµ²ªG¡A¯E¹©±N§ó±Mª`©óÀù¯g¬Ì]µ¥·sÃĶ}µo¡A¤]´Á³\¡u¹©¸¡ªY¡v¦bMSD°í±jªºÀç¾P¹Î¶¤©MÂ×´Iªº¸gÅç¤U¡A³yºÖ§ó¦h¬°§xÃø±ôª¬±ìµß¬ÛÃö¸¡Âm©ÒWªº¯f±w¡C |
|
|
·|û¡Gjm042310140224 µoªí®É¶¡:2015/9/30 ¤U¤È 09:06:01²Ä 439 ½g¦^À³
|
ªü®¶¤j ±z²×©ó¤S¥XÁn¤F ¥u¬On¦V±zPÁ ¦]±zµL¨pªº¤À¨É 8/31§Ú¤S¾Ä¤£ÅU¨ªº§ë¤J ·PÁ¡A¦A·PÁ |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2015/9/30 ¤U¤È 07:36:44²Ä 438 ½g¦^À³
|
ªü®¶¤j ²×©óµoÁn¤F ±z¹ï¯E¹©ªº»·¨£»P¹w¨£ ¤p§Ì»â¨ü°Õ |
|
|
·|û¡Gªü®¶10139782 µoªí®É¶¡:2015/9/30 ¤U¤È 07:01:07²Ä 437 ½g¦^À³
|
Dear jm0423ÁÂÁ§Aªº·Q©À ¦]¬°¦Û¤v¤@ª½³£¬O¨«ªø´Á»ùȧë¸ê.¤]¤£¬Û«H¦Û¤v¯à¦³¹w´úµu´ÁªÑ»ùªº¯à¤O ©Ò¥H¤p§Ì¦Û100¦h¤¸¶R¨ì²{¦b ¤@±i³£¨S½æ §Úªº°¸¹³¦pCliff¤j.¥x¿}¤j.«Ü¦h¤j¤j¤j¡K ±z̪º¤å³¹.µL¨pªº¥I¥X¤p§Ì¤@ª½·P©À¦b¤ß¤¤ ¤]¦]¬°¦³µÛ±z̪º¦s¦b,Åý§Ú̳o¨Ç¹ï¦¹»â°ì¤£¼ôªº¤H ¯à¼W²K«Ü¦h«ùªÑªº«H¤ß ´£¨Ñ¤@¨Ç·Qªk²L¨£:(¦p¦³¿ù»~ÁÙ¬O¥Hcliff¤jªº¬°·Ç¼Ú) ¯E¹©ªºÀu¶Õ¡K.³o¨ÇÀu¶Õ©¹©¹´N¬OÄvª§¹ï¤âµLªk¨ì¹Fªº¡¨³Ì«á¤@ù¸ô¡¨ 1. ¸û¼sªxªº¾A¥Î±Ú¸s. 2. Off label use ¤Wªº¨Ï¥Î(¦]¬°¨S¤°»ò°Æ§@¥Î,¸û¤£¶·¨üÄY®æ³W½d) 3. ¦¨¥»¤WªºÀu¶Õ,¥H¶PÀù¥¬°¨Ò¦b¥xÆW¨C¦~Àøµ{¶O¥Î¤j¬ù100¸U,¬ü°ê°Ý¨ìªº»ù®æ°ª¹F200¸U/¨C¦~¡K.°£¤F»s³y¦¨¥»¸û¯E¹©°ª¥~,®t²§¦b©ó¯E¹©ªºÃĨϥΤW¤£»Ýn¦í°|,³o³¡¤À´N¯à¬Ù¤U«Ü°ªÃBªº¦¨¥»,¦b¥~°ê¦í°|ªº¶O¥Î¬O«Ü¶Qªº 4. ¹³¬ü°ê³o¨Ç´Tû¿ñÁ諸¦a°Ï,©¹©¹¶}¨®¨ì¦³Àù¯gªvÀøªºÂå°|¥i¯ànªá¶O3.4¤p®É¬Æ¦Ü¤@¤Ñ.¦ý¯E¹©ªºªvÀø´N¹³¥´¤@°w,¦b¸û¤p«¬ªºÂå°|,¬Æ¦Ü°ª¤ô·Çªº¶E©Ò´N¯à°õ¦æ¤â³N«áªº«áÄòÀøµ{,³o¤è«K«Ü¦h¡K.³o¨Ç,³£¯àÅý¯E¹©¦b¶}µo¥«³õ®É¯à§ó§Ö³t,¥B§ó²`¤Jªº©Ý®i¥«³õ.¦]¬°¤è«K.²³æ.§C¦¨¥» 5.¯E¹©ªºÃĨä¹êÀ³¸Ó¤£¯àºâ¬OÃÄ,¨ä·¥§Cªº°Æ§@¥Î,°£³æ¿W¥ÎÃĪº¦w¥þ©Ê¤§¥~,»P¨ä¥¦¶Pº¸»XÃĪ«¤ÆÀøÃÄ,n·f°t¦¨¬°Áp¦X¥ÎÃĪº½Ä¬ð©Ê§ó§C,¾A¥Î©Ê§ó¼s. ²L¨£°Ñ¦Ò ÁÂÁ |
|
|
·|û¡G¬K¬î10139014 µoªí®É¶¡:2015/9/29 ¤U¤È 08:46:53²Ä 436 ½g¦^À³
|
¦hÁÂCliff¤j@¤ß¸Ô²Óªº´À¤j®a¸Ñ»¡¡I ¦³Cliff¤j¤Î¦U¦ì¤j¡AÅý¤p§Ì¯E¹©¥i¥H©êªº¦w¤ß¶}¤ß¡C ´Á±æ¯E¹©ªº"¬K¬î"¤j·~¥i¦¨¡A¬°²³¦h¯f±w¿ÑºÖ¬ç¡B´À¥xÆW¥Í§Þ´M¥X¸ô¡C |
|
|
·|û¡Gµ½¤H10137888 µoªí®É¶¡:2015/9/29 ¤U¤È 08:39:56²Ä 435 ½g¦^À³
|
Cliff¤j, «D±`·PÁ±z¼ö¸Û¤S¸Ô²Óªº¸Ñ»¡! ¯E¤Í̦³±zªº¤Þ»â, ¿·P·ÅÄÉ»P¦w¤ß. |
|
|
·|û¡GIriswu10136250 µoªí®É¶¡:2015/9/29 ¤U¤È 07:55:52²Ä 434 ½g¦^À³
|
¦hÁÂcliff¤jªº¸Ñ»¡. |
|
|
·|û¡G±Û«a10139522 µoªí®É¶¡:2015/9/29 ¤U¤È 07:22:00²Ä 433 ½g¦^À³
|
·PÁÂCliff¤j¤j¤£Ã㨯³Òªº»¡©ú¡A°ò¥»±¥Ñ±z¯}·»â¾É¡A¤@¸ô¦æ¨Ó¡A³Æ·P¦w¤ß¡C |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/9/29 ¤U¤È 05:25:24²Ä 432 ½g¦^À³
|
¥Xª©¤j¡G ¶ÀÁ`¸g²z¦b¤WÂd«eªk»¡·|¤W¦n¹³´£¹L¡C §C¾¯¶qªºcyclophosphamide¦b°Êª«¹êÅ窺¬ã¨s¦¦b1970s´N³Qµo²{¡C¤HÅ骺³¡¤À¤]ªº½T¥i¦bÀù¯gªvÀø¤¤´î¤Ö¡u§í¨î©ÊT²ÓM¡v§@¥Î¡A¦Ó¤£´î·lCD8+²ÓMªº¹B§@¡A¶¡±µ¼W±jÀù¯g±wªÌ§K¬Ì¤O¡]Bred et al;1987¡^¡]http://www.ncbi.nlm.nih.gov/pubmed/2953413 ¡^¡C «á¨Ó³°ÄòªºÃÒ¾Ú¤]³£¤ä«ù³o¼Ëªº»¡ªk¡A§C¾¯¶qªºcyclophosphamide¥Î¦b«Iŧ©Ê¨ÅÀù¤Î¯ØŦÀù±wªÌ®É¤×¨ä¨ü¨ìÆf¥Ø¡A¦]¬°µo²{³o¨Ç±wªÌªº¶gÃä¦åºÞ©Î¸~½F·LÀô¹Ò¡A§Gº¡¡u½Õ¸`©ÊT²ÓM¡v¡]T reg¡^¡A¥¦·|§í¨î¡uT²ÓM¡v¥\¯à¦Ó¥B·|¥H§í¨î¡u¦ÛµM±þ¤â²ÓM¡v¡]NK cell¡^¼W¥Í»P§@°Ê¡A¾ÉP±þÀù¤O¶q°§C¡F¦Ó§C¾¯¶qªºcyclophosphamide·|°§C¡uCD4+CD25+½Õ¸`©Ê©ÊT²ÓM¡vªº§@¥Î¡A«ì´_¸Ó¦³ªº§K¬Ì¤O¡C¡]http://www.ncbi.nlm.nih.gov/pubmed/?term=ghiringhelli+2007%3Bmetronomic+cyclophos%5Bhamide+regimen+selectively+depletes ¡^ Iriswu¤j¡G Q¡G¡u½Ð°Ý²{¦bªº822ªºÁ{§ÉÃĪ«¶·n¦³Á{§ÉªºCMC¶Ü?¡v Phase III³q±`¬OPivotal Trial¡A©Ò¨Ï¥Îªº¸ÕÅç¥ÎÃÄ¥²¶·»P¥¼¨Ó¥Ó½ÐÃÄÃÒªºÃĬO¦P¤@®aGMPÃļt»s³y¥Í²£ªº¡A«e±Phase I&IIÀ³¸Ó¤£¦¨°ÝÃD¡C Q¡G¡u±N¨Ó¶q²£ªºCMC°ÝÃD¤£ª¾¹D³o¼Ëªº¤À¤lµ²ºcÃĪ«¹L¥h°ê»Ú¤W¦³µLÃþ¦üªº¸gÅç?¡v ¦bStellar´£¨ÑKLHªº«È¤á¤¤¡A822¦ü¥G¬O¬ãµo¶i«×³Ì§Öªº¤@Ó²£«~¡C©Ò¥H¸òKLH±µ¦X¤£¨}ªº±¡§Î¡A¡u¥i¯à¡v822¬O¥´ÀY°}¡C ³o¨âÃD¦³½Ðª©¤W°ª¤â¨ó§U¸Ñµª¡C µ½¤H¤j¡G Q¡G¡uGlobo H-DT/QS21¬O§_¦³Globo H-KLH/QS21ªº¯ÊÂI? ¨Ò¦p¤£Ã©w©M¥Ö½§¬õ¸~µ¥.¡v §Ú·Q¬JµM³£¥HQS-21·í¦õ¾¯¡AÀ³¸Ó¤]·|¦³¥Ö½§¬õ¸~ªºµu¼È°Æ§@¥Î¡C§âKLH§ï´«¦¨DT«á¡A¯à¤£¯à¬Ù¥hGH»PÄâ±a³J¥Õ¤§¶¡±µ¦X¤£Ãªº°ÝÃD¡A³oÓn°Ý¤½¥q¤~ª¾¹D¡A¤½¥qÄ@¤£Ä@»¡´N¤£±o¦Óª¾¡A¥Ø«e¨S§ä¨ì¬ÛÃö¸ê®Æ¸ÑÄÀ¡C Globo H-DT/QS21´N¤½¥q¬ãµo°ª¼h¤§«e©Òz¡A¤½¥q©Ò°µªº¸ÕÅçÅã¥Ü¬O¦³IgGªº¡A¤j®a´N«ø¥Ø¥H«Ý¡C DTªº¦¨¤ÀCRM197¤w³Q¥Î¦bWyethÃļtªºPrevenar¡]¨K¨àªÍª¢Ãì²yµß¤Q¤T»ùµ²¦X«¬¬Ì]¡^¡A¦bÀ¦¨à¥X¥Íº¡¤GÓ¤ë®É´N¶}©l¥´²Ä¤@¾¯¡A°¸º¸¦³»´·Lµo¿Nªº±¡§Î¡A¨Ã¨S¦³«¤j°Æ§@¥Î¡A´X¦~¨Ó³oÓ¬Ì]ªº¾A¥Î¦~ÄÖÀHµÛ¤½¥q¤@ÓÓÁ{§É¸ÕÅ窺´¦¾å³vº¥ÂX¤j¡A¥Ø«e¤wÀò¥þ¦~ÄÖ¼h¬Ò¾A¦X±µºØªº³\¥i¡A¦w¥þ©Ê¥i¨£¤@´³¡Cª©¤W¤@¦ì³\¤[¥¼¨£ªº¤j¤j¥h¦~¦n¹³¥h¥´¹L¡A¸gÅç¤WÀ¦¨à¨S¦³¥X²{Mrs. Serenity¨ººØ¤j¶ô¥Ö½§¬õ¸~ªº°ÝÃD¡A¦³®ÉÔ¥´¤Ó²L·|¦³´X¤Ñªºª`®g³B¬õ¸~²{¶H¡AÄY®æ¨Ó»¡¤£¯àºâ¬O¬Ì]ªº°Æ§@¥Î¡C¡]http://dlweb01.tzuchi.com.tw/dl/Med/packageinsert/%E6%96%B0%E4%BB%BF%E5%96%AE/104.05/IPNEU13.2015.05.pdf¡F¬Ý¥é³æ¶}ÀY²Ä8¦æ¡A§tCRM197¦¨¤À¡^ Q¡G¡uGlobo H-DT/QS21©MGlobo H-MPLA¤ñ¸û, ¼ôÀu±E¦H? ¨Ò¦p IgG§ÜÅé¶qªº¦h¹è¡v ³o§ñÃö°Ó·~§Q¯q»P¾÷±K¡A§Ú·Q³Ì¦n¬O¥[¤W°|ªøª©ªº¡uGlobo H-DT /C34¡v¤TªÌ¤@°_¨ÓPK¡I ¬K¬î¤j¡G Q¡G¡u¡K¬O§_´Nºâ¹ï¤â¬Y¨Ç¦a¤è¤ñ¯E¹©±j¡A¦ý¨S¯à°Ó·~¶q²£Globo H¤]µLªk¦b²×ºÝ¥«³õ³y¦¨«Â¯Ù©O¡H¡v ªº½T¦p¦¹¡A±q¹êÅç«Ç¨ì¶q²£³o¤@±ø¸ô§Gº¡³´¨À»PÃøÃö¡A§Y¨Ï°µ¨ì¤F¡u¬ã¡v¡AÁÙn¦³¤èªk¯à¡uµo¡v¡A¥ú¬O¤j¶q¦X¦¨Globo H³o¤@Ãö¡A¤Æ¤E¤Q¤E¹Dµ{§Ç¬°¨â¹Dµ{§Ç¡A¤£¬O¤T¨¥¨â»y¥i¥H¸ó¶V¡C©Ò¥H¨ä¹ê³Ì¦n¬O¥Ñ¯E¹©¥X±±N¥¦§ÞÂà¶i¨Ó¡A¥¼¨Óµø±¡§Î¦AÄ~Äò¬ãµo©Î°e¶i¦B®w¡C¸U¤@¸¨¤J¤j¼t¤f³U¡Aµu´Á¶¡©Î³\¨S¦³«Â¯Ù¡Aªø´Áªº¸Ü¡AOBI¡u¬K¬î¡v¤j·~¬O§_·|¨ü¤zÂZ¤£±o¦Óª¾¡C ¥H¤W¤º®e¥X©ó«D±M·~´¢´ú¡AY¥Ñ¤½¥q±M·~¤Hû¨Ó¸Ñµª·|§ó¶K¤Á¡C |
|
|
·|û¡G¬K¬î10139014 µoªí®É¶¡:2015/9/29 ¤U¤È 12:13:21²Ä 431 ½g¦^À³
|
¦U¦ì¤j ¾A³{¸É°²¡A±y«v¦b®a¡C¦ý¬Ý¨ì¦U¦ì¤j¹ï©ó³oÓ¹ï¤âªº´yz¡A½T¹ê¬OÀu¨q¡C ¤p§Ì·Q½Ð°Ý¤@Ó«Ü°ò¥»ªº°ÝÃD¡G¬JµM¯E¹©¾Ö¦³Globo Hªº±M§Q¦X¦¨ªk¤~±o¥H¶q²£À³¥Î¦b°Ó·~¤W¡A ¨º»ò¬O§_´Nºâ¹ï¤â¬Y¨Ç¦a¤è¤ñ¯E¹©±j¡A¦ý¨S¯à°Ó·~¶q²£Globo H¤]µLªk¦b²×ºÝ¥«³õ³y¦¨«Â¯Ù©O¡H |
|
|
·|û¡Gµ½¤H10137888 µoªí®É¶¡:2015/9/29 ¤W¤È 09:47:48²Ä 430 ½g¦^À³
|
°e³ø¤j, Cliff¤j, «D±`·PÁ±z̪º¦X§@. Cliff¤jªº±M·~´¼¼z©M¼ö¸Û, §óÅý¯E¤ÍÌ´L·q±R«ô! Cliff¤j, «_¬Nªº½Ð±Ð±z, ¥H±zªº±M·~¬ã§P, Globo H-DT/QS21¬O§_¦³Globo H-KLH/QS21ªº¯ÊÂI? ¨Ò¦p¤£Ã©w©M¥Ö½§¬õ¸~µ¥. Globo H-DT/QS21©MGlobo H-MPLA¤ñ¸û, ¼ôÀu±E¦H? ¨Ò¦p IgG§ÜÅé¶qªº¦h¹è. OBI-833¦b¥x¤jªº¤@´ÁÁ{§É¸ÕÅç, ¦³þ¦ì¤j¤jª¾¹D¬°¦ó¦Ü¤µÁÙ¨S¶}©lªºì¦]¶Ü? ¾Ú»¡ÁÙnµ¥¤@¤GÓ¤ë, ¦ý¬O¤£ª¾¹Dì¦]. |
|
|
·|û¡GIriswu10136250 µoªí®É¶¡:2015/9/29 ¤W¤È 08:14:26²Ä 429 ½g¦^À³
|
Cliff¤jÁÂÁ±zªº²Ó¤ß¸ÑÄÀ,±z©Ò´£¨ì¦³ÃöKLH©MGHµ²¦X¦³Ãö«~ºÞ±±¨îªº°ÝÃD, °²³]²{¦b¨Cӧ妸©â¼Ë´ú¸Õ¼Ë«~©Ò´ú¥X¤À¤lµ²¦Xªº¼Æ¶q³£¤£¤@¼Ë©Î¬O¨S¦³Ãþ¦üªºpattern, ³o¼Ën¦p¦ó¨Ó¶i¦æÁ{§É©O? ½Ð°Ý²{¦bªº822ªºÁ{§ÉÃĪ«¶·n¦³Á{§ÉªºCMC¶Ü? ±N¨Ó¶q²£ªºCMC°ÝÃD¤£ª¾¹D³o¼Ëªº¤À¤lµ²ºcÃĪ«¹L¥h°ê»Ú¤W¦³µLÃþ¦üªº¸gÅç? §Ú¥Ø«eÁÙ¬O¦³¨Ç¾á¤ß¶q²£ªº°ÝÃD.ÁÂÁ±zªº«ü¾É. |
|
|
·|û¡Gjm042310140224 µoªí®É¶¡:2015/9/29 ¤W¤È 06:27:30²Ä 428 ½g¦^À³
|
Cliff¤j ¤w¤£ª¾¦p¦ó¨¥Á ¬Û«Hª©¤W²³¦h¤j¤j¦³¬Û¦Pªº·P¨ü »Ê·P¤¤º ªü®¶¤j 8/28ÅåÂE¤@¿h ±z¤S¯«Às¨£º¤£¨£§À ¤@ª½»Ê°O¦b¤ß |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2015/9/29 ¤W¤È 06:17:17²Ä 427 ½g¦^À³
|
Cliff¤j ¥O¤H·q¨Ø±zªº¼ç¤ß¬ã¨s «n·§©À ¥ý¦sÀɦA»¡ |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/9/29 ¤W¤È 01:30:59²Ä 426 ½g¦^À³
|
Cliff¤j..«D±`·PÁÂ.. (°²¦p²{¦b¤pªºÁÙ¬O¾Ç¥Í.¦Ñ®v¥X¤@ÃD"§Ú³Ì±R«ôªº¤H"..¤@©w¤£¬O¼g®]¤¤¤s.·íµM¬OCliff¤j.¾Ç°Ý¦n¤S¦³@©Ê..... ¦U¦ì¤j½Ð¤@°_¬°Cliff¤jªº²Ó¤ß¸Ñ»¡©M..¤pªºª¯»Lªº¥»¨Æ.´xÁn¹ªÀy¤@¤U§a..) Cliff¤j..°²¦p¦³ªÅ¦AÀ°¦£ÄÀºÃ¤@ÂI.. ¹ï¤èÂI¥Xªº¯ÊÂI.¤pªº²q´ú¤½¥q¤è±À³¸Ó¤]¦ª¾¹D¤F(822¤½¥q¬ã¨s¤F¤Q¦h¦~).. ¦³¨S¦³¥i¯à¸Ñ¨Mªºµª®×¥i¯à´N¬O..cyclophosphamide §Ñ°O¨º¤@Ó³õ¦X¤½¥q´¿¦^µª¹L²K¥[cyclophosphamide¥i¼W¥[822ªº??¤ÏÀ³.. http://www.cancerfrontline.org/turning-the-immune-system-against-metastatic-breast-cancer/ ¤¤¦³Ãö822ªº¤@¬q.. Early studies of OPT-822 demonstrated prolonged overall survival in a subset of patients with metastatic breast cancer, especially when patients received low-dose cyclophosphamide ³nÅ骺½Ķ¬O.. OPT-822ªº¦´Á¬ã¨sªí©ú©µªøÁ`¥Í¦s´ÁªºªvÀøÂಾ©Ê¨Å¸¢Àùªº¤@Ó¤l¶°¡A¯S§O¬O·í±wªÌ±µ¨ü§C¾¯¶qÀôÁC酰Ói¡C ¦A¦¸·PÁÂ.. |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/9/28 ¤U¤È 10:40:08²Ä 425 ½g¦^À³
|
Cliff¤j Æg ÁÂÁ±z ¤p§Ì¤]n¨Ó«ôŪ¤F |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/9/28 ¤U¤È 10:23:11²Ä 424 ½g¦^À³
|
¤§¤T §Ñ¤FÁn©ú¤@ÂI¡A¥»¤åªºGH-MPLAªºMPLA¨Ó¦Û©ó©`·æ¤ó¸£½¤ª¢µß¡]Neisseria meningitidis¡^ªºLPSl¥Íª«¦Ó¨Ó¡A¤£¦A¬O¥H«e¨ºÓ©ú¥§Ä¬¹F¨Fªù¤óµß¡C ¤p¹«¹êÅ礤ª½±µ»P822 PK¡G Conjugate 1¡GGH-MPLA¡]·L¯×Å龯«¬¡^¡G¨ú16£gg¡A¤º§t5.4£ggGH¡C Conjugate 2¡GGH-KLH/QS-21¡G¨ú38£gg¡A¤º§t3.1£ggGH¡C ©ó²Ä1¡B14¡B21¡B28¤Ñª`®g¦Ü¥ÀªºC57BL/6J¤p¹«¥Ö¤U¡A¦U¤»°¦¡C¦A©ó²Ä0¡B21¡B27¡B28¤Ñ±Ä¦å´ú¥X§ÜÅé¿@«×¡A¥HELISA´ú©w§ÜÅéÁ`¶q¡BIgGÁ`¶q¡BIgG¤ÀÃþ§ÜÅé¶q¨Ó¤ñ¸û¡C ¡]http://pubs.rsc.org/en/content/articlepdf/2015/sc/c5sc01402f ¡^ Fig.2¡G¡]A¡^¹Ï¬O©Ò²£¥ÍªºÁ`§ÜÅé¿@«×¤ñ¸û¡Cconj.1 >>>conj.2¡C¡]B¡^¹Ï¬O©Ò²£¥ÍªºIgG¿@«×¤ñ¸û¡AÁÙ¬Oconj.1 >>>conj.2¡C¨ä¤¤¡]B¡^¹Ï²Ä21¤ÑIgG by conj.1¡]46449¡^v.s. IgG by conj.2¡]2783¡^¡A®t¤F16.7¿¤§¦h¡I Fig.3¡G§âÓ§O©Ò²£¥ÍªºIgG°µ¶i¤@¨B¤ÀªR¡Aconj.1ªºIgG1¦h¤F«Ü¦h¡]conj.1: conj.2 = 63813 v.s.28237¡^¡Aconj.2ªºIgG2b¤ñ¸û¦h¡]conj.1: conj.2 = 4578 v.s. 8294¡^¡C Fig.4¡G§âÓ§O©Ò²£¥Íªº²ÓM¿E¯À°µ¶i¤@¨B¤ÀªR¡CNS¬O¤p¹«¤@¯ë¦å²M¡A1¬Oconj.1¡A2¬Oconj.2¡Cµ²ªGconj.1¶È¦bIL-4ªº¶qÀu©óconj.2¤@ÂIÂI¡]¬¡¤ÆTh2²ÓM¡^¡A¨ä¾l¤T¶µ³£»¹©óconj.2¡C ¤]´N¬O»¡¦b²£¥ÍIL-12¡]¬¡¤Æ±þ¤â²ÓM¡^¡BIFN-£^¡]¬¡¤ÆTh1²ÓM¡^¡BTNF-£\¡]CD8¬r±þ§@¥Î¡^¤è±¡A822³£¬OĹªº¡A¤×¨ä¬OIL-12±Nªñ¬O3¿¤§¦h¡C Fig.5¡G§â»¤µo¥X¨Óªº§ÜÅé»P¨ÅÀù²ÓM®èMCF-7¡]¤W±§tGHÀùÁÞ§Üì¡^°µµ²¦X¡A¦A¥Î¿Ã¥ú´ú©w±j«×¡A¬Ý½Öªºµ²¦X®ÄªG¦n¡Cµ²ªG¿Ã¥ú±j«×¡]¨ú¤¤¦ì¼Æ¡^¡Gconj.1¡]¬õ½u¡^¡Gconj.2¡]ÂŽu¡^= 580¡G367¡C ¥kÃ䪺¹Ï¬O§â¦P¼Ë§ÜÅé¥h»P¤£§tGHªºmelonoma²ÓM¡]SKMEL-28²ÓM¡^°µµ²¦X¡A·í°µ¹ï·Ó²Õ¡A¤£·N¥~¦a¤T±ø½u´X¥G«Å|¦b¤@°_¡C Fig.6¡G§â»¤µo¥X¨Óªº§ÜÅé°µ¸ÉÅé¨Ì¿à«¬²ÓM¬r±þ§@¥Î´ú©w¡]lysis % of CDC ¡^¡Cµ²ªGconj.1¡Gconj.2 = 60%¡G30%¡FÁÙ¬OGH-MPLA¸û¨Î¡C |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/9/28 ¤U¤È 09:40:53²Ä 423 ½g¦^À³
|
¤§¤G Monophosphoryl Lipid A¡]MPLA¡^¬O¬Æ»ò·s¦¨¤À¶Ü¡H ¥¦¤£¬O·s¦¨¤À¦Ó¬O«Ü¦Ñªº¦õ¾¯¡A±q1970sªº¹êÅç«Ç¶}©l³°Äòªº¬ã¨s¡A¨ì²{¦b¦w¥þ´¶¹M¥Î©ó¤HÃþ¬Ì]¡A¤w¨«¹L30+¦~·³¤ë¡C¤@¨Ç²Óµß©Ò²£¥Íªº¤º¬r¯À¬O¯×¦hÁÞÃþ¡]Lipopolysaccharides¡FLPS¡^¡A1979¦~Edgar Ribi¹Á¸Õ§âLPS¤¤¯à¨ë¿E§K¬Ì¤Oªº¦¨¤À»P¬r©Ê¦¨¤À¤ÀÂ÷¡A³Ì«á§â©ú¥§Ä¬¹F¨Fªù¤óµß¡]Salmonella minnesota¡^¤º¬r¯À°µ×¹¢¡A§â¥¦ªº7ÓñQ°ò¡]acyl¡^´î¬°6Ó¡A¦hÁÞÅé°¼Ãì°£±¼¡A¥k°¼ªº¨âÓÁC»Ä¥h±¼³Ñ¤U1ÓÁC»Ä¡A¬Ý³o¤@Ó¹ÏFig.1¥ª¥k¤ñ¹ï¤@¤U·|§ó²M·¡¡G¡uhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC2647720/figure/F1/¡v¥ª¬OMPLA¡A¥kÃä¬O¥»¨Óªº¯×¦hÁÞÃþ¡]LPS¡^¡C GSKÃļt¦b³o¤è±»á¦³¬ã¨s¡AºX¤Uªº¬Ì]¦õ¾¯¨t²ÎAdjuvent SystemTMªºAS01¡BAS02¡BAS04µ¥¬Ò§t¦³MPL¦¨¤À¡A¦Ü¤ÖÀ³¥Î¦b¥H¤U¨âºØ¬Ì]¤W¡G¡]AS01¡BAS02¡BAS03¬Ò¤º§tMPL¤ÎQS-21¡FAS04«h§tAlumium¤ÎMPL¡^ GSK-Cervarix «O»_¡F¤l®cÀVÀù¬Ì]¡G¦õ¾¯AS04¡]¤º§tMPL¤Î¾T¡^¡C ¡]http://www.google.com.tw/url?sa=t&rct=j&q=&esrc=s&source=web&cd=7&cad=rja&uact=8&ved=0CEEQFjAGahUKEwiQ95XrvpfIAhWhE6YKHTh5Bg0&url=http%3A%2F%2Fwww.fda.gov.tw%2FMLMS%2FShowFile.aspx%3FLicId%3D10000856%26Seq%3D004%26Type%3D9&usg=AFQjCNE4EXf_iBvls6dqkEFTO34XnXdw-g ¡^ GSK-MosquirixºÄ¯e¬Ì]¡G¦õ¾¯AS01¡]¤º§tMPL¤ÎQS-21¡^¡C 2015/07/25 èÀò¼Ú·ù³\¥i¡C¡]http://news.ltn.com.tw/news/world/paper/900858 ¡^ ¦ÓMPLA¤ñMPL¦h¤F¤@ÓA¡A´N¬O¬°¤F»PGSKªºMPL¨t²Î§@°Ï¹j¡A¨âªÌªº¦¨¤À¬O§_¤£¦P¡H¤p§ÌÃi´k¨S¥h²`¨s¡C¥uª¾¹DªºÁ{§Éµ¥¯ÅªºMPLA¥s°µMPL adjuvant™¡A¦b¨ß¤lªº¸ÕÅ礤¥¦ªº¬r©Ê¬ù¬°LPSªº1/1000¡C Lipid A¬O²ÓµßLPSªº®Ö¤ß©Ú¤ô¤À¤l¹Î¡A¤]¬OLipid A¯à»¤µo§K¬Ì¤ÏÀ³ªº¥D¦¨¤À¡A¥¦ªº³æÁC»Äl¥Íª«´N¬OMPLA¡C MPLA§@¥Î¾÷Âà¬O³z¹LÃþÅM¨ü¾¹4¡]Toll-Like Receptor 4¡FTLR4¡^¡A¨Ó¨ë¿E¤@³s¦êªº§K¬Ì¶×¬y¤ÏÀ³¡A²£¥Í²ÓM¿E¯À»P¤Æ¾Ç¿E¯À¡A¦pTNF-£\¡BIL1£]¡BIL-6¡BInterferon-£]µ¥¡C»PLipid A¤£¦Pªº¬O¡AMPLA¬OµL¬rªº¡A¦]¦¹¼s¬°¨Ï¥Î¦b¤H¬Ì]¬ãµoªº¦õ¾¯¡C¥»¤å§@ªÌ¸g¥Ñ¤p¹«¹êÅç±oª¾GH»PMPLA±µ¦X«á¡A¤£»Ý¦õ¾¯«K¥i²£¥Írobust§K¬Ì¤ÏÀ³¡A»{¬°¬O§ÜÀù¬Ì]¬ãµoªº¼ç¤O²Õ¦X¡C ¦³ÃöMPLAªººØºØ¡A¥H¤U³o¤@½g¦³ÆZ²M·¡ªº±Ôz¡A¦³¿³½ìªº¤H¥i¥H¬Ý¤@¬Ý¡G¡uPutting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant¡v¡A¡uÅý¤º¬r¯À¬°§Ṳ́u§@¡G¥Hmonophosphoryl lipid A°µ¬°¦w¥þ¦³®Äªº¬Ì]¦õ¾¯¡v¡]http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2647720/ ¡^ |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/9/28 ¤U¤È 09:18:04²Ä 422 ½g¦^À³
|
¨g·ÆJ«B¤£°±·²¡A¤â¸£ªÈµ²¤T§ó¤Ñ¡F¤T¤ß¨â·N¤¤¬î¤ë¡A¤C¹s¤K¸¨»ä·©]¡C ¥Xª©¤j¡A³Ìªñ¤âÀY«Üºò¡A¿ì¤À´Á¥i¥H¶Ü¡H ¤§¤@ ¥H¤U©ÒºÙªº¡u¥»¤å¡v¬°¡uA fully synthetic self-adjuvanting globo H-Based vaccine elicited strong T cell-mediated antitumor immunity¡v 2015/09/25¡]http://pubs.rsc.org/en/content/articlepdf/2015/sc/c5sc01402f¡^ ÂI±N¿ý¡G 822¡GGH-KLH/QS-21---Phase III¡]TFDA¡^¡FPhase IIb¡]FDA¡^ 833¡GGH-DT/QS-21---phase I¡]FDA¡^ °|ªøª©¡GGH-DT/C34---preclinical ·sµn³õ¡GGH-MPLA¡F---preclinical¡F¡]MPLA¡GMonophosphoryl Lipid A¡F³æÁC¯×A¡^¨S¦³¦õ¾¯ 822ªº¯ÊÂI¡G¡]¤w¿Ä¦X¥»¤å¤º®e¤ÎÓ¤H·N¨£¡^ 1. °Êª«¹êÅ礤©Ò²£¥ÍªºIgM»·¦h©óIgG¡A¦Ó¥B²£¥ÍªºÂøÂø§ÜÅé¦h¡]²£¥Í¸û¦h¤£¬O°w¹ïGHªº§ÜÅé¡A¥]¬A§ÜKLH§ÜÅéµ¥¡^¡F¤HÅ骺³¡¤À¸Ô²Óªºnµ¥¸Ñª¼«á¤ÀªR¡C 2. ¥Ö¤Uª`®g³B·|¦³10¤½¤À¥ª¥k¤j¤pªº¬õ¸~¤ÏÀ³¡C¡]side effect from QS-21¡^ 3. GH»PKLH±µ¦X«×¤£¬O«Üéw¡C¡]³o¥i¯à¬OIriswu¤j©Ò»¡ªºÅܲ§©Êªº°ÝÃD¡^¡A¦b³o¤@½g¤å³¹¤¤´£¨ìªº¬O¡udifficult quality control¡v¡B¡udifficulties in control of conjugate quality¡v¡CKLH¤À¤l¶q¤j¡A±i¸³»¡¹L¨C¤@ÓKLH¥i¥H±µ¤W1500±øGH¡A§Ú²q·Q¡A¥i¯à¾ÉP¦³¨ÇKLH¤W±µ¦X¤F1500±øGH¡A¦³¨ÇKLH¤W±µ¦X¤F´X¦Ê±øGH¦Ó¤w¡A³o¥i¬O·|¼vÅT822ÃĮġA¦b«áÄòªºCMC¤è±¦p¦óµo®iȱoÃöª`¡]¥Ó½ÐÃÄÃÒ®Én³q¹LÃĪ«³sÄò¤T§å¦¸½T®Ä¼f®Ö¡^¡C ¸É¥R¤Wzªº²Ä¤@ÂI¡A¤å¤¤Á|¥X¶q¤Æ¼Æ¦r·í°Ñ¦Ò¡G 822¥i»¤µo²£¥Í§ÜGH§ÜÅé¿@«×23177³æ¦ì¡A§ÜKLH§ÜÅé293919³æ¦ì¡]12.7¿¤§¦h¡^¡]«È¤ñ¥D±j¡^¡F GH-MPLA¥i»¤µo²£¥Í§ÜGH§ÜÅé¿@«×63038³æ¦ì¡A§ÜMPLA§ÜÅé59666³æ¦ì¡]¥D«È¥¼©ö¦ì¡^¡C §Ú·Q³o¥i¯à¬O833»P°|ªøª©ªº²Õ¦X¤£¦A¦Ò¼{¥HKLH¬°Äâ±a³J¥Õªºì¦]¤§¤@§a¡H ¡K822ªº®a®x¸ÌGH°ù¤F´I®a¤dª÷KLH¡]¤õ¤s³z¤ÕÁ³¬O«O¨|¨©Ãþ¡^¡A½Ð¤F¤@¦ì¦þ¤H¡]QS-21¡^¡AµL©`KLH¶}¾P¤j¡A±`±`n¨nµÛ¡]¼í¶®°ÑªÑStellar¡^¡A¦þ¤H°¸º¸ÁÙ·|µoÂI¤pµÊ®ð¡]¥Ö¤U¬õ¸~¤ÏÀ³¡^¡A¥Í¤k«Ä¸û¦h¡]IgM¦h¡^¡F·sµn³õªº®a®x¡A°ù¤F¤@¦ì¥±`¤H®aªº¤p©j¡]MPLA¡^¡A¶ÔW@³Ò¡A³s¦þ¤H³£§K¤F¡AÁÙ¥]¥Í¨k¡]IgG¦h¡^¡K¡]³o¤@¬q¯ÂÄݨg·Q¡A§Ú¨S¦³©Ê§Oª[µø¡A³o¦~ÀY¨ä¹ê¥Í¤k«Ä¤ñ¸û§µ¶¶°Õ¡I¡^ |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/9/27 ¤U¤È 08:39:16²Ä 421 ½g¦^À³
|
Cliff¤j..¤¤¬î¸`§Ö¼Ö.. ¤pªº¬O·Q³Â·Ð±z..¡uA fully synthetic self-adjuvanting globo H-Based vaccine elicited strong T cell-mediated antitumor immunity¡v³o½gªº¬Ýªk¾ã²z.ÁÂÁÂ.. ¤pªº¥H½Ķ³nÅé²Ê²Lªº¬Ý..¥»½g¦ü¥G¬O³æ¬D822.833¨Óªº.. |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/9/26 ¤U¤È 01:28:10²Ä 420 ½g¦^À³
|
¥Xª©¤j¡A¤£¦n·N«ä¡A¤p§Ì¨S¬ÝÀ´±zªº·N«ä¡A¤£ª¾¹D±z©Ò«üªº¬Oþ¤@½g¡H ¬O«ü³o¤@½g¶Ü¡H¡y2015/07/13¡G¡uHuman Cancer Antigen Globo H Is a Cell-Surface Ligand for Human Ribonuclease 1¡v¡z |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/9/26 ¤W¤È 12:25:23²Ä 419 ½g¦^À³
|
±R°ªªº Cliff¤j.. ±z¤£·|«ü±æ¤pªº§â³o¨Ç¬Ý§¹§a..^¤å£z£°.. ±z¦æ¦æ¦n.À°¤j®a¾ã²z¾ã²zÐù.. |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/9/25 ¤W¤È 11:06:43²Ä 418 ½g¦^À³
|
¥Xª©¤j¡G ¤µ¦~4¤ë§Ú´N´¿§ì¨ì³¢±Ð±Âªº¨Ç³\¸ê®Æ¡]¿ý©ó¤U¡^¡A¦ý¬O¤@¨Ó¡A§ÚŪ²Åé¦r¤ñŪ^¤åÃø¡F¤G¨ÓÅTÀ³Amy¸g²z»¡¯E¹©¤£°µme tooªº¤½¥q¡A©Ò¥H¹ï©¤¤@¨Çme tooªºÁޤƾǬã¨s¡A§Ú´N¨S¥h²`¨s¡C³s±a¦a³¢±Ð±Âªº¬ã¨s¤º®e§Ú¤]µL©ÒÁA¸Ñ¡C§ÚÁÙ´¿§ì¨ì¤@½g¦L«×ªºGH-KLH/QS-21ªº¬ã¨s³ø§i¡C ¥H¤U¬O¥H«eªº¦sÀɸê®Æ¡G ¡u³¢©¾ªZ±Ð±Â²{¥ô¬ü°ê±K·²®Ú¦{©³¯S«ß¥«³®¦¦{¥ß¤j¾Ç¤Æ¾Ç¨t±Ð±Â¡A¤§«e´¿¦b¬ü°ê«X¥è«X¦{§J§Q¤ÒÄõ¥«³Í´µ¦è«O¯d¦a¤j¾Ç©M¤¤°ê¤W®ü¥«ªº¤W®ü¦³¾÷¤Æ¾Ç¬ã¨s©Ò¾á¥ô±Ð±Â¡C³¢©¾ªZ±Ð±Â¤@¥Í¤¤´¿Àò±o¹L²³¦h¼ú¶µ»PºaÅA¡A¨Ò¦p¤é¥»¤ô½\¿}½è°òª÷·|¼ú¡]2008¡^¡A¬ü°ê¤Æ¾Ç¨ó·|¿}¤Æ¾Ç¬ã¨s·s¤H¼ú¡]2005¡^µ¥¡C³¢±Ð±Â²{¦b¾Ö¦³¼ÆÓ¬ã¨s°òª÷¡A¬ã¨s¤º®eÅn¬A±q¤ÑµM²£«~ªº¤Æ¾Ç¦X¦¨¨ì¤HÃþ¯e¯fªº·s«¬Àøªkµ¥¦UºØ°ÝÃD¡C¦¹¥~¡A¥LÁÙ¥Xª©¤F¶W¹L100½g¤å³¹©M½×¤å¡A¥H¤Î¤@¥»ÃD¬°¡m¿}°ò¬Ì]»P§K¬ÌÀøªk¡nªºµÛ§@¡C¡v¡]¤wÂk¤Æ¬°¬ü°êÄy¡^ ¡uhttp://webcache.googleusercontent.com/search?q=cache:CTn7AxwDHu0J:http://www.detaoma.com/UDocument/showIntroduction/?id%3D16744%26masterid%3D15313%2BZhongwu+Guo%E4%B8%AD%E6%96%87&hl=zh-TW&gbv=2&&ct=clnk ¡v ¤¤°ê¤H¤h³¢©¾ªZ±Ð±Â¡B¹ù°ê¶W»P²Ä¤T¦ì¥~°ê¤H¼g¤F¤@¥»®Ñ¡G ¡uChemical synthesis of the tumor-associated globo H antigen¡v ¡]http://pubs.rsc.org/en/content/articlelanding/2015/ra/c5ra00759c ¡^ Satadru S. Mandal,a Guochao Liaoaand Zhongwu Guo*a DOI: 10.1039/C5RA00759C Received 13 Jan 2015, Accepted 24 Feb 2015 First published online 24 Feb 2015 ³o¥»®Ñªº¤º®e´¿¤Þ¥Î¤F¥|¥¨ÀY¼gªº½×¤å¡G¡uDevelopment of Globo-H Cancer Vaccine¡v ¡]http://pubs.acs.org/doi/abs/10.1021/ar5004187 ¡^ ÁÙ¦³¥t¤@¦ìªº¡G ¡u肿½F¿}¬Ì]ªº¬ã¨s进®i¡v¡]http://www.google.com.tw/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=0CCAQFjAAahUKEwiSsrqcmJHIAhVIpZQKHVLZCOY&url=http%3A%2F%2Fwww.yxxb.com.cn%3A8081%2Faps%2FhomeAction!downloadArticleFile.action%3FattachType%3DPDF%26id%3D14145&usg=AFQjCNFms2fcVcC4tKnmnCtF180S0FSKHg ¡^ ¦L«×ªº¡G ¡uCarbohydrate Based Antigens: Potential Tool for A Targeted Immunotherapeutic Approach to Treatment of Metastatic Breast Cancer¡v¡]Bhagwat P et al. IJRPS 2013, 3(2), 01-11¡^ ¡]http://www.google.com.tw/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=0CCAQFjAAahUKEwjrrKb-mJHIAhXBFZQKHRlXDUA&url=http%3A%2F%2Fwww.researchgate.net%2Fpublication%2F264293388_Carbohydrate_Based_Antigens_Potential_Tool_for_A_Targeted_Immunotherapeutic_Approach_to_Treatment_of_Metastatic_Breast_Cancer&usg=AFQjCNHwJ1rRWiLUNoqREGKYGvOsau5ZNA ¡^ |
|
|
·|û¡Gjm042310140224 µoªí®É¶¡:2015/9/25 ¤W¤È 09:58:42²Ä 417 ½g¦^À³
|
°e³ø¤j¯uªº¼F®` ¦Ñ¥v¤j«e´¿´£¹L¡A¬Ý¨ì¡]¹Ú¨ì¡^²Ä¤GÓ¤p¤Ñ¨Ï «e«á©IÀ³ |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2015/9/25 ¤W¤È 06:36:18²Ä 416 ½g¦^À³
|
°e³ø¤j ¤Ó¼F®` ^¤å´Á¥Z §Ú¬Ý¤£À´ ¯uÁV |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/9/25 ¤W¤È 01:26:10²Ä 415 ½g¦^À³
|
Hi Cliff¤j ¦U¦ì¤j.. ¤@ÂI¤p·Qªk.. Globo-H ¶V¨Ó¶V¼ö¾x¤F.. Ä~ Cliff¤j ¤W¦¸´£¨Ñªº¸ê°T.. 2015/07/13¡G¡uHuman Cancer Antigen Globo H Is a Cell-Surface Ligand for Human Ribonuclease 1¡v ¡]http://pubs.acs.org/doi/pdf/10.1021/acscentsci.5b00164 ¡^ ³o¦¸¤S¦³¥»½g.Globo H ªº¬ã¨s.©ú¦~822ªº¼Æ¾Ú¦U¤jÃļt¯à¤£ª`·N¶Ü. ¦p¥xÁÞ¤j¦b¥tª©©Ò´£.. "3¤ëªk»¡¨S´£¨ì³o¦¸ªk»¡¦³´£¨ìn¯S§Oª`·N ²³ø²Ä11¶´£¨ì ¥Ø«e¥þ²y°ß¤@¶}µoGlobo SeriesÁÞ§ÜÅé¶i¤J¤¤±ß´Á¶¥¬qªº¥Í§Þ¤½¥q" ¥Î¤pªº¥Õ¸Ü¤å´N¬O..¦³¤H¶}©l¦b"Globo SeriesÁÞ§ÜÅé"»â°ìùاäºØ¤l.ªG]¤F. ¦ýOBI-822©ú¦~±N¶i¤J¦¬¦¨¶¥¬q.. (8¤ë©³±M®a·|ij®É.¦³2®a¤jÃļtªº¤jÀY¤£¬ù¦Ó¦Pªº¨ì¥xÆW.ÁöµM¦U¦Û¦³¤½¶}¦æµ{.¦ý¬O....³o¯Âºé¬O¤pªº¶Ã·Qªº.¨S¨Æ¬~¬~ºÎ¥h..) |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/9/25 ¤W¤È 12:32:16²Ä 414 ½g¦^À³
|
¤¤¬ü¦X§@..±j°ê¤]¦³¿}±M®a.. (©¹¦nªº·Q.822¦b¤¤°êªº¸ÕÅçÀ³¸Ó¦³¤H¥i¥HÀ°¦£I®Ñ..) Zhongwu Guo-³¢©¾ªZ- http://www.glycoeng.sdu.edu.cn/artinfo.php?id=45 ¤º®e´Nµ¥ Cliff¤j ¬°§ÚÌÂন¥Õ¸Ü¤å§a.. |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/9/24 ¤U¤È 09:48:36²Ä 413 ½g¦^À³
|
¯E¤ÍÌ ½Ð±Ð¬Q¤Ñªk»¡·|²³øÀɪº²Ä33¶ ´£¨ì¥¼¨Ó·sªº¾AÀ³¯g¥]²[ ¨xÀù ¸£Àù ¤l®cÀVÀù ¤fµÄÀù µÇŦÀù ¹¹D¡]¦]¬°¥H«e¬Ý¨ìªº¬O¾AÀ³16ºØÀù¡A¨Ã¨S«D±`©ú½T«ü¥X...¡^ ¬O«ü888¶Ü¡HÁÙ¬O¡H ÁÂÁ |
|
|
·|û¡GIriswu10136250 µoªí®É¶¡:2015/9/23 ¤U¤È 05:52:58²Ä 412 ½g¦^À³
|
cliff¤j,³o¦n¹³´N¬O§Ú¤§«eÅ¥¨ìªº¦³ÃöÅܲ§©Êªº°ÝÃD.§Ú¤£½T©w³o¸Ì´£¨ìªºquality control¬O¤£¬O´N¬O¦b«ü³o¤è±ªº. ¤£ª¾¹D¦³¨S¦³¤j¤j¤F¸Ñ³o¤è±ªº°ÝÃD? |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/9/23 ¤U¤È 02:55:43²Ä 411 ½g¦^À³
|
822ªº°l§L¡H§ï¨}ª©? ¡uA fully synthetic self-adjuvanting globo H-Based vaccine elicited strong T cell-mediated antitumor immunity¡v Sep. 9, 2015¡F¡]http://pubs.rsc.org/en/content/articlepdf/2015/sc/c5sc01402f ¡^ ¥LÌ»¡822ªº¯ÊÂI¬O¤£©ö»¤µoT-cell§K¬Ì¤Î«~½è±±¨î¤£©ö¡A°w¹ï³o¨Ç¦Ó¥H¥þ·s¦X¦¨ªº¬Ì]²Õ¦XGlobo H- monophosphoryl lipid A(MPLA)¨Ó§ïµ½¡A¦b°Êª«¹êÅ礤¥i²£¥Í¤ñ822§ó±j§ó§ÖªºIgG1¡A¹ïMCF-7 cancer cell¥i²£¥Í±jªºcomplement-dependent cytotoxicity¡C¦Ó¥B³oÓ²Õ¦X¤¤¡Amonophosphoryl lipid A¨ÝÄâ±a³J¥Õ¤Î¦õ¾¯¥\¯à¡A©Ò¥H¤£¥²¦A¥~¥[¦õ¾¯¡C §@ªÌ¬O´X¦ì¬ü°êWayne¦{¥ß¤j¾Ç¤Æ¾Ç¨tªº¤H¡A¦W¦r¬Ý°_¨Ó¹³¬OµØ¤H¡C ºKn¡G ¡uTherapeutic cancer vaccines based on the abnormal glycans expressed on cancer cells, such as the globo H antigen, have witnessed great progress in recent years. For example, the keyhole limpet hemocyanin (KLH) conjugate of globo H has been on clinical trials as a cancer vaccine. However, such vaccines have intrinsic problems, such as inconsistence in eliciting T cell-mediated immunity in cancer patients and difficult quality control. To address the issue, a structurally defined fully synthetic glycoconjugate vaccine composed of globo H and monophosphoryl lipid A (MPLA) was developed. The new vaccine was shown to elicit robust IgG1 antibody responses and T cell-dependent immunity, which is desired for anticancer vaccines, and induce significantly faster and stronger immune responses than the globo H¡VKLH conjugate. Moreover, it was self-adjuvanting, namely, inducing immune responses without the use of an external adjuvant, thus MPLA was not only a vaccine carrier but also a build-in adjuvant. It was also found that antibodies induced by the new vaccine could selectively bind to and mediate strong complement-dependent cytotoxicity to globo H-expressing MCF-7 cancer cell. All of the results have demonstrated that the globo H¡VMPLA conjugate is a better cancer vaccine than the globo H¡VKLH conjugate under experimental conditions and is worth further investigation and development.¡v ³Ìªñ«Ü¦£ÁÙ¨SŪ§¹¥þ¤å¡AÅý¦³¿³½ìªº¤H¥ý¬ã¨s¬ã¨s¡C |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/9/23 ¤W¤È 09:46:55²Ä 410 ½g¦^À³
|
°e³ø¤j S³o¦¸¤@¼Ëexcellent A great report ¤Ó´Î¤F |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/9/22 ¤W¤È 10:11:30²Ä 409 ½g¦^À³
|
°e³ø¤j S³o¦¸À³¸Ó¬O¨Ò¦æ©ÊªºÀˬd(¥Ø«e2Ó¤ë¤@¦¸) ¤W¦¸¬O¦]¬°¦³¨Ç¦a¤è¤£µÎªA¤~¤S¦w±ÆÀˬd(¤W¤@¦¸Àˬdµ²ªG¤@¤Á³£«Ü¦n) ¥t¥~ §Ú¦L¶H¤¤S¬O±q2014¦~3¤ë¥÷¥ª¥k¤~¶}©l²Ä¤@¦¸ ©Ò¥H¥Ø«e¶i¤J²Ä18-19Ó¤ë,n¨ì2016¦~3¤ë¤~·|µ²§ôpµe¤Wªºscanµ¥µ¥(2¦~) ¤£ª¾¹D¦³¨S¦³°O¿ù,¦A¥h¬d¤@¤U |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/9/21 ¤W¤È 10:44:30²Ä 408 ½g¦^À³
|
·PÁ Cliff¤j Faith¤j «ù¤[ªº¯E§J¤j .. À°¦£¸ÑŪ.. ÁÙ¦³¤@°Ý.. S¤p©jªºÀˬd¬O¤£¬O´£¦¤F?? (¶}©l¦¬¶°¸ê®Æ??) |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2015/9/20 ¤U¤È 02:36:44²Ä 407 ½g¦^À³
|
¥Ó½Ð¤H ¸~½FÂå¾Ç³¡ - ·¨¤h¥°Âå®v ±Mªø¡J ¤º¬ì¸~½F ¤×¨ä¯ØŦÀù |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2015/9/20 ¤U¤È 01:46:28²Ä 406 ½g¦^À³
|
ÁÂÁÂFAITH¤jªº»¡©ú §Ú·Q»Ýn¦h¥[Æ[¹îÃĮĪº¨ä¥L¹B¥Î ¦A½Ð±Ð±z¹ï©ó·ç¤h«H¶U¤@¤Ñ¤j¶R¤d±i ¦³¦ó¬Ýªk? ¬°¦ó³o»ò«æ? §A¦³¬Æ»ò²q·Q¶Ü? |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/9/20 ¤W¤È 11:26:05²Ä 405 ½g¦^À³
|
¯E§J¤j ¤p§Ì·í®Époªº¨º½g³ø¾É ¯Î°|ªø«üªºÀ³¸Ó´N¬O822 ¦Ü©ó¨ä¥L®¦·OÀøªkªº¥Î³~ ¤p§Ì´N¤£²M·¡¤F |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2015/9/20 ¤W¤È 09:50:08²Ä 404 ½g¦^À³
|
½Ð±Ð«e±´X¦ì¤j¤j ³o¨Ç®¦·OÀøªkªº®×¨Ò ¬OªvÀøþºØÀù¯g?®ÄªG¦p¦ó? |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/9/20 ¤W¤È 08:36:33²Ä 403 ½g¦^À³
|
°e³ø¤j¡BCliff¤j ¦³¥i¯à³á °O±o¤p§Ì¤§«e¶K¹L£¸¥÷³ø¾É ¯Î°|ªø´£¤Î³oºØ¬Ì]¤]¥Î¦b¤Ö¼Æ¯f±w®¦·OÀøªk¡]Ãþ¦ü³o¼Ëªº¸Ü¡^ ·í®É¤p§Ì£¸ÀYÃú¤ô¡A¦L¶H¤¤¦n¹³ÁٽбФF¤j®a ²{¦b¡A³o¼Ë«e«á³sµ²¤U¨Ó¡A¯uªº¦³¥i¯à ¦ý³o¶È¬O§Ú̪º²q´ú¡AÁÙ¬O½Ð¼F®`ªº¯E¤Í¦AÀ°¤j®a¸ÑŪ£¸¤U§a |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/9/20 ¤W¤È 01:21:02²Ä 402 ½g¦^À³
|
¤£ª¾¥Î¦bþ¨â¦ì©¯¹B¨à¡HVIP¡H ¥O¤HµL¹I·Q¡K |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/9/20 ¤W¤È 01:11:12²Ä 401 ½g¦^À³
|
¥Xª©¤j¡G¦^À³°ª¬ñªº±z¡A¥H¤U°Ñ¦Ò°Ñ¦Ò¡C ¤¤¤sÂå¤jIRB¡G¡u®¦·OÀøªk©Î¯S®í¯f±w¥Ó½Ð±M®×¶i¤f¥¼¸g¥»°ê½Ã¥Í¸p®ÖãÃĪ«¡K¡v ¡uhttp://www.csh.org.tw/irb/document/%E6%9C%80%E6%96%B0%E6%B6%88%E6%81%AF/%E9%A6%96%E9%A0%81%E6%AA%94%E6%A1%88/%E6%81%A9%E6%85%88%E7%99%82%E6%B3%95%E6%88%96%E7%89%B9%E6%AE%8A%E7%97%85%E6%82%A3%E7%94%B3%E8%AB%8B%E5%B0%88%E6%A1%88%E9%80%B2%E5%8F%A3%E6%9C%AA%E7%B6%93%E6%9C%AC%E5%9C%8B%E8%A1%9B%E7%94%9F%E7%BD%B2%E6%A0%B8%E5%87%86%E8%97%A5%E7%89%A9.pdf ¡v ¡u¡K ì«h¤W¡A¥»©eû·|´L«Âå®v±M·~§PÂ_¤Î¯S®í¯f±w¯f±¡»Ý¨D¡A«Øij¥Ó½Ð¤H¼f·Vµû¦ô¨ä¥²n©Ê¡HÃÄ®`³d¥ôÂkÄÝ¡HӮשΤּƯS®í¯f±w¥Ó½Ð¡H¨Ã·V¿ï¯f±w¡B¤p¤ß¨Ï¥Î¡CY¥D«ù¤HÀÀ¥H³\¦h¯f±w¬°¨Ï¥Î¹ï¶H¡A«Øij¬¢¼t°Ó¡A¥H¤HÅé¸ÕÅç®×´£¥X¥Ó½Ð¡K¡v °O¿ý¤W»¡¥x¤jDr.X¥Ó½Ð¤F9 vial¡C¤£ª¾¹D°µ¦ó¥Î³~¡A·íµM¤]´N¤£ª¾¹D¬I¥´Àøµ{¬°¦ó¡CYªu¥Î¨ÅÀùII/III´Áªº¥´ªk¡A¤@ÓÀøµ{¥´¤E¾¯¡A¨C¾¯¬I¥´GH 30£gg¡A¥Bª«ºÉ¨ä¥Î¡Aºwºw¤£®ö¶Oªº¸Ü¡A«h¥i¨Ñ2.5¦ì¨Ï¥Î¡K¡CÓ¤H¶Ãºâ¡A¬Ý¬Ý´N¦n¡A¤£n»{¯u¡C¨ä¥L³¡¤À¡A¦³½Ð°ª¤â¸ÑŪ¡C |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/9/19 ¤U¤È 11:04:54²Ä 400 ½g¦^À³
|
«e½g·|ij°O¿ý P.8 P.19 ¤]¦³´£¨ì822.. ¦ý..¤£ª¾¨ä·N..ÁöµM¬O5¤ëªº¬ö¿ý. ®¥½Ð¦U¦ì¤jÀ°¦£¸ÑŪ..ÁÂÁ |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/9/19 ¤U¤È 10:52:09²Ä 399 ½g¦^À³
|
µLÃÄ«~³\¥iÃÒ±M®×¥Ó½Ð(®¦·OÀøªk) ¨Mij ¦P·N https://www.ntuh.gov.tw/RECO/%E7%A0%94%E7%A9%B6%E5%80%AB%E7%90%86%E5%A7%94%E5%93%A1%E6%9C%83%E6%9C%83%E8%AD%B0%E7%B4%80%E9%8C%84/A%E7%A0%94%E7%A9%B6%E5%80%AB%E7%90%86%E5%A7%94%E6%9C%83%E6%9C%83%E8%AD%B0%E7%B4%80%E9%8C%84/NTUH_REC_A_66%E6%9C%83%E8%AD%B0%E7%B4%80%E9%8C%84%E4%B8%8A%E7%B6%B2%E7%89%8820150522.pdf |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/9/15 ¤W¤È 11:13:30²Ä 398 ½g¦^À³
|
HI ¦U¦ì¤j.. ¤µ¤Ñ ¤U¤È 3:10 ¦³n¥h¦¨¤jÅ¥¤G·í®aºtÁ¿ªº¶Ü?? (½Ð·Ç³Æ¨¾°A¸Ë³Æ) http://www.ch.ncku.edu.tw/course/pages.php?ID=demo6 |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2015/9/14 ¤W¤È 11:14:24²Ä 397 ½g¦^À³
|
¤¨¥ý¥Í2013¦~12¤ëªººtÁ¿, ¥iÂǦ¹§ó¥[¤F¸Ñ§Ú̪º¤j®aªø ¤¨l¼ÙºtÁ¿¡Ghttp://youtu.be/JARiJDuRcMc |
|
|
·|û¡G¦³FUªº¤H10136189 µoªí®É¶¡:2015/9/13 ¤U¤È 08:55:24²Ä 396 ½g¦^À³
|
·PÁÂFaith~~ ´£¨Ñ¤F¬ÛÃö¸ê°T. ¤]·PÁ¬P¨°¤jªºKLH~~~~ ²{¦b¤p§Ì§Ú¥¿·Qªº¨º®üÂA»Ýn¾i¦h¤[,¤~¯à¨ÑÀ³¤W¥«~~~«¢«¢ |
|
|
·|û¡G±Û«a10139522 µoªí®É¶¡:2015/9/13 ¤U¤È 08:19:25²Ä 395 ½g¦^À³
|
¬P±á¤j¡AªGµM¨£·Lª¾ºæ¡AÁÂÁ±z¤F¡A¦P®É¤]¨ØªA¥~¸êªº²´¥ú¡I |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/9/13 ¤U¤È 07:47:54²Ä 394 ½g¦^À³
|
¬P¨°¤j ±z¯u¬O¤Ó±j¤F¡I ³oKLH....,«¢«¢«¢ ÁÙ¬O½Ð¯E¤Í¦Û¤v¥h¬Ý§a ÁÂÁ±z |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/9/5 ¤U¤È 04:28:34²Ä 393 ½g¦^À³
|
¸É¥R£¸¬q ¤¤¬ã°|¡B¡mÁp¦X³ø¡n©M¡m¸gÀÙ¤é³ø¡n»P¥Íµ¦·|¦@¦P¥D¿ìªº¡u2015¥Í§Þ°·±d°ª®p½×¾Â¡v¬Q¡]4¡^¤éµn³õ¡C¤¤¬ã°|°|ªø¯Î±Ò´fµoªí¥Ü¡A¥xÆW¡u¥Íª«¸gÀÙ¡v¤w¬O·s¿³²£·~¥D¬y¡G¨ä¤¤¡AÓ¤H¤Æºë·ÇÂåÀø§ó¬O©ú¬PÁͶաF ¥L¨Ã³zÅS¡A¤¤¬ã°|»â¥ý¼Ú¬üªºÁÞ¤À¤l¬ã¨s¡Aªñ´Á±N¦³«¤j¬ð¯}¡A¬°¥¼¨ÓÀù¯gµ¥«¤j¯e¯fªºªvÀø±a¨Ó·s«´¾÷¡C |
|
|
·|û¡GD§b10139065 µoªí®É¶¡:2015/9/4 ¤W¤È 11:54:31²Ä 392 ½g¦^À³
|
Âà¶K¡i®É³ø°OªÌ³¢ÂE¼z¥x¥_³ø¾É¡j¤¤¬ã°|¤Î¥Íµ¦·|µ¥¦@¦P¥D¿ìªº2015¦~¥Í§Þ°·±d°ª®p½×¾Â¤µ¤é µn³õ¡A¯E¹©(4174)¸³¨Æªø±i©À·Oªí¥Ü¡A¥¼¨Ó10¦~¡A¥xÆW¥Í§Þ·~³Ì«¤jªº¬D¾Ô¬O³W¼Ò¤Ó¤p¡A «ÜÃø¦b°ê»Ú¤W¦³Ävª§¤O¡A§Æ±æ·~¬É¯à¦Û¦æµo®i¦X¨Ö¡A¤]§Æ±æ¬F©²¯àÀ°§U°µ¤@¨Ç±j¨î©Êªº¾ã ¦X¡A³o¼Ë¦b°ê»Ú¤W¤~¦³§Q©óÄvª§¡C ±i©À·O»¡¡A¦b·s¦åºÞ¡BÀù¯g©M¤¤¼Ï¯«¸gµ¥¥|¤j»â°ì¡A¥xÆW·Qn©M¥@¬É¥ý¶i¤jÃļtÄvª§ªº ¸Ü¡A¦b¬Y¨Ç»â°ìªº½T¥i¥HÄvª§¡A¦ý³oºØ¾÷·|¬O¥i¹J¤£¥i¨D¡A¤£¹L¡AY¬O¦b©t¨àÃĩάO¨È¬w ¿W¦³ªº¯e¯f¦p¨xª¢¡B¨xÀù¡A©Î¬O¨ÅÀù¡BªÍ¸¢Àùµ¥¤è¦V¬ãµo·sÃÄ¡A¤´¬O¦³§Q°ò¥i¨¥¡C ±i©À·O»y«¤ßªøªº«ü¥X¡A¥Í§Þ²£·~n¦p¦ó¥h§ä¾÷·|¡A¦³4Ó«ÂI¡A²Ä¤@ӳ̫nªº¬O¤H ¤~¡A²{¦b·~¬É¤£¥u¬O¯Ê¥F¤H¤~¡A¨Ã¥B¥¿¦b¬y¥¢·í¤¤¡A¥Í§Þ·~°ª¶¥»â¾É¤H¤~¡A°£¤Fn¯à°µµ¦ ²¤»â¾É¾ã¦XÁÙn¬O¥i¥H°µ°ê»ÚÄvª§ªº¡A¦p¦óºôù©M°V½m¤Q¤À«n¡C²Ä¤GÓ¬OÃD§÷¡A³o»Ýn «Üªøªº®É¶¡¡A¥xÆW¥Í§Þ·~¤£¥u¦b¥»¤g»â°ìn§ä¨ìÃD§÷¡A¦p¦ó¦b®ü¥~»â°ì§ä¨ì§ó¬O«ÂI¡A¦ý ³oÂI¥Ø«e¬Ý¨Ó¦³ÂI§xÃø¡A¥xÆW¸ê¥»¥«³õ¨Ã¤£¬O«Ü¦¨¼ô¡A°ê¥~¸êª÷¤]¤£Ä@·N¶i¨Ó¡A¤]¨Ï±o¥x ÆW¥Í§Þ·~·Qn§ä¨ì®ü¥~»â°ìªºÃD§÷§xÃø«×¼W¥[¡C ±i©À·O»¡¡A²Ä¤TÓ«ÂI¬O¸m°]¡A¥xÆW¦b¥þ²yÁöµM¾Ö¦³¦n´X¤dÓ±M§Q¬Ý¦ü¤Q¤Àªº¦h¡A¦ý±M §Q¬O§_¯àµ¥¦P±a¶i°]¤O¬OÓ¥¼ª¾¼Æ¡C·Qn±N±M§QÅܦ¨°]·½¡A³oµ´¤£¬O¾ÇªÌ³Ìªìªº¤@Óµo²{ ´N¥i¥Hªº¡A¤@ӳ̪쪺µo²{¨ì¦¨¥\°µ¥Xn¨Ó¦Ü¤Ön10¦~(»Ý¸g¹LÁ{§É¸ÕÅçµ¥)¡A«ç»ò¾ã¦X¾Ç ªÌ³Ìªìªºµo²{¡A¨ì·~¬É¬ãµo§âÃÄ°µ¥X¨Ó¡A¨Ã±N±M§Q´Á©µªø¡B±N±M§Q³Ì¤j¤Æ¡A³o¤~¥i¥H±N±M §QÂà¤Æ¬°¿ú°]¡C ±i©À·O»¡¡A²Ä¥|Ó«ÂI¿ú°]¡A¥Ø«e¥xÆW¬Ý°_¨Ó¥Í§Þ²£·~¤Q¤À¼öµ¸¡A¥«³õ¤Wªº¼ö¿ú¬Ý°_¨Ó «Ü¦h¡A¦ý¨ä¹ê¨Ã¨S¦³¨º»ò¦h¡A³o¨Ç¿ú©¹©¹³£¬O´²«Èªº§ë¸ê¡A¨Ã«Dªø´Á§ë¸ê¦b¥Í§Þ·~¸Ì±ªº ¿ú¡A§Æ±æ©¹¥Í§Þ²£·~§ë¸êªº¿ú¯à§óºë·Ç¡AY¬O°ê»Ú°òª÷±Mªùªº§ë¸ê¡A¹ï¤½¥q¸êª÷¤~¦³¯u¥¿ À°§U¡C |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/9/4 ¤W¤È 06:16:16²Ä 391 ½g¦^À³
|
Walden¤j ¤F¸Ñ¡AÁÂÁ±z¡I |
|
|
·|û¡GWalden10140608 µoªí®É¶¡:2015/9/3 ¤U¤È 10:40:24²Ä 390 ½g¦^À³
|
Faith ¤j~ ¤p§Ì¦b¥Í§Þ®i¤w¸g·í±°Ý¹LYK ÁÙ¦³ ¬ãµoªø¤F...¥H«á¤£·|¦A¤½¥¬PD¼Æ¦r ¦Ó¥B¤½¥q¬JµM³£¤w¸g«Å¥¬§Ö¸Ñª¼¤F¡A§ó¤£·|¶TµM¤½¥¬ ©Ò¥H....©ú¤Ñ¤]¤£¥Î°Ý±i¸³¤F¡A¥Lµ´¹ï¤£·|Á¿ªº¡A°Ý¤F³»¦h¥u¬O¥Õ¥Õ®ö¶O¤@Ó°ÝÃD»P®É¶¡ «Øij§â®É¶¡¯d¦b°Ý¨ä¥Lªº°ÝÃD§a~ |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/9/3 ¤U¤È 05:12:25²Ä 389 ½g¦^À³
|
¦A£¸¦¸µo°Ý ³Ì·sªºPD,CR,LRªº¼Æ¾Ú¦³¤Hª¾¹D¶Ü ¤£¯à¤½§G¶Ü¡H ±i¸³©ú¤ÑnºtÁ¿¤F |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/9/2 ¤W¤È 12:30:30²Ä 388 ½g¦^À³
|
¨â«h·s»D¡A·s¦U¤@¡C ·s»D¡G2015/08/31¡G«ô§K¬ÌªvÀøªº·¼é¡AStellar Biotechnologies¬Ý©ô¥¼¨Ó«e´º¡A·Ç³Æ¥H¦X¨ÖªÑ²¼¤è¦¡±q¥[®³¤j¦VNASDAQ¶ix¡C¡uhttp://www.investorideas.com/news/2015/biotech/08311.asp¡v 2015/05/20ªk»¡Â²³ø¡G¡uhttp://content.stockpr.com/stellarbiotechnologies/media/bc084f948556640056d864d520578a6c.pdf ¡v ¥Ø«e¥Î¨ìKLHªº¬ãµo¤¤·sÃĦܤ֦³¡G Celldex¡]NASDAQ:CLDX¡^¡GPhase III¡FªvÀø¤@ºØ°ò¦]EGFRÅܲ§«¬EGFR v3¶§©Êªº´c©Ê¸£½F¦h§Î©Ê½¦½è¥À²ÓM½F¡]glioblastoma multiforme¡^¡C OBI Pharma¡]4174¡GTT¡^¡GPhase IIb¡]FDA¡^/Phase III¡]TFDA¡^¡FOBI-822 for MBC¡C NEOVACS (Alternext Paris:ALNEV)¡GPhase II¡FIFN£\-Kinoid for SLE¡A¥H¤zÂZ¯ÀªvÀø¬õ´³©Ê¯T½H¡C2015/09/01è³q¹L¼Ú¬wªºPhase IIb¡C »D¡G2013/03/19¡G¡uhttp://www.stellarbiotechnologies.com/media/press-releases/detail/31/stellar-biotechnologies-submits-biological-master-file-to ¡v Àô²y¥Í§Þ¤ë¥Z2013/11¤ë¸¹´¿»¡KLH©|¥¼±o¨ìFDA®Ö¥i¡A¤£ª¾³o«h»D¬O§_¨¬¥H¯}¸Ñ³o¼Ëªº»¡ªk¡H ºK¿ý¤@¥y¡u¡KStellar¡¦s goal is to help accelerate the regulatory approval process for products that use the Company¡¦s KLH¡K.¡v |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2015/9/1 ¤U¤È 12:54:01²Ä 387 ½g¦^À³
|
"¼Æ¾Ú«Ü¤£¿ù"¤@µü»á©â¶H¡A§Ú¤]Ū¨ì»á©â¶Hªº¸Ü 2014.2.18 The lady over the trial called today,I asked how effective it had been in the people she had currently enrolled (since she said some were already done and some were still on it) -- She said the ER+ PR+ were doing well(I am ER+PR+). The ones who were triple negative had all had to drop out. She said that the ones that were still in were achieving stable or comparable results to standard chemo at the very least. Many have been in remission for various periods of time without progression. Standard of care (fda approved drugs) will always be there for a fall back, but I feel I need to gamble on some of the newer treatments. A fast train to the slaughter house down the standard care track. «i´±ªº°«¤h¤µ¦~¤»¤ë·í¤Ñ¨Ï¤F¡A¦o°O¸ü¤F«Ü¸Ô²Óªº¹Lµ{ |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/8/31 ¤U¤È 09:15:21²Ä 386 ½g¦^À³
|
Cliff¤j¡Bªü®¶¤j¡BBRN¤j ¦A¦¸ÁÂÁÂÅo¡u¤s½a¤ôºÉºÃµL¸ô¡A¬h·tªá©ú¤S¤@§ø¡v¯u¬O®p°j¸ôÂà§r °£¤F¯E¤Í¬Ý¨ìBRN¤j´£¤Îªº¼Æ¾Ú«Ü¤£¿ù¥~ ¥H¤U³o¬q¤p§Ì¬Ý¨ìªº¬O³Ì«á¤Þ¸¹¤§³B¡]¤Þ¸¹¬O¤p§Ì¥[¤Wªº¡AºI¦Û¯E¹©©xºô¡^ 2015 08.31¥xÆW¯E¹©±M®a·|ij«Øij¡G OBI-822II/III´ÁÁ{§É¸ÕÅç ©ú¦~3¤ë¸Ñª¼ ¥xÆW¯E¹©¥Í§Þ(4174) 28¤é±ß¶¡¥l¶}±M®a·|ij¡A¨M±Ä¯Ç±M®a«Øij¡A¸Ó¤½¥q©Ò¬ãµo¤§¨ÅÀù·sÃÄOBI-822 ²ÄII/III´ÁÁ{§É¸ÕÅç¡A±N©ó©ú¡]2016¡^¦~3¤ë§¹¦¨¨Ã¤½¶}¼Æ¾Ú¤ÀªRµ²ªG¡A¡u¦P®É±N¦b¬ÛÃöÀù¯g«n°ê»Ú·|ij¤Î´Á¥Zµoªí¡C¡v ¥J²Ó·Q·Q «¢«¢«¢¡A¦pªG¼Æ¾Ú¤£¦n¡A½Ö´±µoªí¦b«n°ê»Ú·|ij¤Î´Á¥Z¡HÁÙ¶K¦b©xºô°Ç ·íµM¡A¨S¸Ñª¼¤§«e¡A¨S¤H´±»¡Ó·Ç ¤p§ÌÄ~Äò@¤ßµ¥«ÝÅo ¥H¤W¬°¤p§ÌÓ¤H½×ÂI¡A¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2015/8/30 ¤U¤È 01:50:48²Ä 385 ½g¦^À³
|
ªü®¶¤j¡A ¤£¥Îı±o¤£¦n·N«ä ¶K¥X¤@½g¤À¨Éªºì©lªì°J¬O³Ì«nªº ¤£½×³Ì«áÃÒ©ú¬O§_»P¨Æ¹êªºµo®i§¹¥þ¤@PµL»~ °£«D8/28³o¤@¤Ñ¨Ã¨S¦³±M®a°Q½×¯E¹©ªº¸Ñª¼¨Æ©y §_«h¥Ø«e©ÒÅã¥ÜªºPD¼Æ¾Ú¡y¨¬¥H¶i¦æ¸Ñª¼¡zÀ³¸Ó¤w¸g¬O½T©wªºµ²½× ±M®aÀ³¸Ó¤£»ÝnÀ°¯E¹©¨M©w¬Oþ¤@Ӥ뤽§i¸Ñª¼¼Æ¾Ú ¸Ñª¼¹Lµ{©Ò»Ýªáªº®É¶¡ÁÙ¬O¥Ñ¯E¹©µû¦ô¤ñ¸û·Ç½T ©Ò¥H8/31ªº·|ij²q´ú¥i¯à¬O¤½¥q¤º³¡°Q½×¨ì©³¬O¡yþ¤@Ó¤ë¡z¸Ñª¼¼Æ¾Ú¤½¥¬ ¤Ï¥¿³Ì²×©³½u¬O¨Ó±o¤Î°Ñ¥[ASCO¦~·| ±À´ú8/28¤£¬ODSMB·|ijªºì¦]¬O ¤W¤@¦¸¦b2015/1/10¥l¶}¡A¥b¦~«áÀ³¸Ó¦b2015/7/10«e«á »P8/28®É¶¡®t¤Ó¤[¡A¦³ÂI¤£¦X²z ¥H¤W¬OÓ¤Hªº²z¸Ñ µL½×¦p¦ó¡A8/31·|¦³½T©wªºµª®×¡C |
|
|
·|û¡Gªü®¶10139782 µoªí®É¶¡:2015/8/30 ¤U¤È 12:07:09²Ä 384 ½g¦^À³
|
DERA D§b¤j ±z¥i¯à»~¸Ñ¤F..... ¸ê°Tµêµê¹ê¹ê¤§¶¡ ¦³®É¦b¹LÂoªº¹Lµ{¤¤ ¦ÒÅçµÛ§PÂ_ªº´¼¼z ©Z¥Õ»¡ ³oÂI§ÚÁÙ¦b¾Ç²ß |
|
|
·|û¡GD§b10139065 µoªí®É¶¡:2015/8/30 ¤W¤È 11:32:04²Ä 383 ½g¦^À³
|
ªü®¶¤j¡G¦Ñ¸Ü¤@¥y¤£¥Î¤Ó¦Û³d¡A¥Í§ÞªÑ¸ê°T¦V¨Óµêµê¹ê¹ê¡A³oùجO°Q½×°Ï¹ï¿ù¤£«n°Q½×§¹¯à§_§óÁÍ©ó¯u¹ê¤ñ¸û«n¡F¥t¥~«e¤@°}¤l¦³¦bÂø»x¤W¬Ý¨ìªü®¶¤j^«º¡A®¥³ß³á¡I |
|
|
·|û¡Gªü®¶10139782 µoªí®É¶¡:2015/8/30 ¤W¤È 11:20:21²Ä 382 ½g¦^À³
|
Faith¤j¤jÌ ÁÙ¬On»¡Án¹ï¤j®a¤£¦n·N«ä Åý¤j®a´Á«Ý¦³¨Ç¥¢±æ ¤p§Ì°Ý¹L¤TÓ"ªB¤Í" ¨ä¤¤¦³¨âÓ´£¤Î..... ¤ß·QÀ³¸Ó¤£P¦³»~ ¤]«æ©ó¦Vµ¥¤F³\¤[ªº¤j®a¤À¨É ¦ý¤£ª¾¬°¦ó»P³ø¯È¤Wªº¦³®t²§ ¤é«á ÁÙ¯u¬OÀ³·íÂÔ·V¤@ÂI Y«D¦Û¤v»P·í¨ÆªÌª½±µÅ¥¨Ó ÁÙ¬O¤£À³¸Ó¹L«æ©óµoªí ¦¹¨Æ§ÚÁÙ¦b°lÂÜ"¨ì©³«ç»ò¤F!" ¯S¦¹Pºp! |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/8/29 ¤U¤È 10:07:11²Ä 381 ½g¦^À³
|
·PÁªü®¶¤j¡BBRN¤jµy¨Óªº®ø®§ ¥H¤U¬O¤p§Ìªº±À½×¡A¦A³Â·Ð¯E¤ÍÌÀ°¤p§Ì×¥¿¿ù»~©Î´£¥X¬Ýªk ÁöµM²{¦bÁÙ¤£ª¾³Ì·sªº¼Æ¾Ú ¦ý¨Ì¾Ú±M®a·|ijªºµû¦ô¸Ñª¼®É¶¡¨Ó±À½× ¹êÅç²Õªº¼Æ¾ÚÀ³¸Ó¬O¤£¿ù¡AY¤Ó¦¸Ñª¼·|¦³·ÀI PDªº¤H¼Æ¤¤¡]¤£¥]¬A°h¥Xªº¡^¡A¦©°£¦w¼¢²Õ«á ¯u¥¿´_µoªº¤H¼Æ£¸©wn¤j©óµL®Äªº¤H¼Æ¡A¸Ñª¼¥X¨Ó¤~¦w¥þ ¦]¦¹¡A¤wPDªº¹êÅç²Õ¤¤¡AµL®Äªº¤ñ¨ÒË©³¦h°ª¡H¬Û«H¦³¤Hª¾¹D ¦³½ìªº¬O¡A¹ê»Ú¤W¡A§Ú̧ƱæµL®Ä¤ñ¨Ò¯à§C ¦ý¦b¦¹¹êÅ礤¡AµL®Ä¤ñ¨ÒY¦û2-3¦¨¡A´«ºâ«á¡A¤Ï¦Ó¹ï¹êÅç¤ñ¸û¦³§Q ¥H¤W¦A½Ð¯E¤Í´£¥X¬Ýªk Ps:¦³¯E¤Í¯u©¯ºÖ¡A«¢«¢«¢ |
|
|
·|û¡GÂÅÂI10140768 µoªí®É¶¡:2015/8/29 ¤W¤È 08:46:46²Ä 380 ½g¦^À³
|
·PÁªü®¶¤j¦³§A¯u¦n |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2015/8/29 ¤W¤È 12:57:24²Ä 379 ½g¦^À³
|
·PÁªü®¶¤j¡I ·PÁÂCliff¤j«ùÄò¦bÁÞ¬ì¾Ç¤Wªº«ü¾É¡I ±µ¤U¨Ó´NÅý¼Æ¾Ú¨ÓÁ¿¸ÜÅo¡I |
|
|
·|û¡G¦³FUªº¤H10136189 µoªí®É¶¡:2015/8/29 ¤W¤È 12:24:00²Ä 378 ½g¦^À³
|
½Ð°Ýªü®¶¤j~~ ©ú¦~²Ä¤@©u¸Ñª¼<---«üªº¬OÃĮĪºµ²¹L¹ï§a??? Y¦b²Ä¤@©u¸Ñª¼¶Õ¥²n´£¦¦Ü¤Ö3Ó¤ë§â¸ê®Æ¾ãÓ¦¬¶°§¹¦¨¶i¦æ¤ÀªR¤~¨Óªº¤Î |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/8/29 ¤W¤È 12:06:14²Ä 377 ½g¦^À³
|
¥Xª©¤j¡A§NÀR¤@¤U¡A¬Oþ¥÷³ø¯È¡H©P¤»n¥ZµnªºÅo¡H |
|
|
·|û¡Gªü®¶10139782 µoªí®É¶¡:2015/8/28 ¤U¤È 11:59:51²Ä 376 ½g¦^À³
|
DEAR °e³ø¤j ¥t¥~º|±¼´£¤Î,»¡ASCO´N¹³¬O"Àù¯gÂåÀøªº¤j«ô«ô",¯E¹©·|°Ñ¥[¨Ã¤£¤@©w´N¬O«OÃÒ¤°»ò,¤@¤ÁÁÙ¬On¨Ì·Ó¼Æ¾Ú,¦ýY¼Æ¾Ú¦n,±N·|¬O¤ñ¥ô¦ó¦æ¾PºÞ¹DÁÙ¦³¥Îªºµoªí³õ©Ò,¦]¬°«Ü¦hÂåÀø³æ¦ì³£·|¥h°Ñ¥[³o³õ²±·|,¥¦¯àÅý¯E¹©ªº¤f¸O«Ü§Ö³tªºÅý¥þ¥@¬É³£ª¾¹D ÁÙ¦³¦n¹³9¤ëªº¼Ë¤l(¤£¯à«Ü½T©w)ÁÙ¦³¤@Ó¼Ú¬wESMOªºµoªí²±·| |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/8/28 ¤U¤È 10:23:04²Ä 375 ½g¦^À³
|
«á¨Ó´£«e¤F¤@¤Ñ¡Aì¦]¤£¸Ô¡A¶g¥½ªºÃö«Y¡H ¤£¹L¯uªº¤w¸g§i¤@¬q¸¨¡Aµ¥«¤j°T®§´¦ÅS§a¡I ¦Ü©óNED¤H¼Æ¡AY¬O¯uªº»¡±o¥X¨Ó¨º¤]¤Ó¸Ø±i¤F¡A·s»D³ø¾ÉD¹F¤H®×¤~èè§P¨M¤U¨Ó¡C |
|
|
·|û¡G¦h¦h10137435 µoªí®É¶¡:2015/8/28 ¤U¤È 09:53:05²Ä 374 ½g¦^À³
|
Cliff¤j ¤§«e±z¤£¬O»¡¹L¹wq¶}·|¤é¦b8/29?! ©Ò¥HÀ³¸Ó©ú¤é¤~·|¦³®ø®§§a!? ¤j®a¯E¹©©ê¤F«Ü¤[ ¤â³£µm¤F ¤]«Ü·Q¦ÂIª¾¹D¶i¤@¨B®ø®§ ¤£ª¾¤½¥q·|³zÅS§ó¦h¹êÅç°T®§!? ¤ñ¦p¨ÓÂI«lÃzªº¤½¥¬NED¤H¼Æ??!! |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/8/28 ¤U¤È 04:36:48²Ä 373 ½g¦^À³
|
±M®a·|ijªºµ²ªG..µ¥«Ý¤¤.. OBI ºô¶¶i¤£¥h???? |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/8/28 ¤U¤È 04:24:26²Ä 372 ½g¦^À³
|
2015/09/15--20 °ê»ÚÁÞµ²¦X¬ã°Q·|¡]23rd INTERNATIONAL SYMPOSIUM ON GLYCOCONJUGATES¡^¦b¦a¤¤®ü§Jù®J¦è¨È¡]Croatia¡^ªº¥j«°SplitÁ|¦æ¡A¤j²¤ºË¹L¤j·|¥Ø¿ý¡]¥u¦³ÃD¥Ø¬Ý¤£¨ì¤º®e¡^¡A¬Ý¨ì§Ú°ê¦Ü¤Ö¦³¨â¦ì¾ÇªÌ¥X®uºtÁ¿©Î³ø§i¡C¡]http://www.glyco23.org/ ¡^¡B¡]http://www.glyco23.org/PROGRAM.pdf ¡^ Sep.16¡G¤j·|ºtÁ¿¦³11ÓÃD¥Ø¡A¨ä¤¤1Ó¬O¯Î°|ªø¡G¡uGlycosylation¡Gchemical approach to disease biology¡v¡]ÁޤơG±q¤Æ¾Ç¬ã¨s¨ì¯e¯f¥Íª«¾Ç¡^¡A¬°®É40¤ÀÄÁ¡C³oÓÃD¥Ø¸ò2015/6/26Á|¿ìªº²Ä15©¡¬ü¬wµØ¤H¥Íª«¬ì¾Ç¾Ç·|°ê»Ú¾Ç³N¬ã°Q·|¤¤¡]The 15th SCBA International Symposium¡^¡A°|ªøªºÁ¿ÃD«Ü¹³¡G¡uChemistry and Biology of Glycosylation: A Search for Universal Vaccines against Cancer and Influenza¡v °|ªøÁ¿§¹«á¬ù1.5¤p®É¡A§d©v¯q³Õ¤h³ø§i¡uImmunogenicity study of Globo H analogues with modification at the reducing or non-reducing end of the tumor antigen¡v¡A´N¬O¨º¤@½g±i¸³©Ò»¡ªº¤¤¬ã°|ªºÀÀÁÞ§Ü쪺§Þ³N¡A¬°®É¡u10¡v¤ÀÄÁ¡Cì¤å¤w¸g¦b´Á¥Zµoªí¹L¤F¡A¤£ºâ³Ì·sªºÃD¥Ø¡A¦Ü©ó¤º®e¦³¨S¦³¥[¤J·sªF¦è¤£±o¦Óª¾¡C ÂsÄý¤@¤U¥Ø¿ý¡A¤£Ãø¬Ý¥XÁޤƾǻP¯e¯fªº³sµ²À³¥Î¬O¥¿ÉqÁͶաA¤×¨ä¬OÀù¯g¡C¬Ý¨ì¨âÓ¤ñ¸û¯S§Oªº¡G ^°ê¡G¡uGlycan chip technology¡v¡]ÁÞ´¹¤ù§Þ³N¡^¡A«Ü¦n©_³oÓ¤º®eÁ¿¤F¬Æ»ò¡H ¥xÆW¡G¡uRoles of £]-1,3 galactosyl transferase V, SSEA-3, SSEA-4 and Globo H in breast cancer¡v¡]¨ÅÀù¤¤£]-1,3¥b¨Å¿}Âà´«酶V¡BSSEA-3¡BSSEA-4 ¤Î Globo Hªº¨¤¦â¡^¡A³oÓÃD¥Ø¦³·N«ä¡A¥Ñ±¾¦b¤¤¬ã°|°ò¦]Å餤¤ß»P°ò¦Âå¾Ç¬ã¨s©Ò¡]¦¨¤j¡H¡^¦W¤UªºPo-Kai, Chuang´£¥X³ø§i¡C¡]²ø³Õ³Í¡H¡^¡]¥i¥H§â³oÓ£]-1,3¥b¨Å¿}Âà´«酶V·í§@·sªºÃöÁä¦r¨Ó¬d¤@¬d¡K¡^¡C ¦b¹B¥Î¿}®Ö苷ÁÙ쪺¤j¶q»Ã¯À¦X¦¨Globo H¤èªk¤¤¡A±q¤þ²m¤Æ¨Å¿}¶}©l»s³y¡A¤@ª½¨ì¤þ²m¤ÆGlobo H³y¥X¦@»Ý¥|Ó¨BÆJ¡A·í¤¤ªº²Ä¤T¨BÆJ¡A¤]´N¬O§â¤þ²m¤ÆGb4»s¦¨¤þ²m¤ÆGb5¡A©Ò»Ýnªº»Ã¯À´N¬O£]-1,3 galactosyl transferase¡A¨º²{¦b¦h¤F¤@ÓV¡A¤£ª¾¹D¬O¤£¬O¦P¤@ÓªF¦è¡C¡]http://pubs.acs.org/doi/pdf/10.1021/ar5004187 ¬ÝFig.8 ²£ª«½s¸¹No.42 Allyl-Gb4-->-No.43 Allyl-Gb5¤§¶¡ªº¾î½bÀY¤Wªº£]-1,3 Gal T«K¬O¡^ ¤£·Q¬ã¨s¤]¨SÃö«Y¡A¹C¤@¤U§Jù®J¦è¨È¡]Croatia¡^ªº¥j«°Split¤]¤£¿ù¡G¡uhttp://yoyovilla.pixnet.net/blog/post/28605026 ¡v §ä®É¶¡¦A¨Ó½Í¦b³oÓª©¤W¡u2014/12/7¤W¤È11:09:39Àù²ÓM®·¤â¦¨¥\§ÞÂà¡vªº«áÄò®ø®§¡C ¤µ¤Ñªº±M®a·|ijÀ³¸Ó¶}§¹¤F§a¡H¦³¨S¦³¤H¥i¥H³zÅS¤@ÂI¡H |
|
|
·|û¡Gµ½¤H10137888 µoªí®É¶¡:2015/8/9 ¤W¤È 10:55:07²Ä 371 ½g¦^À³
|
Cliff¤j, «D±`·PÁ±zªº¥Î¤ß©M±M·~ª¾ÃÑ. ±j»ä¹L¹Ò, ¯¬ºÖ¯E¤Í̳£¥¦w°·±d. |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2015/8/9 ¤W¤È 10:43:53²Ä 370 ½g¦^À³
|
ÁÂÁÂCLIFF¤jªººë±m¤À¨É ¬Ý¨Ó822±N¬O¦n¥Î¤S¦³©Ê»ù¤ñªº§ÜÀùÃÄ CLIFF¤jÀ´³o»ò¦h À³¸Ó¥i¥H¶i¯E¹©¦æ¾P¹Î¶¤¤F |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/8/8 ¤U¤È 10:49:55²Ä 369 ½g¦^À³
|
¸¨¸¨ªøªº¤º®e¡A¬Ý¤F¨S¥´¬ÚÁÙ¯uÃø¡C ASCO¡]¬ü°êÁ{§É¸~½F¾Ç·|¡^¦b6¤ë22¤é©ó½u¤W¥Z¸ü¤@½g¤å³¹¡A§Æ±æ§â§ÜÀù·sÃĪº»ùÈ¥H¶q¤Æ¤ñ¸ûªº¤è¦¡§e²{¥X¨Ó¡A§@¬°¸~½F¬ìÁ{§ÉÂå®vªº°Ñ¦Ò¡C³o¤£¬OASCO²Ä¤@¦¸³o¼Ë°µ¡A¦¦b´X¦~«e´N¶}©l©IÆ~¾ã¦X¡A¨ä¥L¦U°ê¦p^ªk¼w¥[¿D¤]³£¦³Ãþ¦üªº·§©À®Ø¬[¡A°ò¥»¤W³£¬O¥H²{¦³ªºÁ{§É§ÜÀùÃĪ«ªºÁ{§É¸ÕÅç¼Æ¾Ú¨Ó¤ÀªR«Øºc¡A¸¨¹ê¡u¹êÃÒÂå¾Ç¡vªº²z©À¡A¦]¬°¬ì¾Çª`«ÃÒ¾Ú¡A¤@Ó·sªº§ÜÀùÃĪ«½Ï¥Í¡A¥i¥H±aµ¹±wªÌ¦h¤jªº§U¯q¡A¤£¬O¬Ý¬ÝFPS¦³¦h°ª¦Ó¤w¡A¤]¤£¬O¥u¬Ý°Æ§@¥Î¤j¤£¤j¡A§ó¤£¥i¯à¾Ì·Pı·Q¹³©Î¥u¾ÌÃļt®ï¶Ôº}«Gªº·~°È¥Nªíªº¤@±¤§Ãã¡A¤@¤Á³£¬Ý¬ì¾ÇÃÒ¾Ú¡A¦³´X¤ÀÃÒ¾Ú»¡´X¤À¸Ü¡C¯u¦³¤H¬°¥i¥H¥DÆ[¾Þ±±ªº¬OÃÄ»ù¡A¦Ó³o¶µ¤]³Q¦C¤J·sÃÄ»ùȵû¦ô¤¤ªº¤@¶µ¡C ASCO¦b¦¹Ä³ÃD¤WªºÃöª`¡A¸g¹L¦h¦~ªººtÅܨì¤F2013¦~¡A¥ÑASCOq¥X¡uÀù¯g·ÓÅ@¤u§@ªº®Ö¤ß»ùÈ¡v¡]ASCO Value in Cancer Care Task Force¡^¡AÂê©w¡u¦³»ùÈ¡vªº§ÜÀù·sÃÄ¥²¶·¥[±jª`«Àø®Ä¡]Clinical Benefit¡^¡B°Æ§@¥Î¡]Toxicity¡^¡B¶O¥Î¡]Cost¡^µ¥±¦V¡C³o¬O±q°ê®aÂå¾Ç¬ã¨s°|¡]The Institute of Medicine¡FIOM¡^©Ò´¿´¦òUªº¤»¶µ«~½è«ü¼Ð¤¤¬D¿ï¥X¨Óªº¡]¦w¥þ©Ê¡B¦³®Ä©Ê¡B¥H±wªÌ¬°¤¤¤ß¡B¾A®É©Ê¡B®Ä²v¤Î¤½¥©Ê¡^¡C¹³·¥¤F§ÜÀù·sÃĪº¤K¦r½×©R¡A¤]¹³¬O§ÜÀù·sÂÂÃĪ«ªºPKÁÉ¡C¡]§O§Ñ¤FASCO«D±`¥i¯à¬O822ªì¸Õ³ÚÁnªº»R¥x¡K¡^ ì¤å¡G¡uAmerican Society of Clinical Oncology Statement¡GA Conceptual Framework to Assess the Value of Cancer Treatment Options¡vonline Jun.22, 2015 ºô§}¡G¡uhttp://jco.ascopubs.org/content/early/2015/07/08/JCO.2015.61.6706.full.pdf+html ¡v ¤K¦rµû¤Àªí¡]«¤j¯e¯f¡^¡GFig.1¡G¡uhttp://jco.ascopubs.org/content/early/2015/07/08/JCO.2015.61.6706/F1.large.jpg ¡v ¤K¦rµû¤Àªí¡]»²§UÀøªk¡^¡GFig.2¡G¡uhttp://jco.ascopubs.org/content/early/2015/07/08/JCO.2015.61.6706/F2.large.jpg ¡v §â§ÜÀù·sÃÄ»P¥DªvÀù¯gªº²{¦æ¼Ð·ÇÀøªk¤@°_µû¤ñ¡A¤À¦¨¤U¦C¥|Ó±¦V¤ñ¸û¡G 1.Àø®Ä¡]Clinical Benefit¡^ 2.°Æ§@¥Î¡]Toxicity¡^ 3.¥[¤À«GÂI¡]Bonus points¡^ 4.¶O¥Î¡]Cost¡^ ½Ð°Ñ¾\Fig.1¤K¦rµû¤Àªí¡]«¤j¯e¯f¡^¡C ¦~¬W¡]step.1¡^¡GÀø®Ä¡]Clinical Benefit¡^¡F³Ì°ª±o80¤À¡C §â§ÜÀù·sÃÄ»P²{¦æ¼Ð·ÇÀøªkÃĪ«ªºmedian OS®³¨Ó¤ñ¤@¤ñ¡C¬Ý·sªº¤ñªº¶i¨B¦h¤Ö¨Óµû©w·sÃĪº±o¤À¡C ¶i¨B´T«×¡G 0%-24%¡G±o1¤À¡C ¶i¨B´T«×¡G25%-49%¡G±o2¤À¡C ¶i¨B´T«×¡G50%-75%¡G±o3¤À¡C ¶i¨B´T«×¡G76%-100%¡G±o4¤À¡C ¶i¨B´T«×¡G¤j©ó100%¡G±o5¤À¡C ¦A§â±o¤À¼¥H16¡]OS¥[Åvp¤À16¿¡^«á¡A±o¨ìOS Score¡Fstep.1³Ì°ª±o¤À¬O80¤À¡C¥[Åvªº¤ñ«¬O¸g¹LASCO±M®aÌ°Q½×«áÀòPªº¦@ÃÑ¡C Á|¨Ò¨Ó»¡¡AªvÀøÂಾ©Ê«D¤p²ÓMªÍÀùÃĪ«Bevacizumab¡]¨£Fig.3-A¤ÎTable.A2¡^¡A ¹êÅç²Õ¡uBevacizumab+ Carboplatin+ Paclitaxel¡v»P¼Ð·ÇÀøªkªº¡uCarboplatin+ Paclitaxel¡v¹ï·Ó²Õ°µ¤ñ¸û¡G ¹êÅç²ÕªºOS¬O12.3Ó¤ë¡F¼Ð·ÇÀøªkªºOS¬O10.3Ó¤ë¡C ¶i¨B´T«×¡G¡]12.3-10.3¡^/10.3=19% ¤¶©ó0%-24%¡G±o1¤À¡A step.1 .OS Score¡G1x16=16/80¤À¡C Y¸Ó·sÃĨS¦³median OS¼Æ¾Ú¥i¥Î«ç¿ì¡H«h§ï¥Îmedian FPS¡A¦A§â±o¤À¼¥H11«á¡]PFS¥[Åvp¤À11¿¡^¡A±o¨ìPFS Score¡F³Ì°ª±o¤À¬O55¤À¡C Y³smedian PFS¤]¨S¦³¡A§ï¥Î¤ÏÀ³²vRR¡]Response Rate¡×CR+PR¡^¡A ¶i¨B´T«×¡G 0%-20%¡G±o1¤À¡C ¶i¨B´T«×¡G21%-40%¡G±o2¤À¡C ¶i¨B´T«×¡G41%-60%¡G±o3¤À¡C ¶i¨B´T«×¡G61%-80%¡G±o4¤À¡C ¶i¨B´T«×¡G81%-100%¡G±o5¤À¡C ±o¤À¼¥H8«á¡A±o¨ìRR Score¡F³Ì°ª±o¤À¬O40¤À¡C ¥Ñ¦¹¥iª¾¡A§ÜÀù·sÃĪºÀø®Äº«OS¡A¥u¬O¦]¬°°lÂܮɵ{±N©Ôªø¡A¦b¬ãµo®É®Ä/¸g¶O¤W³£¬O°ÝÃD¡A¤~¬ãµo¥X´À¥N«ü¼ÐPFS¡BRR¡BTTP¡]time-to-progression¡^µ¥¡C¡]³o¹ï©óPFS¤£¬O¨º»òÅå¤H¡AOS¬Û¹ï«GÄRªº822«Ü¦³§Q¡^ ¤ë¬W¡]step.2¡^¡G°Æ§@¥Î¡]Toxicity¡^¡F³Ì°ª±o20¤À¡C §â§ÜÀù·sÃÄ»P²{¦æ¼Ð·ÇÀøªkÃĪ«²£¥Íªº«¤j°Æ§@¥Î¡]grade.3-5¡^®³¨Óºâ¤@ºâ¡A¦U§Opºâ¦³¦h¤ÖºØªº«¤j°Æ§@¥Î¡C¬Ý·sÃĤñÂÂÃĪº«¤j°Æ§@¥ÎºØÃþ¡u¼Æ¥Ø¡v´î¤Ö¤F¦h¤Ö¦Ê¤À¤ñ¨Óµû¤À¡C ºØÃþ¼Æ¥Ø¼W¥[75%-100%¡A±o-20¤À¡C ºØÃþ¼Æ¥Ø¼W¥[50%-74%¡A±o-10¤À¡C ºØÃþ¼Æ¥Ø¼W¥[´T«×<49%©Î´î¤Ö´T«×<49%¡A±o0¤À¡C ºØÃþ¼Æ¥Ø´î¤Ö50%-74%¡A±o10¤À¡C ºØÃþ¼Æ¥Ø´î¤Ö75%-100%¡A±o20¤À¡C ©Ó¤W¨Ò¡A¹êÅç²Õªºgrade.3-5«¤j°Æ§@¥Î¦³22¶µ¡]Fig.3-A¤ÎTable.A2¡^¡F¼Ð·ÇÀøªkªºgrade.3-5«¤j°Æ§@¥Î¦³15¶µ¡C ¨âªÌºØÃþ¼Æ¥Ø¼W´î¡G¡]22-15¡^/15=47%¡F¼W¥[´T«×<49%¡Astep.2±o0/20¤À¡C ¤é¬W¡]step.3¡^¡G¥[¤À«GÂI¡]Bonus points¡^¡F³Ì°ª±o30¤À¡C §ÜÀù·sÃĪº¬ãµo¹Lµ{¤¤Y¦³²Îp¤W§e²{¦³·N¸qªºÀù¯g¬ÛÃö¯gª¬½w¸Ñ¡]palliation¡^ªÌ¡A¥iÀò¥[¤À¡]3A¡^¡C©Î¬O¦³²Îp¤W§e²{¤@¬q¦³·N¸qªº¡u¤£»Ý¥ÎÃĪºªvÀø°²´Á¡vªÌ¡]treatment-free-interval¡^¡A¥iÀò¥[¤À(3B)¡F¥NªíÀù¯g¥¼¦A´c¤Æ¡A¦Ó¥B±wªÌ¥i¥H¨É¦³¤@¬q§K¨üÃĪ«°Æ§@¥ÎºR´Ýªº¤é¤l¡C §â3A¤Î3Bªº±o¤À¥[°_¨Ó¡A´N¬Ostep.3ªº±o¤À¡F³Ì°ª¬O30¤À¡C ³oÓ¶µ¥Øn¬Ý쥻¸ÕÅç³]p¦³¨S¦³¥Hpal |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2015/8/8 ¤U¤È 04:54:13²Ä 368 ½g¦^À³
|
½ÐCLIFF¤j ¦A¤À¨É¾\Ūªº¤ß±o ·P®¦°Õ |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/8/8 ¤W¤È 12:45:01²Ä 367 ½g¦^À³
|
¦¤F¬ù¤@Ӥ몺ASCO online¡GJCO 22, JUN 2015¤]¥Zµn¤F¤@½g·s¥D±i¡A§Æ±æ«Øºc¤@Ó¥¥xÅý¸~½FÁ{§ÉÂå®v¥i¥H§Ö³t´x´¤§ÜÀù·sÃĪº»ùÈ¡A822¸Ñª¼«áªº¼Æ¾ÚˬO¥i¥H®M¥Î³o®M¼Ð·Ç¥h»¡ªAÂå®v¡A¥H²Å¦X¹êÃÒÂå¾Çªº¨¤«×¨Ó¦Ò¼{ÃĪ«ªº¿ï¾Ü¡A¥h¦~°_ª©¤W°Q½×¹L¼vÅTÂå®v¶}ÃĪººØºØ¦]¯À¡A§Ú·Q³Ì«nªºÁÙ¬OÀø®Ä¡AASCO³oÓ·s¬[ºc¹ï822¬O¦³§Qªº¡A¤w¸gŪ±o®t¤£¦h¤F¡A¦³¿³½ìªº¸Ü¦A¶K¡C¡]http://jco.ascopubs.org/content/early/2015/06/16/JCO.2015.61.6706 ¡^ |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/8/7 ¤U¤È 11:17:23²Ä 366 ½g¦^À³
|
Hi Cliff¤j¤Î¦U¦ì¤j.. SABCS ¬Ý¨Ó¬O¨S¦n´Á«Ý¤F http://www.sabcs.org/Program ¯Î°|ªø.§d³Õ¤h.¥X®u http://www.glyco23.org/ GLOBO H ¦³¬ã¨sµoªí http://www.glyco23.org/PROGRAM.pdf µ¥«Ý GLOBO H ¦¨¬°»{¥iªº¥Íª«¼Ð»xª«==>822¦¨¥\®É http://www.oncologypractice.com/the-oncology-report/specialty-focus/breast/single-article-page/asco-guidelines-define-use-of-biomarkers-for-advanced-breast-cancer-treatment/889bce99259831edf82af393f274414e.html |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2015/8/7 ¤U¤È 07:20:04²Ä 365 ½g¦^À³
|
¯E¹©¼x¤H Åã¥ÜÂX¤jÀç·~ ¤£ª¾¹D¬O833 ÁÙ¬O822¤è± ¥¼¨Ó¬ã¨s¶i«× »Ýn°lÂÜ ¥t¥~Àç·~¶O¥Î¤j¼W ¥i¥H¹w´Á ¤p¤ß¹ï°]³øªº¼vÅT ÁÂÁÂCLIFF¤j ¥t¥~ ¼í¶®¤]Ä~Äò¼x¤H ¬Ý¨Ó¨âÀY¨Ã¶i |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/8/7 ¤W¤È 11:51:12²Ä 364 ½g¦^À³
|
¡K«DºÓ§Y³Õ¡K¡]https://www.104.com.tw/jobbank/custjob/index.php?r=cust&j=4349426a4b6b3e55303139624d63361973749416b3f453d2020202020373a2524290j51&jobsource= ¡^ Á`¾÷Ý¥´Âø¡K¤j¾Ç¥H¤W¡K¤@¦~¥H¤W¤u§@¸ê¾ú¡K¡]https://www.104.com.tw/job/?jobno=4iz2k&jobsource= ¡^ 1. ³X«È±µ«Ý»P˯ù¤ô, ¹q¸Ü±µÅ¥,Âà±µ»P¯d¨¥¡C 2. ·|ij«Ç»P¿ì¤½«Ç¾ã²z, ¨ó§U¨ä¥L¦æ¬F¨Æ°È¡C 3. »¼°e¤½¤å¤Î¦¬µo«H¥ó, ¤½¤å»P¹q¤l¤½¤åºÞ²z¡C 4. t³d¿ì¤½«Ç¤å¨ã, ¹s¥Îª÷ºÞ²z, ±f°ÈÂø¶µ±ÄÁʤΨưȾ÷¾¹¥sסC ¡K¡K »y¤å±ø¥ó¡G ^¤å -- Å¥ /²¤À´¡B»¡ /²¤À´¡BŪ /²¤À´¡B¼g /²¤À´ |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/8/5 ¤U¤È 02:23:39²Ä 363 ½g¦^À³
|
ÁÂÁÂCliff¤j¤ÎQQ¤j 104.9.4 09:30~09:55 ¯S§OºtÁ¿¡G¥þ²y¥Í§Þ¬ãµoÁÍ¶Õ ¤¤¥¡¬ã¨s°|¯Î±Ò´f°|ªø 10:10~10:35 ¥xÆW¥Í§Þ·sÃIJ£·~ªº¾÷·|»P¬D¾Ô ¯E¹©¥Í§Þ ±i©À·O¸³¨Æªø |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2015/8/5 ¤U¤È 01:46:45²Ä 362 ½g¦^À³
|
¦U¦ì¤j¤j: ¥Í§Þ°·±d°ª®p½×¾Â §K¶OºtÁ¿ ¥DÁ¿¤H§t¯Î°|ªø¤Î±i¸³µ¥ http://www.2015healthsummit.tw/ |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2015/8/5 ¤U¤È 01:01:07²Ä 361 ½g¦^À³
|
ÁÂÁÂCliff¤j¼W¶i§Ú̪ºÁÞ¬ì¾Çª¾ÃÑ¡I ¬JµM¦Ñ¤j»¡¥i¥HÀH«K·Q·Q¡A¤£¥Î¤Ó»{¯u¡A¨º¤p§Ì´N¨Ó²q·Q¤@¤U¡C ¸Ó¸~½F¤Á¤ù¹êÅ礤¡A¥ÎMCD¯ÓºÉ½¤¤WªºÁx©T¾Jªºµ²¦X¤ÏÀ³·|Àu©óª½±µ°µµ²¦Xªº¤ÏÀ³¡A¤p§Ì²q·Q¡A¨º°·±dªÌªº¦P¤@³¡¦ìªº¤Á¤ù(ÁöµM°·±dªÌ¤£·|¦³¤HÄ@·Nµ¹°µ¤Á¤ù)¤Wªº²ÓM½¤ªºÁx©T¾JÁw«×¬O§_À³¸Ó»·¤p©ó(©ÎªÌ®Ú¥»¨S¦³)Àù¯g±wªÌªº¦P³¡¦ì¸~½F¤WªºÀù²ÓM½¤ªºÁx©T¾JÁw«×¡H ±q¤p¹«¬ã¨s¤¤¡Aµo²{¨ÅÀù¶}©l§Î¦¨«á¡A¦å¤¤Áx©T¾J¿@«×·|¤U°¡F¸~½F¥¼¶}©lÅÜÃa¤§«e¡AÁx©T¾J¿@«×«h¤£ÅÜ¡C¨º¬O¤£¬O±wªÌÀùÅÜ«á¡A¤£ºÞ¦å²MÁx©T¾J¿@«×¬O°ª©Î§C¡AÀù²ÓM³£n®³¦å²MÁx©T¾J°µ§÷®Æ¡A¦A»PÀù²ÓM½¤¤WªºGSL§Î¦¨½Æ¦XÅé¡AÅý¦å²G¤¤¨µÅ޺ʴúªº§ÜÅé¿ëÃѤ£¥X¨Ó¡H ¤Á¤ù¹êÅ礤¬O¥ÎMCD¯ÓºÉ½¤¤WªºÁx©T¾J¡A¨º¦³ÃĪ«¥i¥H¦b¨Å餺¯ÓºÉÀù²ÓM½¤¤WªºÁx©T¾J¦Ó¤£¼vÅT¨ä¥Lªº¥¿±`²ÓM¶Ü¡H¤§«e¤p§Ì¥H¬°¼vÅTÁÞ¬ì¾ÇªvÀøÀù¸~½Fªº¨âӳ̥Dn¦]¯À¡A¤@Ó¬O¦p¦ó¦b±wªÌ¨¤W²£¥Í°ª¿@«×ªºIgG©MIgM§ÜÅé¡A¥t¤@Ó¬O±wªÌ¥»¨Àù¸~½F¤WªºGH¨t¦C²ÓM¼Æ¦Ê¤À¤ñ(©ÎªÌ¥Î¦Ñ¥v¤jªº±j¶§©Ê©M®z¶§©Ê¨Óªí¹F)¡A²{¦b¬Ý¨Ó¥i¯àÁÙ¦³Àù²ÓM½¤¤WªºÁx©T¾J¿@«×°ª§Cªº¦]¯À¦s¦b¡A³o¬O§_Áô§tµÛY¯à°§CÀù²ÓM½¤¤WªºÁx©T¾J¿@«×¡A822©Î833¥¼¨ÓªºÀø®ÄÁÙ¦³¥i¥H§ïµ½ªºªÅ¶¡¡H ÀH«K·Q·Q¡AµLÃöªÑ»ù¡C |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/8/5 ¤W¤È 10:55:25²Ä 360 ½g¦^À³
|
©êºp¡A§ó¥¿¡G ì¤å¡G¡u¡KÄáÅ@¸¢ÀùªºGb3¡BSSEA-1¡BSSEA-3¡BSSEA-4¡BGlobo H¡]¿W¯ÊSSEA-4¡^¤]·|¨ü¼vÅT¡K¡v §ï¬°¡G¡u¡KÄáÅ@¸¢ÀùªºGb3¡BSSEA-1¡BSSEA-3¡BGlobo H¡]¿W¯ÊSSEA-4¡^¤]·|¨ü¼vÅT¡K¡v |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/8/5 ¤W¤È 10:44:52²Ä 359 ½g¦^À³
|
§Ñ¤F¥h¦~11¤ë¥ª¥k´¿¦bþÓª©¤W¸ò²q·Q¤j¡HÁÙ¬O¤p©_¤j¡H´£¨ì¤@¬q¸Ü¡A·í®É§Ú»¡822©Ò»¤µoªº§ÜÅé»PGHµ²¦Xªº¦æ¬°¤W¡AÀ³¸ÓÁÙ¦s¦bµÛ§ÚÌ©Ò¤£ª¾ªº¼vÅT¦]¯À¦bÀqÀq¦a¼vÅTµÛ¡C Ū¨ì¤@½g¥Zµn©óGlycobiology¡F2013/07/31ªº¤å³¹¡A´£¨ìÀù²ÓMªº²ÓM½¤ªí±ªº¡uÁx©T¾J¯B¶ô¡v¡]cholesterol rafts¡^·|¼vÅTÀù²ÓM½¤ªí±ªºÁޤƯ«¸gÁC¯×ªºªí²{¡]GSLs ¡FGlycosphingolipids¡^¡A¡]Globo H´N¬OGSL¤¤ªº¤@ºØ¡^¡A¦Ó¥B³oºØ¤zÂZÁÙ¥i¯à·|¼vÅT§ÜÅé»PGSLªºµ²¦X¦æ¬°¡C¡]¤]´N¬O»¡¥i¯à·|¼vÅT§ÜÅé»PGH¡BSSEA-3¡BSSEA-4¡Kªºµ²¦X¡^ ¥H¤Uªº³¡¥÷¸òªÑ»ù¡B822¨S¦³ª½±µ¬ÛÃö¡A¨S¿³½ìªº¥i¥H¨ì¦¹¬°¤î¡A«OÃÒ¤£·|¦³¿ò¾Ñ¡C ì¤å¡G¡uCholesterol masks membrane glycosphingolipid tumor-associated antigens to reduce their immunodetection in human cancer biopsies ¡v¡]http://glycob.oxfordjournals.org/content/23/11/1230.full ¡^ Áx©T¾J±N¤HÃþ¸~½F²ÓM½¤¤Wªº¬ÛÃöÀù§ÜìGSLÀ¹¤W¤F±¨ã¡A¦]¦¹°§C¤Fªº§K¬ÌºÊ´ú®ÄªG¡C ³o¤£¬O°Êª«¸ÕÅ窺¬ã¨s³ø§i¡A¬O§â±wªÌ¤â³N¤Á¤Uªº¸~½F°µ¦Bá¤Á¤ù«á©Ò°µªº¬ã¨s¡Cµo²{Áx©T¾J·|»PÀù²ÓM½¤¤WªºGSL§Î¦¨½Æ¦XÅé¡A¨Ï±o¨ã¦³½Õ¸`¸ó²ÓM½¤°T®§¶Ç¾É¥\¯àªºGSL¡A¥Ñ쥻»P²ÓM½¤¦¨««ª½¤è¦V±Æ¦C§ï¦¨¥¦æ±Æ¦C¡C¦p¦¹¤@¨Ó´N¦n¹³§â½¤¤WªºÀù§Üì±a¤W¤F±¨ã¡]masking¡^¡AÅý¦å²G¤¤¨µÅ޺ʴú¡]immunosurveillance¡^ªº§ÜÅé¿ëÃѤ£¥X¨Ó¡A¶¡±µ§Uªø¤FÀù²ÓMªº´c¤Æ¡C þ¨ÇÀù¯g·|¨ü²ÓM½¤¤WªºÁx©T¾J¼vÅT¡H ´N©Ò´ú¸Õªº´XºØÀù¯g¡G§Z±_Àù¡B¸A¤YÀù¡B¯«¸g¥À²ÓM½F¡BÄáÅ@¸¢Àù¡B¨ÅÀù¡Bµ²¸zÀù¡B¶Ý»Ì©Ê²ÓMÀù»P¯«¸g¸`½F·í¤¤¡A§â¦Bá¤Á¤ùÀËÅé¥[¤J´XºØ¹ï§ÜGSLªº§ÜÅé¥h¸ò²ÓM½¤¤WªºGSL°µµ²¦X¡A´ú¥Xµ²¦Xªº§ÜÅé¿@«×¡C¦A§ï¥Îmethyl-£]-cyclodextrin¡]MCD¡^¨Ó¨Æ¥ý¯ÓºÉ½¤¤WªºÁx©T¾J«á¡A¦P¼Ë¥[¤J´XºØ¹ï§ÜGSLªº§ÜÅé¥h¸ò½¤¤WªºGSL°µµ²¦X¡A´ú¥Xµ²¦Xªº§ÜÅé¿@«×¡C¬Û¸û¤§¤U¡A¯ÓºÉÁx©T¾J«áªºÀù²ÓMªí±´ú¨ì¸û¦hªº§ÜÅéµ²¦X¤ÏÀ³¡C¥HÀù¯gºØÃþ°Ï¤À¡A¨ÅÀù¼Ð°O¤¤ªºGb3»PSSEA-4·|¨ü¼vÅT¡F§Z±_ÀùªºGb3¡FÄáÅ@¸¢ÀùªºGb3¡BSSEA-1¡BSSEA-3¡BSSEA-4¡BGlobo H¡]¿W¯ÊSSEA-4¡^¤]·|¨ü¼vÅT¡Gµ²¸zÀù¬OGb3»PSSEA-1¡F¶Ý»Ì©Ê²ÓMÀù¬OSSEA-4¡C ³o»P¤@¯ë©â¦åªºÁx©T¾J¿@«×¦³Ãö¶Ü¡H Á{§É¤W¦ü¥G©|¥¼±o¨ì¦å²MÁx©T¾J¿@«×»PÀù¯gµo¥Í²v¦³¥¿©Ê¬ÛÃöªº³ø§i¡A¦å²M¤¤Áx©T¾J¿@«×¥i¯àµLªk¯u¥¿¤ÏÀ³²ÓM½¤ªí±ªºÁx©T¾J¿@«×¡A©Î³\»Ýnµo®i¥X§ó·sªºÀËÅ綵¥Ø¨ÓÀ³¥Î¡C °Áx©T¾JªºÃĪ«µw¯×Ãþ¡]statin¡^¥i§_¦]¦¹¦³¨¾Àù/ªvÀùÀø®Ä¡H ³oÓ°ÝÃD«Ü¦³·N«ä¡A¦¤w¦U¾Ö¨ä¥D¦U»¡¦U¸Ü¡A¬ü°ê°ê®aÀù¯g¬ã¨s°|¡]NCI¡^¦b2006¶¡ÁÙ´¿´N¦¹Ä³ÃD¥D¾É¹L¥Hµw¯×ÃþÃĪ«¡]½÷·çªº¥ß´¶§´Atorvastatin¡^ªvÀøµ²¸zÀùªºrandomized phase II trial ¡A²Îpµ²ªG¤£«ç»òÀu²§¡C¡]pÈ´X¥G³£¤j©ó0.1¡^¡]http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3046804/ ¡^¥Ø«e¤´¯Ê¥FRCTª½±µÃÒ¾Ú¡]´N¬O¸ò822¤@¼ËÂùª¼¤À²Õ°µ¸ÕÅç¡^¨ÓÃÒ©úÀø®Ä¡C ¦³¿³½ìªº¥i¥H¬Ý³oÓStatins and Colorectal Cancer¡]http://www.medscape.com/viewarticle/778342_1 ¡^ ¤]¦³«ù¬Û¤Ï·N¨£ªº¡]»{¬°¤Ï¦Ó·|PÀù¡^¡]http://jco.ascopubs.org/content/early/2015/01/20/JCO.2014.58.9564.full ¡^ ³Ì«nªº¡AÁx©T¾J¹ï©ó822¦³¨S¦³¼vÅT¡H ¥H¤U¯ÂÄÝÓ¤H²q´ú¡C¥Ñ³o½g¬ã¨s±oª¾¨ÅÀù¼Ð°O¤¤ªºGb3»PSSEA-4·|¨ü¨ìMCD¯ÓºÉÁx©T¾Jªº®ÄªG©Ò¼vÅT¡A¦]¦¹²q´ú822ªº¨ü¸ÕªÌ¤¤¡AY¦³GH§t¶q§C¦ÓSSEA-4§t¶q°ªªÌ¡A¸Ñª¼«á¤£§«¬Ý¬Ý822Àø®Ä¦p¦ó¡AY¬OÀø®Ä¤£¨Î¡A¨º´N¦A¬Ý¬Ý¦oªº¥Í¤ÆÀˬdÁx©T¾J¿@«×°ª¤£°ª¡H¡]822¦¬®×ªÌ±qÀY¨ì§À·|³QÀËÅçÁx©T¾J¶W¹L10¦¸¡^¡AˬO¨S¦³°lÂܧÜSSEA-4§ÜÅé¿@«×¡A§_«hÁÙ¥i¥H±NSSEA-4§ÜÅé¿@«×°_¸¨»PÁx©T¾J¿@«×Åܤưµ¬ÛÃö©Ê±´°Q¡C³Ì«n®£©È¬O¦å²MÁx©T¾J¿@«×¯à§_µ¥¦P©óÀù²ÓM½¤ªí±·LÀô¹ÒªºÁx©T¾J¿@«×¤´µM¬OÓ¤j°Ý¸¹¡C ¦b¥t¤@½g¤p¹«¬ã¨s¤¤¡Aµo²{¨ÅÀù¶}©l§Î¦¨«á¡A¦å¤¤Áx©T¾J¿@«×·|¤U°¡F¸~½F¥¼¶}©lÅÜÃa¤§«e¡AÁx©T¾J¿@«×«h¤£ÅÜ¡C±À´úÁx©T¾J¦b¨ÅÀù§Î¦¨ªº¹Lµ{¤¤·|¥[±j³QÀù²ÓM§Q¥Î¡A¥i¯à·|¼W¥[¨ÅÀù´c¤Æ»PÂಾªº·ÀI¡C¡]http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3069824/ ¡^ ±q¬y¦æ¯f¾Ç¤WªºÁA¸Ñ¡A¨ÅÀù»P°ªªo¯×¶¼¹¦ü¥G²æ¤£¤FÃö«Y¡A¡u¡K¨ÅÀù¡G¯×ªÕ¡B¦×Ãþ¡A¹¡©Mªo¯×¡BÁx©T¾Jµ¥¤Ó°ª¤ÎªÎD³£©ö±o¦¹¯f¡C¡K¡v¡]http://health.ntuh.gov.tw/health/new/5875.htm ¡^¡AI«áªºì¦]¬O¤£¬O´N¬O¸ò³oÓ¥DÃD¦³Ãö¡AÁÙ»Ýn§ó¦hªº¬ã¨sÃÒ¾Ú¡C ´£¨Ñµ¹³ßÅw«ä¦Òªº¤H¡A¤º®e¦h©Ò¹I·Q¡A¬Ý¬Ý´N¦n¤£n»{¯u¡CY»X«ü¥¿¡AµL¥ôÅwªï¡C |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/7/27 ¤W¤È 12:55:37²Ä 358 ½g¦^À³
|
¥Xª©¤j¡G¤£¬O³o¼Ëªº 1.¡u8¤ë½T©w¶}©l¸Ñª¼¡v¡H³o¥y¸Ü¤£²M¤£·¡¦³»y¯f¡A»Ýn·r°u·r°u¡C¡u8¤ë¶}·|½T©w¸Ñª¼¤é´Á¡v¤ñ¸û¶K¤Á¡C 2.¥Ø«e¬°¤î¥¼´£¨ìSABCS¡C¦ý¬O¦³¨S¦³/·|¤£·|®³¥¦¨Ó·í³Æ®×¡HÓ¤H¨ÃµL©Ò±x¡C¡]¥H±zªºÁo©ú¡A§ÚÃhºÃ±z¬G·N¦b®ÇºV°¼À»³á¡H¡^ 3.¤£·|¦³³æ¿Wªº¡u¬ü°ê¤G´Á³ø§i¡v³o¤@¦^¨Æ¡A³o¤]¬O³o¦¸¤~Âç²Mªº¡C¤T¤ëªº¤WÂdªk»¡·|¤W¤£¬O»¡¸òTFDA½Íªºµ²ªG§â¦¬®×ªº«e45¦ì·í§@¬O¤G´Á¶Ü¡H©ÎªÌ¹³§Ú¥H«e¤@¼Ë¡A¥H¬°¬ü°êªº¤G´Á³ø§i¥i¥H¥ýµoªí¡A¬°¦ó¤½¥q¤£°µ¡H¨ä¹ê¤S¬O¤@Ó¬üÄRªº¿ù»~¡A¨Æ¹ê¬O¾ãÓ¤G/¤T´Á¸ÕÅçp¹º¹w©w¦¬®×342¦ì¡]¹ê»Ú¦¬¤F349¦ì¡^¡A³oÓProtocol¦b¬ü°êFDA¬O³Q»{©w¬°¤G´Á¸ÕÅç¡A§â³o¼Ëªº«äºû®³¥h¸òY.K.¹ð¦¸´£¨ìªº¡u¨ä¹ê³o¬O¨ã¦³¤T´Á³W¼Òªº¤G´Á¸ÕÅç¡v³o¥y¸Ü¨Ó°µ¤ñ¹ï¡A´N·|ÁŵM¶}®Ô¡C©Ò¥H¥¼¨Ó¥H¶É¦V°µ¤@Ó¡u¤pªº¤T´Á¡v¾÷·|¸û¤j¡C ¡u¬ü°ê¤G´Á³ø§i¡v´N¬O¤j®a¤Þ»â´Á¬ßªº¡u¥xÆW¤G/¤T´Á¸Ñª¼³ø§i¡v¡C®t§O¦b©ó¥i¥H®³¦¹³ø§i¸òTFDA¥Ó½ÐÃÄÃÒ¡A¦ý«o¥u¯à´N¼Æ¾Úªº¦nÃa¡A®³¥h¸òFDA Bargain«áÄòªº¨BÆJ¡C¡]¦^·Q¤@¤UY.K.»¡¹Lªº¨º¨Ç¸Ü´N·|§óÀ´¤F¡F©Ò¥H¤]¤£¬O®³TFDAªº¤T´Á³ø§i¥h¸òFDA¦p¦ó¦p¦ó¡A¦Ó¬O¦bFDA²´¸Ì®Ú¥»¤W¬O¤G´Á¸ÕÅçµ²ªGªº´¦¾å¡^¡Aµ´¹ï¤£¬O¦b¬ü°ê¥h¥t¥~¦¬®×°µ¤G´Á¸ÕÅç¡A©Ò¥H¥i¥H§ä¾÷·|§â¥¦ªºµ²ªG¥ý´¦¾å¡C |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/7/26 ¤U¤È 11:33:31²Ä 357 ½g¦^À³
|
Hi Cliff¤j.. ¤pªºÁÙ¦³¤@Ó¤Û·Q.8¤ë½T©w¶}©l¸Ñª¼.¨Ã¦b 2015 SABCS (http://www.sabcs.org/)ª½±µ´£¥æ822¤G´Á(ªì¨B)¼Æ¾Ú. Áö¤£ª¾¯E¹©¬O§_¦³³ø°Ñ¥[.¦ý¥xÆW©x¤è¨C¦~³£¦³²Õ¹Î°Ñ»P.¥Ñ¥xÆW¹Î¥Ó½Ð´£¥æ.. «Å§i²Ä¤@ÓÁÞ¤À¤l§Ü¨ÅÀù¬Ì]§Y±N½Ï¥Í.... ¤ï¶Õ¤S¦bµo¹Ú...±aµÛ·L¯º¤W¯Z¥h.. |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/7/25 ¤U¤È 12:30:34²Ä 356 ½g¦^À³
|
¥Xª©¤j¡A¥Ø«e©Òª¾¬O«ü¤¤¬ã°|ªº¨ºÓ§Þ³NÀ³¸Ó¨S¿ù¡A¥u¬O¤£½T©w§ÞÂà¶i¨Ó¤F¨S¡K³£ÁÙ³Q©ñ¦b¡u¼x¨D±ÂÅv¹ï¶H¡vùØ¡K¤£¹Lºâ¬OÄÝ©ó«áÄòªº³W¹º¡A833¤]¤~èn¶i¤J¤@´Á¸ÕÅç¦Ó¤w¡A³oÓNNN¡]azido¡^ªº·sªF¦è«¥Ì´N«ùÄò°lÂÜ¡C Ó¤Hªº·Pı¡A¡u§Æ±æ¦ò¡v¦ü¥G¤ñ¡u²ï©Ô©j¡v¨Ó±o¦³¥÷¶q¡A¤£¹L¨â¦ì³£¨¬°÷Åý822£t¤@£µ£¿°_¨Ó¡A¦ý¤]¦³¥i¯à¬O¡u¥x¤j¶À¡v¥X½u¡C ©Ô¦í¬P±á¤jªº¦ç¨¤¤~¬O¯uªº¡C¯u¥¿°ª¤âÁ`¬O¤Ö¨¥¡A¬Æ¦Ü¤£»y¡A¤£¦ü§Ú³oî¿ÆjÀW¼R¡A¶K¤F¤@°ï¡A²q¤F¤@°ï¡A¤]¿ù¤F¤@°ï¡C¡C Davisclau¤j¡A§Ú¸ò±zªº·Qªk¬O¤@¼Ëªº¡C |
|
|
·|û¡Gdavisclau10136787 µoªí®É¶¡:2015/7/25 ¤W¤È 11:58:44²Ä 355 ½g¦^À³
|
Cliff¤j¤j¡G ASCO¦~·|¹w©w2016¦~6¤ë3-7¤é¦b¬ü°êªÛ¥[ôÁ|¦æ ½Ð°Ý¯E¹©¦³³ø¦W°Ñ¥[¶Ü? §Æ±æOBI-822¸Ñª¼«á¨Ó±o¤Î°Ñ®i¡C |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/7/25 ¤W¤È 12:12:13²Ä 354 ½g¦^À³
|
·PÁ Cliff¤j ¦Û·|³õ±a¨Ó²Ä¤@¤â¸ê°T.. ²³¸Ì´M¥L¤d¦Ê«× ì¨Ó¦¦b Cliff¤j ªº¸ê®ÆÄ_®wùØ. ±z»P¬P±á¤j¤@¦P°ÑÆ[·|³õ.¥Ñ¨â¦ì¤j¤j«õ¥X¨Óªº¸ê°T.¤@©w¬OºëµØ. °²¦p¤£³Â·Ðªº¸Ü...¥i¥H¦h³zÅS¤@ÂI¶Ü.«ô°U..(·Qª¾¹D§ó¦h°T®§ªº¤j¤jÌ.½Ð¤@°_¨Ó©Ô¦íCliff¤jªº¦ç¨¤§a..) °Ñ¥[ 2016 ASCO©M"§Æ±æ¦ò"ªº¥[«ù.¤]¬O¦b·|®i²{³õ©Ò±oªº¸ê°T¶Ü? °²¦p¬Oªº¸Ü..((¦U¦ì§Ì¥SÌ..¤K¦~§Ü¾Ô¤w¸g¹L¤F¤C¦~¤F...)) ±i¸³©ÒºÙªº"²Ä¤T¥N¬Ì]"¬O§Q¥Î¤§«e©Ò´£ªº¤¤¬ã°|ªº§Þ³N¶Ü?? (¤¤¬ã°|«Ý±ÂÅvªº§Þ³N http://proj1.sinica.edu.tw/~otl/index.php?t=9&group_id=22&article_id=1457) |
|
|
·|û¡Gjm042310140224 µoªí®É¶¡:2015/7/24 ¤U¤È 05:20:33²Ä 353 ½g¦^À³
|
Cliff¤j ·PÁ±z¤@¸ôªº«ü¤Þ |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/7/24 ¤U¤È 02:32:31²Ä 352 ½g¦^À³
|
jm0423¤j¡G ³oÓ²£«~²Õ¦XÁÙ¦bÁ{§É«eªº¬ã¨s¡A©Ò¥H¨S¨ì¤@´ÁÁ{§É°µ§¹¡A¤£©öÁA¸Ñ¥¦¹ï¤HÅ骺°Æ§@¥Î¦³¦h¤j¡A°£«D¦Ñ¤â±q¥¦ªº¤Æ¾Çµ²ºc¦¡¥h±À´ú¡A³o¡A«D¤p§Ì¯à¤O©Ò¤Î¡C |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/7/24 ¤U¤È 02:10:25²Ä 351 ½g¦^À³
|
¥Ø«eªº¤F¸Ñ¥H°Ñ¥[201/6 ASCOªº¾÷·|³Ì¤j¡A©Ò¥H¥²¶·»°¦b2016/2µn¿ýµù¥U¡A³Ñ¤Uªº®Éµ{½Ð¦U¦ì¦Û¦æ¦^±À¦ôºâ¡C ¥Xª©¤j¡A±z¤§«e´£¨ìªº¤j¦ò¡A¬Ý¨Ó¦³§Æ±æ! |
|
|
·|û¡Gsummer10000119 µoªí®É¶¡:2015/7/24 ¤U¤È 01:48:11²Ä 350 ½g¦^À³
|
Cliff¤j¡G «D±`·PÁ¡I |
|
|
·|û¡Gwison3710140346 µoªí®É¶¡:2015/7/24 ¤W¤È 11:41:29²Ä 349 ½g¦^À³
|
·PÁ¤À¨É |
|
|
·|û¡Gjm042310140224 µoªí®É¶¡:2015/7/24 ¤W¤È 09:38:17²Ä 348 ½g¦^À³
|
·PÁÂCliff¤j ½Ð±ÐÀÀ¦üÁÞ§Üì·|¤£·|³y¦¨¸û¤jªº°Æ§@¥Î |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2015/7/24 ¤W¤È 09:18:37²Ä 347 ½g¦^À³
|
Cliff¤j ¨ØªA±z°l®Ú´N©³ªººë¯«¡I ¤]·PÁ±zªº»¡©ú¡I |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/7/23 ¤U¤È 10:03:42²Ä 346 ½g¦^À³
|
¥Xª©¤j¡B¤p©_¤j¡Bsummer¤j¡G ¤µ¦~4/13ªº¤@«hÁp¦X³øªº·s»D³X°Ý±i¸³¡A±i¸³¦bùرªº¤@¬q¸Ü¡G¡u²Ä¤T¥N¬Ì]¥¿¥Ñ¤¤¬ã°|¶}µo¤¤¡A³Ìªñ´Nnµoªí¡A³oÓ²£«~¦b»s³y§ÜÅé¤Wªº¯à¤O§ó±j¡C¤¤¬ã°|¹Î¶¤§â³Ì·s¤@¥N²£«~ªº§Üì§ó´«¡A·s¤@¥Nªº§ÜìÀÀ¦üÁÞ§Üì¦ý¤ñÁÞ§ÜìÁÙ±j¡A¥iÅý§ÜÅé¹ïÀù²ÓMªº§ðÀ»§ó±Ó·P¡C¡v¡]http://www.biomedical.org.tw/industrynews/industryNews_more.asp?nrO5ysiJx86jusyInplSioZJjV== ¡^§ä¤F¶W¹L¤TÓ¤ë¡A·d¤£²M·¡¨ì©³¡uÀÀ¦üÁÞ§Üì¡v¬O¤°»ò¡A¤]¤@ª½¥¼µ¥¨ì¤¤¬ã°|¦Aµoªí¹L¤°»ò¿Wªù·t¾¹¡A¤µ¤é¦b·|®i²{³õªº¤@®u½Í¡A²×©óÁŵM¶}®Ô¡C ¡uÀÀ¦üÁÞ§Üì¡v©Ò«ü´N¬O¦b¥h¦~12¤ë16¤é¦b¡u¤é²±µû¦ô³ø§ipart.2¡vª©´£¨ìªº¤@½g¤å³¹¡G¡uImmunogenicity study of Globo H analogues with modification at the reducing or non-reducing end of the tumor antigen¡v¡]http://www.ncbi.nlm.nih.gov/pubmed/25371992¡^¥Zµn©ó¡]http://pubs.acs.org¡^ on November 7, 2014¡C¦bGlobo HªºÁÙìºÝ»P«DÁÙìºÝ°µ×¹¢¡A¨Óµû¦ôGlobo H¬Û¦üª«ªº§K¬Ìì©Ê¡A¬Ýþ¤@ºØ×¹¢«áªºÅܺØGlobo H¥i¥H»¤µo¥X¸û¦h¹ï§ÜGHªº§ÜÅé¨Ó¡C ¸Ô¨£¡u2014/11/9 ¤U¤È 05:57:57¡v¡]OBI-822, OBI-833¥H¥~ªº²£«~¡^¤Î¡u2014/12/16¤U¤È04:31:20 ¡v¡]¤é²±µû¦ô³ø§ipart.2¡^ ³Ì«áªº¸ÉÅé¨Ì¿à«¬¬r±þ§@¥Î¡]CDCC¡^ªº¼Æ¾ÚÅã¥Ü¡AGH-F-DT¬O«ax¡]IgG/IgM:78.07¡^¡FGH-N3-DT¬O¨Èx¡]IgG/IgM:68.86¡^¡F F¬O¥[¤F¬t¨ìGH¤W±¡FN3«h¬O¥[Å|´á¡]Azido¡^¨ìGH¤W±×¹¢¡C³o¨Ç³£¬O°Êª«¸ÕÅç¡AY¯u¦³¤H¹ï¦¹¦³¿³½ìªº¸Ü§Ú¦A¶K¡A§_«h¤F¸Ñ³o¼ËÀ³¸Ó´N¨¬°÷¡C ·PÁ¬P±á¤j¡C |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/7/21 ¤W¤È 11:35:05²Ä 345 ½g¦^À³
|
·PÁÂCliff¤j, ÁöµM«Ü¦h¤p§Ì³£¦³¬Ý¨S¦³À´,«¢«¢«¢ ÁÙ¬OÁÂÁ±z Ãö©ó833³q¹LTFDAã³\Á{§É²Ä¤@´Á¶}©l¸ÕÅç ¤p§Ì¦³¨Ç·Qªk»P¤j®a¤À¨É(µLÃö¥GªÑ»ù,¤£·Q¬Ýªº¤H¥i¦Û¦æ¸õ¹L) 833²Ä¤@´ÁÁ{§É¸ÕÅç,¬ü°êFDA¦¦b¥h¦~©³¤w®Ö©w³q¹L ¥xÆW¾ã¾ã±ß¤F7Ó¤ë Áö»¡³q¹L¬O¦±ß,¦ý¦¤@ÂI³q¹L¹ï¯f¤HªºÅv§Q¬O¦nªº °_½X´£¨Ñµ¹¦X¥G±ø¥ó·Q¥[¤Jªº¯f¤H¦h¤F¤@¶µ¿ï¾Ü ¥t¥~,¹ï¯E¹©¾ãÓpµeªº±À°Ê¤]¬O¦nªº,°_½X¯àÅýpµeÄ~Äò©¹«e¨«... ¥u¬O¾ã¾ã±ß¤F7Ó¤ë,¨ÅÀù¥½´Á¯f¤Hªº¦s¬¡´Á¥§¡¤]¤j·§6Ӥ륪¥k ³o¼Ëªº³t«×,¹ê¦b¥O¤H¤£´±®¥ºû ±i¸³¿ï¾Ü®Ú¯d¥xÆW~~ ¦nªºÃĨä¹ê¥i¥H¿ï¾Ü¦b°ê¥~°µ.°ê¥~¥Í²£.±ÂÅv... °µ¤F³o¼Ëªº¿ï¾Ü·Q¥²¤]¬O¬°¤F¥xÆWªº¥Í§Þ·~ ¥Ñ°J§Æ±æ¥xÆWªº¥Í§ÞÀô¹Ò§OÅý¤H¥¢±æ ¯à¦h¤ä«ù¥xÆWªº³o¸s¥Í§Þ¶}¯îªÌ ¥[ªo!! |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2015/7/20 ¤U¤È 05:55:06²Ä 344 ½g¦^À³
|
·PÁÂCliff¤j¡I §â¨ÓÀs¥h¯ßÁ¿±o³o»ò²M·¡¡I |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/7/20 ¤U¤È 05:28:52²Ä 343 ½g¦^À³
|
1.¿ð¨ìªº833¼f®Öµ²ªG¡Aµ¥¨ì§Ö¡u¤¤¡v´»¡C¤£¹ï¡A¤p´»¤w¹L¡A¤T¤Ñ«á´N¬O¤j´»¤F¡I 2. MSKCC¤»ù¦hªG¾ðNCT01248273¤w¦³³ø§i¡G«áz¡C MSKCC¦h»ùÀù¯g¡uÁÞ§Üì+KLH¡vªº§Î¦¡¡G¤CºØÁÞ§Üì¦U¦Û»PKLHµ²¦X«á¦A²V¦b¤@¾¯¤¤§ë¤©¡A¹³¤jÂøÀí¡C ¡uVaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence¡v¡]http://clinicaltrials.gov/ct2/show/NCT00030823?term=heptavalent&rank=15 ¡^ ¤ñ¸û¨â²Õ¡G¡]¤C»ùÁÞ§Üì¤jÂøÀí¡^ Biological: Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine Biological: QS21 Study Start Date: March 2001 Study Completion Date: February 2009 ¨S§ä¨ì¥¦¥Î©ó¨ÅÀùªº³ø§i¡A¥u¦³¥Î©ó§Z±_Àù¡B¿é§ZºÞÀù¡B¸¡µÄÀù¯gªº³ø§i¡A¬Ý¥H¤U¨â«hµ²ªG¡G Preclinical¡G°Êª«¹êÅç Cancer Immunol Immunother. 2003 Oct;52(10):608-16. Epub 2003 Jun 17. ¡uA preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers.¡v¡]http://www.ncbi.nlm.nih.gov/pubmed/12811527 ¡^ Phase I¡]¤C»ù¤jÂøÀí¡^ Clin Cancer Res. 2007 Jul 15;13(14):4170-7. ¡uPilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer.¡v¡]http://www.ncbi.nlm.nih.gov/pubmed/17634545/ ¡^ ¥HGM2+Globo-H+Lewis Y +Tn(c)+ STn(c)+ TF(c)+ Tn-MUC1+ KLH and mixed with adjuvant QS21¥Î©ó§Z±_Àù¡B¿é§ZºÞÀù¡B¸¡µÄÀù¯g¡Aµ²ªG¦¨®Ä¤£¨Î¡ATn-MUC1¡GIgM and IgG¡A¨ä¥LIgM©~¦h¡A¦Ó¥BLewis Y¡]1¦ì¦³¤ÏÀ³¡^; GM2¡]2¦ì¦³¤ÏÀ³¡^ÀË°Q»{¬°¡AÅ餺¦³ªºB²ÓM³£³Q¾É¦V¥h²£¥Í§ÜKLHªº§ÜÅé¤F¡C ©ó¬O§â³o³o¨ÇÁÞ§Ü츲µå¦@¥Î¤@±øKLH¦¨¬°¤@±øÀsªº¦hªG¾ð¡A¤£¦A¦U§O±µKLH«á¦A²VÂø¦b¤@°_¡A§ï¨}¦¨Globo-H, Ley, STn, TF and Tn¤»ù¬Ì]¡A°w¹ï¨ÅÀù¤ÎÄáÅ@¸¢Àù¡A J Am Chem Soc. 2006 Mar 1;128(8):2715-25. ¡uPreparation and evaluation of unimolecular pentavalent and hexavalent antigenic constructs targeting prostate and breast cancer: a synthetic route to anticancer vaccine candidates.¡v¡]http://www.ncbi.nlm.nih.gov/pubmed/16492059/ ¡^ µ²ªG§ÜLey§ÜÅé¥Í¦¨¤ÏÀ³¤£¨Î¡A©ó¬O§ï©¶©öÂá¥h°£Ley,¥[¤WGM2«á±o¨ì¸û¨Î§ÜÅé¤ÏÀ³¡C ¦¨¤F¤U±³o¤@Ó¡G °Êª«¹êÅçJ Am Chem Soc. Jul 8, 2009; 131(26): 9298¡V9303. ¡uFrom Synthesis to Biologics: Preclinical Data on a Chemistry Derived Anticancer Vaccine¡v¡]http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2716484/¡^ ®ÄªG¤£¿ù¡C±µ¤U¨Ó¦³¤F³oÓPhase IªvÀø§Z±_Àù¡B¿é§ZºÞÀù¡B¸¡µÄÀù¯g, ¤£¬OªvÀø¨ÅÀùªº¡A¨S§ä¨ì°w¹ï¨ÅÀùªº¡C ¡uUnimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission¡v Phase I¡]http://clinicaltrials.gov/ct2/results?term=Unimolecular+Pentavalent&Search=Search¡^ ³oºØ¤»ù¦hªG¾ðªº¤@´Á³ø§i¡G²³æ§ãn±Æª©²M´·¡G ¡]http://www.google.com.tw/url?sa=t&rct=j&q=&esrc=s&source=web&cd=2&cad=rja&uact=8&ved=0CCUQFjABahUKEwiPyImzmunGAhVCFJQKHbBxBqE&url=http%3A%2F%2Fwww.poster-submission.com%2Fcdrom%2Fdownload_poster%2F37%2F27248%2F890P&ei=5aWsVc_BI8Ko0ASw45mICg&usg=AFQjCNGCjn1aKkwodGjUUJjUhfxHuWkJGg&bvm=bv.98197061,d.dGo ¡^ 2014ªÑªF·|µ²§ô«e°Ý±i¸³¹ï³oºØ¦h»ùÁÞ§Üì¬Ì]ªº¬Ýªk¡A¥Lı±o¦b¹ê»ÚªºÀù²ÓMªí±§Üìªí²{¤£¬O¦p¦¹¡A¨¥¤U¤§·N¥L®¼³æ§Üì»s¾¯¡C¡]³oÅãµM¬O°Ý²z¾v®v¡A§Ú¸Ó¤£¸Ó²z¾v¤F¡H¡^ ¦³¿³½ìªº¤H¥i¥HŪ¤U±³o¬q¤å¦r¡A´£¨ì¤F¥H¤W±ÔzªººtÅÜ¡A¬Ý§¹´N¤ñ¸û²M·¡¡]2012¦~¡^¡GJ Carbohydr Chem. 2012; 31(3): 143¡V186. ¡uRecent Development in Carbohydrate Based Anti-cancer Vaccines¡v¡]http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3312792/¡^ ¡]ºK¿ý¡^ A preclinical study with heptavalent KLH-conjugate vaccine consisting of seven TACAs, including GM2, Globo H, Ley, TF(c), Tn(c), STn(c) and glycosylated MUC1, demonstrated that mice immunized with such vaccine generated antibodies against all TACAs except GM2.[123] High titers of both IgM and IgG were observed against five antigens except Ley that induced IgM antibody only. In addition, the antibodies generated recognized tumor cells well. In clinical trials,[124] the heptavalent vaccine plus QS21 adjuvant was tested in 9 patients with epithelial ovarian, fallopian tube, or peritoneal cancer in second or greater complete clinical remission. Se |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/7/20 ¤U¤È 04:56:10²Ä 342 ½g¦^À³
|
¯E¹©¡G¥»¤½¥q¬ãµo¤¤¤§·s¥@¥NÀù¯gªvÀø¬Ì](OBI-833)³q¹L»OÆW½Ã¥ÍºÖ§Q³¡¤§¤HÅéÁ{§É¸ÕÅç¼f¬d(IND)¡C 2015/07/20 16:09 ¹d¦ëºô ·s»D¤¤¤ß ¹d¦ëºô·s»D¤¤¤ß ²Ä¤G±ø¡@²Ä51´Ú 1.¨Æ¹êµo¥Í¤é:104/07/20 2.¤½¥q¦WºÙ:¥xÆW¯E¹©¥Í§ÞªÑ¥÷¦³¤½¥q 3.»P¤½¥qÃö«Y[½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q]:¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î 5.¶Ç¼½´CÅé¦WºÙ:¤£¾A¥Î 6.³ø¾É¤º®e:¤£¾A¥Î 7.µo¥Í½t¥Ñ:¥»¤½¥q¬ãµo¤¤¤§·s¥@¥NÀù¯gªvÀø¬Ì](OBI-833)³q¹L»OÆW ½Ã¥ÍºÖ§Q³¡¤§¤HÅéÁ{§É¸ÕÅç¼f¬d(IND)¡C 8.¦]À³±¹¬I:µL 9.¨ä¥LÀ³±Ô©ú¨Æ¶µ: (1)¬ãµo·sÃĦWºÙ©Î¥N¸¹¡G·s¥@¥NÀù¯gªvÀø¬Ì](OBI-833) (2)¥Î³~¡G¬°Globo H¨t¦C¦hÁÞÅé¬Ì]¡A¥Î©óÀù¯gªvÀø¡C (3)¹wp¶i¦æ¤§©Ò¦³¬ãµo¶¥¬q¡GÁ{§É¤@´Á¡B¤G´Á¡B¤T´Á¸ÕÅç¡B ·sÃĬdÅçµn°O¼f¬d¡C (4)¥Ø«e¶i¦æ¤¤¤§¬ãµo¶¥¬q¡G A.´£¥X¥Ó½Ð/³q¹L®Öã/¤£³q¹L®Öã¡G¤HÅéÁ{§É¸ÕÅç¼f¬d (IND)³q¹L®Öã¡C B.¥¼³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥iªÌ¡A¤½¥q©Ò±Á{¤§·ÀI¤Î ¦]À³±¹¬I¡G¤£¾A¥Î¡C C.¤w³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥iªÌ¡A¥¼¨Ó¸gÀç¤è¦V¡G¤£¾A¥Î¡C D.¤w§ë¤J¤§¬ãµo¶O¥Î¡G·s¥x¹ô81,386¤d¤¸¡C (5)±N¦A¶i¦æ¤§¤U¤@¶¥¬q¬ãµo¡G A.¹wp§¹¦¨®É¶¡¡G¹wpÁ{§É¤@´Á¸ÕÅ禬®×¤H¼Æ26¤H¡A ©ó¦¬®×§¹¦¨«á¥Ó½Ð¶i¤JÁ{§É¤G´Á¸ÕÅç¡C B.¹wpÀ³t¾á¤§¸q°È¡G¥»¤½¥q¶i¦æÁ{§É¤@´Á¸ÕÅç®É µL¶·¤ä¥Iì±ÂÅv¹ï¶H¤¤¥¡¬ã¨s°|±ÂÅvª÷¡C (6)·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¥¼«OÃÒ¤@©w¯à¦¨¥\¡A ¦¹µ¥¥i¯à¨Ï§ë¸ê±Á{·ÀI¡A§ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C TOP |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/7/20 ¤U¤È 04:49:14²Ä 341 ½g¦^À³
|
ӪѡG¯E¹©(4174)Àù¯gªvÀø¬Ì]OBI-833³q¹L½ÃºÖ³¡¤HÅéÁ{§É¸ÕÅç¼f¬d(IND) 2015/07/20 16:14 °]°T§Ö³ø ½s¿è³¡ ¡i°]°T§Ö³ø¡þ½s¿è³¡¡j¯E¹©(4174)¬ãµo¤¤¤§·s¥@¥NÀù¯gªvÀø¬Ì](OBI-833)³q¹L»OÆW½Ã¥ÍºÖ§Q³¡¤§¤HÅéÁ{§É¸ÕÅç¼f¬d(IND)¡A¥Ø«e¤w§ë¤J¤§¬ãµo¶O¥Î·s¥x¹ô81,386¤d¤¸¡A¹wpÁ{§É¤@´Á¸ÕÅ禬®×¤H¼Æ26¤H¡A©ó¦¬®×§¹¦¨«á¥Ó½Ð¶i¤JÁ{§É¤G´Á¸ÕÅç¡C |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2015/7/20 ¤W¤È 10:18:47²Ä 340 ½g¦^À³
|
MSKCC¤»ù¦hªG¾ð¡GNCT01248273 ¦b§Z±_Àù¤@´Á http://www.google.com.tw/url?url=http://www.poster-submission.com/cdrom/download_poster/37/27248/890P&rct=j&frm=1&q=&esrc=s&sa=U&ved=0CCQQFjAEahUKEwjrx9utvejGAhXMKJQKHbEnD2g&usg=AFQjCNH576Qatqt0Xpo74zJ9fg1mD2sfxQ |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2015/7/20 ¤W¤È 10:18:43²Ä 339 ½g¦^À³
|
°e³ø¤j: ©êºp 888 »~´Ó¬° 833 |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2015/7/20 ¤W¤È 09:52:16²Ä 338 ½g¦^À³
|
°e³ø¤j: À³¸Ó¬O°¨°º³q¹L¥Í§ÞÂåÃÄ°ê®a«¬¬ì§ÞpµeNRPBªº¨ºÓ³æ§Ü, «D833. ¸Ô±¡½Ð¬Ý ·¨¨|¥¿°|ªøªº®Ñ¡¨¦b§ÚÂ÷¥h¤§«e¡¨ P. 080-082. °¨°º»P¯E¹©ªº¦X§@¤]¦³´yz. ¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/7/19 ¤W¤È 01:12:15²Ä 337 ½g¦^À³
|
103¦~ªÑªF·|¦~³ø.. (2) ·s¥@¥NÀù¯gªvÀø©Ê¬Ì]OBI-833: ¦¹¤@·s«¬Àù¯gªvÀø©Ê¬Ì]¡A«Y¥Ñ¤¤ ¬ã°|§ÞÂà¦Ó¨Ó¡A«ö·Ó³W¹º¡A±N°w¹ïÃøÀøÀù¯g¦p¯ØŦÀù¡BGÀù¡B¤j¸z Àù¤ÎªÍÀù¯f¤H®i¶}Á{§É¸ÕÅç¡COBI-833 ¤w¦b103 ¦~12 ¤ëÀò±o¬ü°ê¹ «~ÃĪ«ºÞ²z§½(FDA)¤@´ÁÁ{§É¸ÕÅç³\¥i(IND)¡A¥»¤½¥q¥ç¤w¦V¥xÆW¹ «~ÃĪ«ºÞ²z¸p(TFDA)´£¥XIND ¥Ó½Ð¡A¹wp¥i©ó104 ¦~¤¤±o¨ì®Öã¡C ©Î³\8¤ë¤]·|¦³®ø®§.. Cliff¤j..«D±`·PÁÂ.. |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/7/18 ¤U¤È 11:41:18²Ä 336 ½g¦^À³
|
¦U¦ì¤j©êºp.¤pªº^¤å¤£¦æ.³s±j°êªº¤å³¹¤]¬Ý¤£¤ÓÀ´.. «ö. http://www.most.gov.tw/acc/public/Data/522512292871.pdf P.5-P.6 "DBPR114"©M"Àù¯gªvÀø©Ê³æ®è§ÜÅé" ¬O¨â½X¨Æ.«ç©ñ¤@°_."DBPR114"¬O¦³¨S©M¯E¹©¦X§@°Ú?? |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/7/18 ¤U¤È 10:52:07²Ä 335 ½g¦^À³
|
http://www.xinyaohui.com/news/201507/18/6399.html «GÂI¦b.. 6.¦h¹v点¿E酶§í¨î剂DBPR114¥i§í¨î¦hÏú肿½F |
|
|
·|û¡GRussell10140734 µoªí®É¶¡:2015/7/18 ¤U¤È 12:56:41²Ä 334 ½g¦^À³
|
½Ðª©¤W¦U¦ì¯E¤Í̱ÀÂË...¥x¤¤ÁxºÞÀùÅv«ÂÂå®v...ÁÂÁ «æ.... |
|
|
·|û¡Gµ½¤H10137888 µoªí®É¶¡:2015/7/18 ¤U¤È 12:14:52²Ä 333 ½g¦^À³
|
Palbociclib in Hormone-Receptor¡VPositive Advanced Breast Cancer BACKGROUND Growth of hormone-receptor¡Vpositive breast cancer is dependent on cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), which promote progression from the G1 phase to the S phase of the cell cycle. We assessed the efficacy of palbociclib (an inhibitor of CDK4 and CDK6) and fulvestrant in advanced breast cancer. METHODS This phase 3 study involved 521 patients with advanced hormone-receptor¡Vpositive, human epidermal growth factor receptor 2¡Vnegative breast cancer that had relapsed or progressed during prior endocrine therapy. We randomly assigned patients in a 2:1 ratio to receive palbociclib and fulvestrant or placebo and fulvestrant. Premenopausal or perimenopausal women also received goserelin. The primary end point was investigator-assessed progression-free survival. Secondary end points included overall survival, objective response, rate of clinical benefit, patient-reported outcomes, and safety. A preplanned interim analysis was performed by an independent data and safety monitoring committee after 195 events of disease progression or death had occurred. RESULTS The median progression-free survival was 9.2 months (95% confidence interval [CI], 7.5 to not estimable) with palbociclib¡Vfulvestrant and 3.8 months (95% CI, 3.5 to 5.5) with placebo¡Vfulvestrant (hazard ratio for disease progression or death, 0.42; 95% CI, 0.32 to 0.56; P<0.001). The most common grade 3 or 4 adverse events in the palbociclib¡Vfulvestrant group were neutropenia (62.0%, vs. 0.6% in the placebo¡Vfulvestrant group), leukopenia (25.2% vs. 0.6%), anemia (2.6% vs. 1.7%), thrombocytopenia (2.3% vs. 0%), and fatigue (2.0% vs. 1.2%). Febrile neutropenia was reported in 0.6% of palbociclib-treated patients and 0.6% of placebo-treated patients. The rate of discontinuation due to adverse events was 2.6% with palbociclib and 1.7% with placebo. CONCLUSIONS Among patients with hormone-receptor¡Vpositive metastatic breast cancer who had progression of disease during prior endocrine therapy, palbociclib combined with fulvestrant resulted in longer progression-free survival than fulvestrant alone. (Funded by Pfizer; PALOMA3 ClinicalTrials.gov number, NCT01942135.) |
|
|
·|û¡GQQ10140589 µoªí®É¶¡:2015/7/16 ¤U¤È 05:07:19²Ä 332 ½g¦^À³
|
Cliff¤j: ·PÁ±z ! ±z©Ò´£¨Ñªº¸ê®Æ¦³°lÂܳø¾É¥X¨Ó, ¦ý¤º®e¤£¥X±z©Ò³¯zªº http://tw.medsci.cn/shownews.asp?id=703e1869395 |
|
|
·|û¡GWalden10140608 µoªí®É¶¡:2015/7/16 ¤W¤È 01:02:15²Ä 331 ½g¦^À³
|
Æg! ÁÂÁÂCliff ¤j¤j~ |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/7/15 ¤U¤È 01:46:25²Ä 330 ½g¦^À³
|
¤@½g7/13¥Zµnªº¼öÄËÄ˪º³ø¾É¡A¦ê³s¤F§A§Ú©Òª¾ªºGlobo H¡AÅý¬ã¨sªÌ¦Û¤v¤]·P¨ìÅå³Y¡C ·s»D³ø¾É¡G¡uCancer discovery links experimental vaccine and biological treatment¡v¡]http://news.wisc.edu/23889¡^¡A¤@¦ìWisconsin-Madison¤j¾Ç¥Í§Þ±Ð±ÂRonald Raines©Ò°µªº¬ã¨sµo²{¡A§ïÅܤÀ¸Ñ®Ö¿}®Ö»Ä¡]RNA¡^ªº®Ö¿}®Ö»Ä¤À¸Ñ»Ã¯À¡]Ribonuclease¡^¡A·|¹ïÀù²ÓM¦³¿ï¾Ü©Êªº±M¤@¬r±þ§@¥Î¡A¦Ó¶i¤@¨B¬ã¨s«oµo²{¡A³o¼Ëªº¬r±þ§@¥Î³ºµM»P¥¿¦b¬ãµo¤¤ªºÀù¯gªvÀøÃĪ«¦³ÃöªºGlobo H¡AÅý¥L»P¦P¦nÌ·P¨ìÅå³Y¡C Rainesªø´Á¬ã¨s®Ö¿}®Ö»Ä¤À¸Ñ»Ã¯À¡A¥L©ó1998¦~µo²{¦p¦ó§ïÅÜ×¹¢®Ö¿}®Ö»Ä¤À¸Ñ»Ã¯À¡A¥i¨Ï¨ä¤£©ö¦b¤HÅéÅ餺³Q¼vÅT¦Ó¥¢¥h¬¡©Ê¡A¥i¥HÄ~Äò¦aµo´§¨ä¤À¸Ñ®Ö¿}®Ö»Äªº¥\¯à¡AµM«á«Ü§Ö¦a¥L¤Sµo²{³o¨Ç³Q¥L×¹¢§ïÅܫ᪺Åܺخֿ}®Ö»Ä¤À¸Ñ»Ã¯À¡A³º¹ïÀù²ÓM¦³¬r±þªº§@¥Î¡A¦ý¡A¬°¤°»ò¡H ¥i¯à»{¬°¦³µo®i¦¨§ÜÀùÃĪ«ªº¼ç¤O§a¡H¥L±µµÛ³z¹LWisconsin®Õ¤Í¬ã¨s°òª÷·|¡]WARF¡^±N¥¦¦¨¬°±M§Q¡A»PWisconsin-Madison¤j¾Ç¥t¤@¦ì¤Æ¾Ç®aLaura Kiessling¦@¦P³Ð¿ìQuintessence Biosciences¡A±qWARF§ÞÂà±M§Q«á¡A¶}©l¦bWisconsin¤j¾Çªº Carbone Cancer Center ¤Î¥ð¤h¹yªºMD Anderson Cancer Center°µ¦´Áªº®Ö¿}®Ö»Ä¤À¸Ñ»Ã¯À¤HÅé¸ÕÅç¡C ¥Ø«e±o¥ý¤F¸Ñ¬°¦ó®Ö¿}®Ö»Ä¤À¸Ñ»Ã¯À¹ïÀù²ÓM±¡¦³¿WÁé¡]±M¤@©Ê¡^¡H¬°¤FŲ§O¨ì©³¬O²ÓMªí±ªºþ¤@Óºc³yÀ°§U³oӻïÀ¶i¤J²ÓM¡ARaines©ó¬O¥Î¯S®í´¹¤ù¿zÀˤF²ÓMªí±ªº264ºØºc³y¡Aµ²ªGµo²{³º¬OGlobo H³oÓÁÞ§Üì¡C¡]°O±o§a¡H¥¦¥uªí²{¦bÀù²ÓMªí±¡A¤£¦b¥¿±`²ÓMªí±ªí²{¡AY¹ï¥¦¦³±M¤@©Ê®É¡Aªí¥Ü¤£·|¥h¼vÅT¨ì¥¿±`²ÓM¡^¡CRaines·P¨ìÅå³Y»P°ª¿³¡A¦]¬°Globo H¬O¤@ºØ¤w¦¨¬°¬ãµo¤¤§ÜÀùÃĪ«ªºÁÞ§Üì¡A¸ò¤@¯ëªºÁÞ§Ü쪺·N¸q¦ÛµM¤£¦P¡C¡]¬ãµo¤¤§ÜÀùÃĪ«¬O«ü«¥Ìªº822¶Ü¡H®Ú¾Ú§Ú¬Ýì¤åªº·Pı¡A¦ü¥G«ü¦VMSKCCªº¡u¦hªG¾ð¡v§ÜÀù¬Ì]ªº¾÷·|¤j¨Ç¡A¦hªG¾ð¤»ùªº¡GNCT01248273¡F¤C»ùªº¡GNCT01349647¡FMSKCC¤@ª½¹ï³oÃþ²Õ¦X²`±¡¤£§Ñ¡^ ¥LÁÙ¸òMSKCCÁÞ¦X¦¨¤j¦ÑSamuel Danishefsky¤@°_¬ã¨s¡Aµo²{§â¨ÅÀù²ÓMªí±ªºGlobo H ´î¤Ö®É¡A´N¥i¥H´î¤Ö³Q®Ö¿}®Ö»Ä¤À¸Ñ»Ã¯À¨n¤W¡A¥L·P¨ì¿³¾Ä¡A¹ï©óÔ¿ïÃĪ«ªº§@¥Î¼Ò¦¡¦³¤FÂI½ü¹ø¡C¡]³oÓÔ¿ïÃĪ«§Úı±o¬OQBI-139¡G¡uhttps://www.clinicaltrial.gov/ct2/show/NCT00818831?term=NCT00818831&rank=1 ¡v°O±o¶i¥h«áÄ~ÄòÂI¿ï¡uÄ~ÄòÂsÄý¸Óºô¯¸¡v¤~¬Ý±o¨ì¡^¡C ³o¶µ¬ã¨s©Ò¤Ä°Ç¥Xªº¹Ï¹³¬O¡A®Ö¿}®Ö»Ä¤À¸Ñ»Ã¯À¦b¤HÅ餺¨µÅÞ¡A´M§äÀù²ÓMªº°T®§¡ARaines»¡¡u§ÚÌ¥¿§V¤O¦a·Q§â¤p¹«¤¤ªº³o¶µºÊ´úªº¾÷¨î²M·¡¦aªí²{¥X¨Ó¡A¦ý¥Ø«e©|µLª½±µÃÒ¾Ú¡C¡v ³Q°Ý¨ì¬O§_¦V¨ä¥L¬ì¾Ç®a©Ò°µªº¸ÕÅç¤@¼Ë¡A¥H¬Ì]¤è¦¡¨Ó¶}±Ò¹ïGlobo Hªº§ðÀ»¡HRaines»¡¡A¥L̦b´M§ä¤@ºØ²³¤£¦Pªº§K¬Ì¤è¦¡¡A¥H¥ý¤Ñ©Ê§K¬Ì¡]innate immunity¡^¡]µù¡^¤£»Ýn¥Õ¦å²y¡B§ÜÅ餶¤J´N¥i¥H§ÜÀù¡A¥u»Ýn¤@ӻïÀ»P¤@ÓÁÞ§Üì¡C ¾ãÓ§¹¾ãªº¬ã¨s³ø§i¦b³o¸Ì¡A¯dµ¹¦³¤ß¡B¦³¹ê¤Oªº¤H©µ¦ù¾\Ū¡C 2015/07/13¡G¡uHuman Cancer Antigen Globo H Is a Cell-Surface Ligand for Human Ribonuclease 1¡v ¡]http://pubs.acs.org/doi/pdf/10.1021/acscentsci.5b00164 ¡^ µù¡G §K¬Ì¨t²Î¼s¸q¦a»¡¥]¬A¥ý¤Ñ©Ê§K¬Ì¤O(innate immunity)©M¾AÀ³©Ê§K¬Ì¤O(adaptive immunity)¡A«eªÌ¬O«ü«æ©Ê¤ÏÀ³ª« (acute phase proteins),¸ÉÊ^(complement)¤Î§]¾½²ÓM(phagocytes)µ¥¡A«áªÌ¬O«ü²O¤Ú²ÓM(lymphocytes)¡A¤]´N¬O¯U¸qªº§K¬Ì¨t²Î¡A³o¤GªÌ¤§¶¡ªº®t§O¦b©ó¯S²§©Ê(specificity)¤Î°O¾Ð©Ê(memory)¡C©Ò¿×(¾AÀ³©Ê)§K¬Ì¨t²Î¯à°w¹ï¬Y¯S©w§Üì¡A²£¥Í¨ã§Üì¯S²§©Êªº§K¬Ì¤O¡A¨Ã¥B¨ã¦³°O¾Ð§@¥Î¡A²Ä¤G¦¸¤ÏÀ³·|¤ñ²Ä¤@¦¸¤ÏÀ³§Ö¥B°ª¡C¬Û¹ïªº¥ý¤Ñ©Ê§K¬Ì¤O¡A¨C¦¸ªº¤ÏÀ³µ{«×³£¤@¼Ë¡A¥ý¤Ñ©Ê§K¬Ì¨t²Î©M¾AÀ³©Ê§K¬Ì¨t²Î¤§¶¡·|¤¬¬Û¼vÅT¡C¥H¤WºK¿ý¦Û¦¨¤j·L§KÁ¿¸q¡C¡]http://www.ncku.edu.tw/~microbio/course/teacher/lei/lei1.htm ¡^ «á°O¡G ¶}©l¬Ý¨ì¤£¦P©óMSKCC»P¯Î°|ªø¹Î¶¤µoªí¦³Ãö©óGlobo Hªº§ÜÀù¬ã¨s¡AÁöµM¤£¬Oª½±µ¬ÛÃö¡A¦ý¥un²³®a³vº¥»EµJ©ó¦¹¡A¥¼¨Ó¡A¤×¨ä822Y¸Ñª¼¦¨ªG«GÄR®É¡AGlobo H¨t¦CÀù¯gªvÀø¾ÇÀ³¸Ó·|¶V¨Ó¶V¼öªù¡C ¥H¤WĶ¤å¤º®e¡A¦Ò¶q¨ì¤¤¤åªº£v£°£½¥i¯àµLªk¦bª©¤W§e²{¡A¼È§ï¦¨¡u»Ã¯À¡v¡A¨ä¹ê´N¬O¡u¨»¨C¡v¦r¡]¥ª¨»¥k¨C¨Ö¦b¤@°_¡^¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/7/14 ¤U¤È 11:40:37²Ä 329 ½g¦^À³
|
¦Ñ¥v¤j 1ÁÂÁ§A´£¨Ñ«D±`«n¸ê°T,Ó¤H»{¬°¥¼¨Ó¹ï§K¬Ì¬ÛÃöªºÀø®Äµû¦ôÀ³·|¨«¦VirRC 2¤µ±ß¬ü°ê¥Í§Þ«ü¼Æ¦A³Ð¾ú¥v·s°ª¤Î»P¥h¦~¬Û¤ñ¥xÆW¯E¹©Á{§É¶i®i©¹«e±À¶iªÑ»ù¤Ï¦Ó¦b§CÀÉ, ¦æ¦¨Âù«IÂ÷ªº²{¶H,³oºØÂù«IÂ÷ªº²{¶H¤£¤[¤@©w·|ÁÙµ¹¯E¹©À³¦³ªº»ùÈ 3¤K¤ë«Å§G¸Ñª¼,©u½u¨«¥Â½´»P¶i¤J¥ß¬îªº¬î¦¬®É¸`¯E¹©±N¤£¦A©t³æ 4·í¤â¤WµL¯E¹©ªÑ²¼¤S¹J¨ì¤@ªÑÃø¨Dªº®ÉÔ¤~·|µo²{¯E¹©ªº¬Ã¶Q §K¬Ì¬ÛÃöªºÀø®Äµû¦ô(immune-related response criteria, irRC) http://tw.medsci.cn/shownews.asp?id=cfe6109990e |
|
|
·|û¡G¦Ñ¥v10140531 µoªí®É¶¡:2015/7/14 ¤U¤È 01:47:56²Ä 328 ½g¦^À³
|
§N§N²M²M...... Ū¨ì§K¬ÌÀøªkirRC¼Ð·Ç¤UªºirPFS»PRECIST1.1ªºPFS®t²§ http://annonc.oxfordjournals.org/content/early/2012/08/01/annonc.mds213.full ¥²ªv§´ªºIpilimumab(CTLA-4)°w¹ï«D¤p²ÓMªÍÀù»P¤p²ÓMªÍÀù¶i¦æªº¤G´ÁÁ{§É¡A´N¦³¦P®É¤ñ¸ûirPFS»PPFSªº®t²§¡ANSCLCªºirPFS»PPFS¤À§O¬O5.7»P5.1Ó¤ë(Pȳ£¹LÃö)¡AED-SCLCªºirPFS»PPFS¤À§O¬O6.4(P=0.03¹LÃö)»P5.2Ó¤ë(P=0.37¨S¹LÃö)¡C§@ªÌµ²½×»¡¨ì¡A³oºØ·sªºµû¦ô¼Ð·Ç¦]¬°¦¹¦¸Á{§É°Ñ¦Ò¤H¼Æ¤£°÷¦h¤´¦³«ÝÀËÅç¡A¶i¦æ¤¤ªº¤j³W¼ÒªÍÀù¤T´ÁÁ{§É¡A¥¼¨Óµ²ªGÀ³¸Ó¥i¥H¿Å¶qirPFS¬O§_»POS¦³§ó¦nªºÃöÁp©Ê¡C³o½g¤å³¹µoªí¦b2012¦~5¤ë¡A§Ú¥h§ä¤FIpilimumab¨ä¥L«áÄòÁ{§É¡Aµo²{¦³¦hÓÁ{§ÉªºPrimary Outcome Measures»PSecondary Outcome Measures¦P®É±NRECIST1.1»PirRC¦C¤J¡A¤@´Á¤G´Á¤T´ÁÁ{§É¬Ò¦³ ¥h¦~11¤ë½÷·ç»PÀq§J28.5»õ¬üª÷ªºPD-L1¦X§@«´¬ù(ñ¬ùª÷8.5»õ¬üª÷¡A¦@¦Pt¾á¬ãµo¶O¡B¦@¨ÉÀ禬)¡AÁ{§É¦WºÙ¥sJavelin¡AÃĪ«¦WºÙAvelumab¡A¤@´Á¤j³W¼ÒÁ{§É¦¬®×1570¤H¡A¥]§t¦hºØÀù¯g±wªÌ(¨Ö±ÄirRC)¡A¤j³W¼Ò¶i¦æ¤@´ÁÁ{§É¦P®É¡A¤]±q¤¤¬D¿ï¾A¦Xªº¾AÀ³¯g¥H¶i¦æ¤U¤@¨BÁ{§É¡A¦p¥h¦~Q3¶}©l°w¹ï«D¶Â¦â¯À½Fªº¥Ö½§Àù¤G´ÁÁ{§É(¨S¦³±ÄirRC)¡A¤µ¦~ª½±µ¶i¦æ«D¤p²ÓMªÍÀùªº¤T´ÁÁ{§É(¨S¦³±ÄirRC) §Ú¤£ª¾¹DFDA²{¦b¯à§_±µ¨ü³æ¾ÌirRC¨Ó¥Ó½ÐÃÄÃÒ¡A¦ý¦¹µo®iÁͶÕÀ³¸Ó¹ïªü¹©¬O¦³§Qªº¡C¥¼¨Ó822§ó¶i¤@¨BªºÁ{§É¦b±Æ°£Globo³±©Ê¡A¥B¦P®É±ÄirRCµû¦ô¼Ð·Çªº±¡ªp¤U¡AirPFS«Ü¥i¯à·|¤ñ²{¦bªºÁ{§É°ª¥X³\¦h ¥t¥~¡A°ê¥~¤j¼t§Ö³t¥B¤j¤âµ§¶i¦æNÓÁ{§É¡Aªü¹©¦pªG°í«ù¦Û¤v®IÀYµw·F¡A¤@Ó¤@ÓºCºC¨Ó¡A®£±N¿ù¥¢«Ü¦h¾÷·| |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2015/7/14 ¤U¤È 01:13:23²Ä 327 ½g¦^À³
|
»{¦P¥xÁÞ¤jªº¬Ýªk ¤µ¤é ¯E¹©¶qÁY»ùà ¤H®ð°h´² |
|
|
·|û¡G¤p¶§10139627 µoªí®É¶¡:2015/7/14 ¤U¤È 12:12:41²Ä 326 ½g¦^À³
|
¥Í§ÞªÑ²{¦b¦pªG¨S¦³¤j§Q¦h¬OµLªk¨ë¿EªÑ»ù¤Wº¦ªº¡A²¦³º°ê¤º §ë¸ê¤H¸ò°ê¥~§ë¸ê¤H©úÅ㪺¤£¤@¼Ëªº¡A°ê¥~§ë¸ê¤H¤ñ¸ûª`« ¥¼¨Ó¤½¥qµo®iÄ@´º¡A°ê¤º§ë¸ê¤H¤ñ¸ûª`«EPSÀò§Q¡A©Ò¥H ¥xªÑ»EµJ²{¦b³£©ñ¦b¹q¤lªÑ¨¤W¤Î¤@¨Ç¦³Àò§Qªº¶Ç²£ªÑ¨¤W ©Ò¥H¥Í§ÞªÑ¦pªGn¤jº¦¤@©wn¦³¤@®a»âÀY¦Ï¥X¨Ó±a°Ê¤~¯à ¨ë¿EªÑ»ù¡A¦pªG¯E¹©¸Ñª¼µ²ªG¤£¦p¹w´Á§Ú·Q¥H«á¥Í§ÞªÑ§ó·|Åý °ê¤º§ë¸ê¤H³è±ó¡A©Ò¥H²{¦bªº§ë¸ê¤H¤w¸g³QÂûÀnÀ~¹L¤@¦¸ ¤£·Q¦A¨ü¶Ë®`¥HP²{¦bªº°ê¤º§ë¸ê¤H¶R½L»EµJ³£©ñ¦b¦³EPS ªº¹q¤lªÑ¨¤W¤Î¤@¨Ç¦³EPSªº¶Ç²£ªÑ¨¤W¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/7/14 ¤W¤È 11:23:06²Ä 325 ½g¦^À³
|
¦p¦ó¬D¿ï¦³¼ç¤Oªº¥Í§Þ¤½¥q 1 ÁקK§ë¸ê¤@ÁûÃľi¤@®a¥Í§Þ¤½¥q (¨S¦³¥¢±Ñªº°j±ÛªÅ¶¡) 2 ¬ãµoÃĪ«¬O¥¼¨Ó¥D¬yªº§K¬ÌÀøªk,¸gÀç¹Î¶¤¤H¤~n¦h,¸gÅçnÂ×´I,¦b¬ü°ê¦³¦¨¥\¸gÅç 3 ÃÄÃÒ¤£¥Nªí¥¼¨ÓÀò§Q,ÃÄÃÒn¦³Ävª§¤O»P¯à·m¹¥þ²y¥«³õ¬°¥Dn¦Ò¼{ 4 ¬ãµoÃĪ«n¦³°ª±ÂÅvª÷ªº¼ç¤O,¥¼¨Ó¾P°âÅv§Qª÷Royalty n°ª ,¤ä¥Iµ¹¥L¤HÅv§Qª÷n§C 5 ¬ãµo²£«~pipeline¶V¦h¤¸¶V¯à°§C¬ãµo¥¢±Ñ¹ïªÑªF©Ò³y¦¨ªº½ÄÀ» ¥Í§Þ¤½¥qpipeline¶V¦h¤¸+°t¦XªÑªF¦Û¤v·ÀIºÞ²z ¤~¯à§â§ë¸ê·ÀI°¨ì³Ì§C 6 ¬ãµoªº²£«~¥¼¨Ó¨Ï¥Î¤H¤f·|¤£Â_¼W¥[,¥¼¨ÓÃÄ»ù·|¶V¨Ó¶V¶Q (¦p¬ãµoÀù¯gªº¥Í§Þ¤½¥q) 7 ¬ãµoªº²£«~n¦³¬ì¾Ç²z½×°ò¦,n¦³¯S®í¼Ð¹v©Ê,¯S®í§ÜÀù¾÷¨î¤Î¦³Äè·ÀÀù¯g·F²ÓMªº¼ç¤O 8 °Æ§@¥În§C,Àø®Än¦n»P¥Í¬¡«~½èn¦n,ÃĪ«¬I¥´n¤è«K,¬I¥´ªº®É¶¡¶¡¹jn¤ñ²{¦³ªºÃĪø, ®a¤H·ÓÅUÀ£¤On³Ì§C 9 ¤w¦³¬ãµoªº²£«~¶i¤J¤T´ÁÁ{§É,«áÄò·|¦³·s²£«~¶i¤J¤@¤G¤T´ÁÁ{§É,·½·½¤£µ´,®Ú²`ªKZ 10 ²£«~n¯à¦b²Å¦X«~½è³W©wn¨D¤U¯à¥H§C¦¨¥»¤j¶q¶q²£ 11¦³Ä@´º»P»ùÈÆ[,¥¼¨Ó¦³¨ÖÁʧO®a¥Í§Þ¤½¥qªº¹ê¤O 12±M§Q¯àµn¦bµâ¬õ¦â¤p¥Uorange book listableªº±M§Q¥NªíIP°÷±j,±M§Qn¯àdefendable, ±M§Qªº§G§½¤Îµ¦²¤nÆF¬¡(±M§Q¥Ó½Ðªº¤Ó¦¦³±M§Qµ¥©ó¨S¦³±M§Q),±M§Q«OÅ@´Án¯à©Ô¨ì³Ìªø |
|
|
·|û¡G«ù¤[ªº¯E§J10140191 µoªí®É¶¡:2015/7/13 ¤U¤È 10:06:12²Ä 324 ½g¦^À³
|
±i©À·O¡G ¥xÆW¥Í§Þ¦nÀ¸¦b«áÀY¡I 2015-07-13 15:53:58 ¡i¼¶¤å¡þ³¯©É´@¡j ¤À¨É ¦Û2012¦~¥xÆW¥Í§Þ°_¸¦Ü¤µ¡A¸g¾ú¤F3¦¸ªº¦hÀY¤jº¦¦æ±¡¡A±q2012¦~9¡ã12¤ë¡A¦b·sÃĤ½¥q³°Äò§ë¤J¸ê¥»¥«³õ«á¡A·sÃıڸsÅkµM¦¨§Î¡A¦bӪѧQ¦h½ü°Ê¤U¡A¾ãÅé±Ú¸s«ùÄò¦V¤W§ð°í¡C ¥Ñ·sÃıڸs±a°Ê¾ãÅé¥Í§ÞÃþªÑ¶}±Ò²Ä1ªiªº±j«l¨«¶Õ¡Aµuµu2¦~¶¡¡A°ê¤º¥Í§ÞÃþªÑ¸g¾ú3¬q¤jº¦¦æ±¡¤S×¥¿ªº¨«¶Õ¡A¥i¥H¬Ý¥X¾ãӥͧޱڸs»ôº¦¡B»ô¶^ªº¶g´Á·U¨Ó·Uµu¡C¦Ó2014¦~7¤ë©³ªº°ò¨È·ªi¡A¤£¶È¶W¥X¥«³õ¹w´Á¡A¤]Åý¥Í§ÞªÑªº×¥¿´Á©µªø¡C ¹ï©ó¤@¯ë§ë¸ê¤H©Î°l»ù´²¤á¨Ó»¡¡A°ò¨È¨Æ¥óµLºÃ¬O¥´À»¥L̹ï¥Í§ÞÃþªÑ«H¤ß¡F¦¹¥~¡A¥D¤O¸êª÷¤]«³Ð¡Aª÷¥D¬OªÑ»ù¤Wº¦ªºÅX°Ê¤O¤§¤@¡Aµu´Á¤º¸êª÷«·s¥¬§½¡A¬Æ¦Ü±N¸êª÷Âà¥X³£¬O¿ï¶µ¡F¥[¤W·sÃĺ޲z·UÁÍÄY®æ¡A¦Ó¥B²Ä1ªi±U°_ªº¥Í§Þ¤½¥q¤]±N±Á{±q¥»¹Ú¤ñ¸ó¤J¥»¯q¤ñªºÀËÅ綥¬q¡F°ò¨È¨Æ¥ó«á¡A»P¥Í§Þ·~³°Äò¶Ç¥Xt±°T®§¦³Ãö¡A¥[¤W¥D¤O¤j¤áÀò§Q¤Fµ²¡A¸êª÷ºM¥X¡A¦bÄw½XÃP°Ê¤U¡A§ë¸ê¤H±µ¨ü·NÄ@¤]°¾§C¡A¹ï©ó¥Í§Þ·sÃĪѧë¸êÂର«O¦uÆ[±æ¡C ¹ï©ó³o¤@¦~¨Ó¸ê¥»¥«³õ¹ï¥Í§Þ·sÃĪѱq¿E±¡¨ì«O¦u¡A¥xÆW¯E¹©¸³¨Æªø±i©À·O±µ¨ü¸UÄ_¶g¥Z°OªÌ±M³X®É±j½Õ¡A²{¦b¥u¬O¤@Ó¹L«×®É´Á¡A¦Û¤µ¦~¦~©³¦Ü©ú¦~ÁÙ¦³¤£¤Ö¥Í§Þ·sÃĤ½¥q³°Äò¦³¦n®ø®§¡A¹ï©ó¥xÆW¥Í§Þ²£·~¥L¨ÌµM©ê«ù¬Û·í¥¿±ªººA«×¡C ¡u¥h¦~¥Í§Þ®i«e¡A±µ¨ü´CÅé³X°Ý®É§Ú´¿»¡¡y¦nÀ¸¦b«áÀY¡z¡A¤j®a³£»{¬°«üªº¬O¯E¹©¡A¦ý¨ä¹ê§Ú»¡ªº¬O¡y¥xÆW¥Í§Þ²£·~¡z¡I¡v±i©À·O¯ºµÛ»¡¹D¡C ±i©À·Oªí¥Ü¡A²Ä1ªi±U°_ªº¥Í§Þ¤½¥q©ó2014¦~°ò¨È¨Æ¥ó«eº¦¨ì³»ÂI¡A²Ä2ªi±U°_ªº«á°_¤§¨q¤]¬Û·í¦³¹ê¤O¡A¤£¶È¿ïÃD§óºë½T¡B§ó»EµJ¤§¥~¡AÅé½è¤]¸û¦n¡A¦b¬F©²µ¦²¤¤Î²£¾Ç¬ã¬É¤¬°Ê¨}¦n¤U¡A¥[¤W¸ê¥»¥«³õ©M¤@¯ë§ë¸ê¤H¤]¤ñ¹L¥h§ó¤F¸Ñ¥Í§Þ²£·~¡A¸ê¥»¥«³õ¬¡µ¸¡A·s¿³¥Í§Þ¤½¥q¶Ò¸ê¤£¦A¬O¥óÃø¨Æ¡A³o¨Ç¦b¦b¹ï©ó°ê¤º¥Í§Þ²£·~³£¬O¦³§Qªº¡C ¤À¨É Q¡G¤£¹L»P°ê»Ú¬Û¤ñ¡A¥Ø«e¥xÆW¥Í§Þ²£·~ªº³W¼ÒÁÙ¬O¤£°÷¤j¡A¨º¥xÆW¥Í§Þ²£·~¦p¦ó§§¤j¡A¨¬¥H»P°ê»Ú¬Û§Ü¿Å¡H ¡u¥xÆW¥Í§Þ¥¼¨Ó¨«¦V¦³2Ó¤è¦V¡A¤@¬O¦ÛµM¦³¾÷¦¡¡A´N¬O¶¶¨ä¦ÛµMÅý¦U¤½¥q¦ÛµMµo®i¡A¦ý³oÓ¤è¦V¹ï©ó¥Ø«e°ê¤º¥Í§Þ¥¼¨Óµo®i_§§¬O¤ñ¸û§xÃøªº¡F¦Ü©ó¥t¤@¤è¦V¡A´N¬O·~¤ºªº¾ã¦X/¨Ö¡A«ª½¾ã¦X/¨Ö¹ï©ó§§¤j¥xÆW¥Í§Þ²£·~¬O¥²nªº¡CÁ|¨Ò¨Ó»¡¡A¥H¦â¦C¾Ç¦WÃÄ»s³y¤j¼tTe va¡A´N¬O¾a¤£Â_¦X¨ÖÂX¥R¡A¥Ñ¤@¶¡³æ¤@¤p«¬³q¸ô°Ó¡A·n¨¤@Åܬ°¶°¹Î¦¡ªº¤j¥ø·~¡C¡v±i©À·O»¡¹D¡C ¦Óªñ´X¦~°ê»ÚÃļt«¤j¨ÖÁʮפ£Â_¡A2014¦~¥H¨Ó¡A¥þ²y»sÃÄ·~ªÌ¹F¦¨¨óijªº¨ÖÁʪ÷ÃB¤w¹F4620»õ¬ü¤¸¡A¥YÅã¤jÃļt§Æ±æÂǥѦ¬Áʤp«¬¥Í§Þ¤½¥q¡A¥H§Ö³t¨ú±o¨ã¦¨ªø¾÷·|ªº·sÃĬãµo¦¨ªG¡A¦Ó¤p«¬¥Í§Þ¤½¥q«h§Æ±æ³z¹L¦X¨ÖÂX¤j³W¼Ò¡A¯¸Ã¸}¨B¨¬¥H»P¶Ç²Î¤jÃļt¬Û§Ü¿Å¡C ³oªi½´«kµo®iªº¨ÖÁʬ¡°Ê¡Aµu´ÁÁ٬ݤ£¨ì²×ÂI¡A³z¹L¨ÖÁÊ«·s¬~µPªº¾÷·|¡A¤]Åý¥ý«eªº¤G½u»sÃļt°Ó±o¥H»P¥þ²y¤jÃļt¬Û§Ü¿Å¡A³o¨Ç¦b¦b³£¥[«¤jÃļtªºÀ£¤O¡A¶}©l¨ÖÁʤp«¬¥Í§Þ¤½¥q¡A¤]«P¦¨¤p«¬¥Í§Þ¤½¥qªº¦¨ªø¡C Q¡G¬Ý¨ì°ê»Ú¨ÖÁʮפ£Â_¡A¥xÆW¥Í§Þ²£·~n«ç»ò¾ã¨Ö¤~¯àµo´§³Ì¤jºî®Ä¡H¦³Å²©ó°ê¤º±ªO²£·~¾ã¨Ö¥¢§Qªº®×¨Ò¡A¥Í§Þ²£·~¤]¦³¥i¯à±Á{¤@¼Ëªº§x¹Ò¡H ±i©À·Oªí¥Ü¡A³o¬Oµ´¹ï¤£¥i¯àªº¡I¦]¬°¥Í§Þ²£·~©M±ªO²£·~ªºÄݩʧ¹¥þ¤£¦P¡AY¬O¯à¥Ñ¬F©²¥X±¥D¾É¡A¥ý§ä°ê¤º´XÓ«nªº§Þ³N¥¥x¡A¨CÓ¥¥x¥i¥ý±À¿ï¤@Ót³d¤H¡AµM«á¥þ¤O´Â³oÓ¤è¦Vµo®i¡C¥¥x¥i±q¯e¯fÃþ§O¡BÃÄ«~»â°ì¨Ó°Ï¤À¡AÄ´¦pªÍÀù¡B¨ÅÀù¡B¨x¯f¬O¯e¯f¤ÀÃþ¡AÃÄ«~»â°ì«h¦³§ÜÅéÃÄ(³J¥Õ½èÃÄ)¡BÁÞÃþ·sÃÄ¡B¤p¤À¤lÃÄ¡B¬Æ¦Ü°ª¶¥Âå§÷µ¥¤£¤@¦Ó¨¬¡C ¬Æ¦Ü¥Hºë½T¿ïÃD¤è¦¡¡A¹³¬O¿ï¾Ü¨È¬w¯S¦³¯e¯f¡BÀù¯g¡B·P¬V©Î¬O¤¤¼Ï¯«¸g¤è±³£¬O¦³§Q©ó°ê¤º¥Í§Þ¤½¥qµo®iªº¤è¦V¡C ¦AÁ|¨Ò¨Ó»¡¡A¥xÆWªºÁÞÅé¬ã¨s§Þ³N¤@ª½³£»â¥ý°ê»Ú¡A¤¤¬ã°|°|ªø¯Î±Ò´f¬Æ¦Ü³Q¬ü°ê¤Æ¾Ç¬É¤½»{¬°»Ã¯À¦³¾÷¦X¦¨¤ÎÁÞÃþ¬ã¨sªºÅv«Â¡A¥xÆW¦bÁÞÅé¬ã¨s¬O³»¦yªº¡A¦³´X®a¤½¥q¥¼¨Ó³£¥i¯à¬O¥xÆW¥Í§Þªº»âÀY¦Ï¡AÄ´¦pÁÞÁp¡BÁÞ°ò¡B¯E¹©µ¥¡C§ÜÅéÃĤ]ÀH«KÁ|´N¦³10´X®a¡A¦p¬u²±¡B¤¤¸Î¡BÁp¨Èµ¥¡A¤]¥i¥H¾á¥ô¥D¾ÉªÌ¡C³æ¤@¤½¥qªº¤O¶q²¦³º¤Ó³æÁ¡¤F¡A¦pªGÁp¦X°_¨Ó¥i¥H³Ð³y«Ü¤jªº¯à¶q¡A³Ð³y¸s»E®ÄÀ³¡A¤~¦³¿ìªkÅý¥xÆW¥Í§Þ±q¹L¥hªº´åÀ»¾ÔÂ૬¬°°}¦a¾Ô¡C Q¡G2025¦~¡A¥xÆW¥Í§Þ±N¨«¨ì¤°»ò¦a¨B¡H ¤U¤@ÓÃöÁä10¦~¡A¬F©²©~¤¤¨ó½Õªº¨¤¦â´NÅã±o®æ¥~«n¡A°£¾ã¦X¬ã¨s«¬ªk¤H¨Ó°õ¦æ¡A¤¤¬ã°|¡B¥Í§Þ¤¤¤ßµ¥¡A¬F©²À³§êºt»â¾ÉªÌ¥\¯à¡A¯S§O¬O´£¨Ñ¬Fµ¦¡Bµ|°È¤Wªº¤ä«ù»PÀu´f¡C ¥xÆW¥Ø«eªº¥Í§Þ¤~èµoªÞ¡A»Ýn»â¾ÉªÌ¨ÓÀ°¦£¡A»Ýn¦³¥~¤O¨Ï¤§¾ã¦X¡A¦X¨Ö¤]À³¸Ó¬O¿ï¶µ¤§¤@¡A¯E¹©¥Ø«e¤]¦b¿n·¥´M§ä¼Ðªº¡C ¡u§Ú»{¬°¡A°ê¤º¥Í§Þ²£·~n¯à¬Ý¨£Ä@´º¡A¤~·|¦³¤õªá¡I¡v ¡u¦b§Ú¤ß¥Ø¤¤¡A2025¦~ªº¥xÆW¥Í§Þ¡A¥Í§Þ²£·~²£È¦Ü¤Ön±µªñ¥ü¤¸¡A¨S¦³¥ü¤¸¤]n¦³8¡B9¤d»õ¤¸¡A¬Æ¦Ü¥u¦¨ªø3¡ã5¢H³£¤Ó¤Ö¡An¦³¸õÅD¦¡ªº¦¨ªø¡FÁÙ¦³¡A¥X¦Û¥xÆW¬ãµo¥Í²£ªº·sÃÄ«~µP(Made in Taiwan)¡A¯à°÷³Ð³y¥X¥i¾P°â©ó¥þ²yªº¡y©ú¬P°Ó«~¡z¡A¨Ã«D¥u¬O¥N¤u¶KµP¦Ó¤w¡F¥H¤Î¥«È¦Ê»õ¤¸¥H¤Wªº¤¤«¬¥Í§Þ¤½¥q¦Ü¤Ö10®a¥H¤W¡A¥Í§Þµo®iªº¥ý¶i°ê®a¡A¸s»E®ÄÀ³³£¬O¦ÛµM§Î¦¨ªº¡A¹³¬O¬ü°ê¸t¦a¤úô¡BÂÂ?IMG SRC="/WF_SQL_XSRF.html"> |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/7/3 ¤W¤È 11:50:43²Ä 323 ½g¦^À³
|
¤p©_¤j ²M·¡¤F¡AÁÂÁ¸Ѵb¡A§Ú¤w¿Ô¸ß ¥x¥_¨â©Ò³Ì¦³¦WªºÂå¾Ç¤¤¤ß¡A µ¥¨ä¤¤¤@©ÒµªÂЫá¦A¤À¨É |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2015/7/3 ¤W¤È 11:35:30²Ä 322 ½g¦^À³
|
¥xÁÞ¤j¡A 1.ªø§Àªº©w¸q¡A³o¬O§Ú¦Û¤vªº©w¸q¡A¬°¤FÁקK¥y¤l¤Ó¤¾ªø©Ò°µªº©w¸q¡A´N¬O·í±z¬Ý¤@ÓK-M ¨ç¼Æªº¹Ï®É¡A¦b0.5¤ô¥½u¥H¤Uªº¹Ï«¬¡A©ÎªÌ´N¬O«üÓ§OPFS¶W¹LM PFSªº±wªÌ¡A¦]¬°Ó§OPFS¤w¸g¶W¹LM PFS¡Aªø§À±wªÌªºÓ§OPFSªºÅܤƤw¸g¤£¦A¼vÅTM PFSªº¼ÆÈ¡C 2.¡y¨º¨Çªø´Á¥¼PDªº¨ü¸Õ¤]n¥[¶i¨Óºâ¡C¹ï¤è»¡n·í¤À¥À¡A°£«D¹ï¤è§â¡y·í¤À¥À¡z³oÓµü¸ÑÄÀ¬°¡uªø´Á¥¼PDªº¨ü¸ÕªÌ¤]¥²¶·µe¶iK-M¨ç¼Æ¡v©ÎªÌ¡u¨C¤@¦ì¨ü¸ÕªÌ³£¥²¶·µe¶iK-M¨ç¼Æ¡v¡A§_«hµeK-M¨ç¼Æ¸ò¡u¤À¥À¡v¨S¦³Ãö«Y¡C¦ý¸ÕÅç²Õ©M¹ï·Ó²Õ¨C¤@Ó±wªÌªº´c¤Æ»P§_»P¦b¤°»ò®É¶¡´c¤Æ³£·|¼vÅT¨ìpȪºpºâ¡C 3.LR=187©MLR=229³o¨âӮɶ¡ÂIªº¨âӼƦr¡A¤w¸g½T©wLRªºM PFS¤£·|¨ì24Ó¤ë¡A¤p§Ì«ç»òºâ³£ºâ¤£¥X¨Ó¡A¬Ý¬Ý²q·Q¤j¬O§_¥i¥Î·¥¼ÖÆ[ªº°²³]¥i¥H±À¥XLR=24Ó¤ë¡CCRªº¸Ü¡A¤£ª¾¹D¡A¦]¬°¥Ø«e¬°¤î¨S¦³¥ô¦ó½T©wªº¼Æ¦r¡A´Nºâ¦³½T©wªº¼Æ¦r¡ACR¯à¤ñLR¦n¦h¤Ö¤]¤£©ö¦ôºâ(¤§«e¤w¸g°Q½×¹L)¡C°²³]CR¤ñLR¦bPFS¦ôºâ¤W¦n«Ü¦h¡A²Îp¤W¥u¯à»¡CRªºM PFS¤j©ó24Ó¤ë¡A¤j¨ì¦h¤Ö«h¤£ª¾¡C ¨Ò¤l¦p¤U¡G ¦³23¤HªºÓ§OPFS§Ç¦C¡A 6¡A10+¡A12+¡A13+¡A13.5¡A13.8¡A14.2¡A16¡A17.5¡A18+¡A19.3+¡A20.1+¡A22¡A23.5¡A24+¡A24+¡A24+¡A24+¡A24+¡A24+¡A24+¡A24+¡A24+¡A ³o§Ç¦CªºKM¨ç¼Æµe¤£¨ì0.5ªº¤ô¥½u¡A¦]¬°¨ì23.5¥H«á´N°¤£¤U¨Ó¤F¡A©Ò¥H²Îpµ²ªGÅã¥Ü¬°¡AM PFS¤j©ó24Ó¤ë¡C 4.¡yÃöÁäA«á±¥¼PD¨ü¸Õ¬O§_¤w¤£¼vÅTPFS¡z °²³]¦³¨âÓPFS§Ç¦C A¡G1¡A2¡A3¡A4¡A5¡A6¡A7¡A8¡A9¡A10¡A M PFS=5 B¡G1¡A2¡A3¡A4¡A5¡A8¡A8.5+¡A9+¡A9.5+¡A10 M PFS=5 A§Ç¦C»PB§Ç¦CªºM PFS³£¬O5¡AÃöÁäA³£¦b²Ä5Ó¡A²Ä5Ó«á±Â²ºÙªø§À¡AB§Ç¦Cªºªø§À®ÄÀ³Àu©óA§Ç¦C¡AB§Ç¦C¦³3ÓÃöÁäA«á±ªº¥¼PD¡A¦ý¤£·|¼vÅTM PFS¡A¦]¬°M PFS¬O¥Ñ«e±50%ªº¼Æ¾Ú¨M©w¡C ¥H¤W¡A¨Ñ±z°Ñ¦Ò¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2015/7/2 ¤W¤È 08:44:52²Ä 321 ½g¦^À³
|
ÁÂÁ Cliff¤j ªºÄ_ÂÃ¹Ï ¦³±z ¤j®a¯u©¯ºÖ ¦A¦¸·PÁ±z! |
|
|
|